REVIEW ARTICLE review R RE REV REVI BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 10 1 1 0 0 1
OPEN OPEN open O OP OPE OPEN BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 10 1 1 0 0 1
The signal the T Th The The BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 10 1 0 0 0 1
COVID-19 COVID-19 covid-19 C CO COV COVI BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 0 - 1 1 1 0 0 0 1
Lan Yang lan L La Lan Lan BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 0 ,,,,,,,,, 9 10 1 0 0 0 1
The Coronavirus the T Th The The BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 (-) 3 9 0 0 0 0 1
infectious disease. infectious i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 ., 2 9 0 0 0 0 1
businesses and businesses b bu bus busi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 .-, 3 8 0 0 0 0 1
including lymphopenia, including i in inc incl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 ,,,(-) 6 9 0 0 0 0 1
response, antibody-dependent response, r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 ,-,,(). 7 9 0 0 0 0 1
array of array a ar arr arra BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 -.- 3 9 0 0 0 0 1
cytokines initiate cytokines c cy cyt cyto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 , 1 10 0 0 0 0 1
medical symptoms medical m me med medi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 ,,, 3 9 0 0 0 0 1
syndrome, and syndrome, s sy syn synd BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 ,,., 4 9 0 0 0 0 1
understand the understand u un und unde BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 -., 3 9 0 0 0 0 1
discuss the discuss d di dis disc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 - 1 9 0 0 0 0 1
research status research r re res rese BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 0 .,,, 4 9 0 0 0 0 1
potential interventions potential p po pot pote BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 . 1 9 0 0 0 0 1
CS in cs C CS CS CS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 - 1 9 0 0 0 0 1
and inflammatory and a an and and BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 . 1 2 0 0 0 0 1
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 3 (): 3 10 0 0 0 0 1
; https://doi.org/10.1038/s41392-021-00679-0 ; ; ; ; ; BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 3 ;://././--- 11 8 0 0 0 0 1
INTRODUCTION INTRODUCTION introduction I IN INT INTR BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 4 no 0 1 1 0 0 0 1
Coronavirus Disease coronavirus C Co Cor Coro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 4 (-) 3 8 1 0 0 0 1
respiratory syndrome respiratory r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 (--) 4 9 1 0 0 0 1
worldwide and worldwide w wo wor worl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 .- 2 9 1 0 0 0 1
destroyed people's destroyed d de des dest BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 ' 1 9 1 0 0 0 1
global economic global g gl glo glob BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 .,, 3 8 1 0 0 0 1
infections, including infections, i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 ,., 3 9 1 0 0 0 1
(source: World (source: ( (s (so (sou BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 4 (:).-- 6 9 1 0 0 0 1
host by host h ho hos host BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 -() 3 8 1 0 0 0 1
receptors broadly receptors r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 no 0 9 1 0 0 0 1
cells. 1-5 cells. c ce cel cell BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 .-- 3 10 1 0 0 0 1
tions from tions t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 4 ,, 2 8 1 0 0 0 1
moderate forms moderate m mo mod mode BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 ( 1 8 1 0 0 0 1
localized inflammation) localized l lo loc loca BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 )/- 3 9 1 0 0 0 1
comes. 6,7 comes. c co com come BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 .,- 3 9 1 0 0 0 1
monia, 8,9 monia, m mo mon moni BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 4 ,,(), 5 9 1 0 0 0 1
respiratory distress respiratory r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 (),, 4 9 1 0 0 0 1
multiorgan failure multiorgan m mu mul mult BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 4 (.).- 5 5 1 0 0 0 1
Several lines several S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 4 no 0 9 1 0 0 0 1
damage may damage d da dam dama BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 -. 2 9 1 0 0 0 1
Particularly, multiple particularly, P Pa Par Part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 4 , 1 10 1 0 0 0 1
levels of levels l le lev leve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 - 1 9 1 0 0 0 1
crosstalk between crosstalk c cr cro cros BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 4 -, 2 9 1 0 0 0 1
which has which w wh whi whic BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 () 2 8 1 0 0 0 1
complications and complications c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 .- 2 8 1 0 0 0 1
CS is cs C CS CS CS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 6 -,-, 4 9 1 0 0 0 1
which the which w wh whi whic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 no 0 8 1 0 0 0 1
excessive activation excessive e ex exc exce BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 no 0 9 1 0 0 0 1
syndromes from syndromes s sy syn synd BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 ,, 2 9 1 0 0 0 1
hypotension, to hypotension, h hy hyp hypo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 6 ,,,,- 5 8 1 0 0 0 1
gocytic lymphohistiocytosis gocytic g go goc gocy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 6 (),, 4 10 1 0 0 0 1
treatment is treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 ., 2 9 1 0 0 0 1
and treatment and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 -. 2 9 1 0 0 0 1
used in used u us use used BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 --,, 4 9 1 0 0 0 1
inflammatory diseases inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 6 , 1 8 1 0 0 0 1
transplantation, cancer transplantation, t tr tra tran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 6 ,() 3 9 1 0 0 0 1
therapy, and, therapy, t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 ,,,-.-, 7 8 1 0 0 0 1
profile and profile p pr pro prof BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 no 0 9 1 0 0 0 1
greatly vary. greatly g gr gre grea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 ., 2 9 1 0 0 0 1
for CS for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 . 1 9 1 0 0 0 1
definite alterations definite d de def defi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 no 0 9 1 0 0 0 1
involved in involved i in inv invo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 --(-) 5 8 1 0 0 0 1
extremely important extremely e ex ext extr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 no 0 8 1 0 0 0 1
and effective and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 . 1 3 1 0 0 0 1
Although some although A Al Alt Alth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 6 no 0 9 1 0 0 0 1
previously, a previously, p pr pre prev BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 ,- 2 9 1 0 0 0 1
Received: 21 received: R Re Rec Rece BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 9 ::: 3 10 1 1 0 0 1
1 1 1 1 1 1 1 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 0 9 no 0 10 1 0 0 0 1
Institute of institute I In Ins Inst BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 9 ,',',, 6 10 1 1 0 0 1
Co-laboratory of co-laboratory C Co Co- Co-l BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 9 -,,,,,; 7 9 1 1 0 0 1
Health Commission health H He Hea Heal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 0 9 (),,,;,',, 10 9 1 1 0 0 1
China; 4 china; C Ch Chi Chin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 9 ;,, 3 9 1 1 0 0 1
Medicine, Shenzhen, medicine, M Me Med Medi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 9 ,,,,,, 6 6 1 1 0 0 1
Correspondence: Damo correspondence: C Co Cor Corr BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 9 :(@..)(@..) 11 4 1 1 0 0 1
www.nature.com/sigtrans www.nature.com/sigtrans www.nature.com/sigtrans w ww www www. BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 11 ../ 3 10 1 1 0 0 0
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 11 no 0 10 1 1 0 0 0
© The © © © © © BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 11 (), 3 10 1 1 0 0 0
1234567890();,: 1234567890();,: 1234567890();,: 1 12 123 1234 BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 0 11 ();,: 5 10 0 0 0 0 0
diagnosis and diagnosis d di dia diag BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 . 1 9 0 0 0 0 1
Herein, we herein, H He Her Here BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 ,- 2 9 0 0 0 0 1
basic research basic b ba bas basi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 ,,., 4 10 0 0 0 0 1
we discuss we w we we we BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 8 0 0 0 0 1
of COVID-19, of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 -,; 3 8 0 0 0 0 1
differences with differences d di dif diff BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 ; 1 8 0 0 0 0 1
individual cytokines individual i in ind indi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 - 1 8 0 0 0 0 1
pathological role, pathological p pa pat path BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 ,,- 3 8 0 0 0 0 1
tions. In tions. t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 ., 2 9 0 0 0 0 1
and treatment and a an and and BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 -. 2 6 0 0 0 0 1
THE IMMUNOPATHOLOGY the T TH THE THE BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 1 - 1 4 0 0 0 0 1
In general, in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 0 1 ,- 2 8 0 0 0 0 1
immune landscape, immune i im imm immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 ,, 2 9 0 0 0 0 1
innate immune innate i in inn inna BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 ,, 2 8 0 0 0 0 1
immune response. immune i im imm immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 .- 2 8 0 0 0 0 1
pathology of pathology p pa pat path BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 -., 3 8 0 0 0 0 1
clinical trials clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 no 0 10 0 0 0 0 1
of immunopathology of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 -,, 3 8 0 0 0 0 1
antibody-dependent enhancement antibody-dependent a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 1 -(),,- 6 8 0 0 0 0 1
tion of tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 1 , 1 8 0 0 0 0 1
interferon (IFN-I) interferon i in int inte BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 1 (-),(.). 8 6 0 0 0 0 1
Lymphopenia Lymphopenia lymphopenia L Ly Lym Lymp BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 2 no 0 1 0 0 0 0 1
Lymphopenia was lymphopenia L Ly Lym Lymp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 2 -, 2 8 0 0 0 0 1
and is and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 ., 2 9 0 0 0 0 1
results showed results r re res resu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 2 no 0 8 0 0 0 0 1
including CD4 including i in inc incl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 ,,,(), 6 10 0 0 0 0 1
B cells b B B B B BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 2 -.- 3 9 0 0 0 0 1
from single-cell from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 -,, 3 8 0 0 0 0 1
primate models primate p pr pri prim BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 - 1 8 0 0 0 0 1
lymphopenia to lymphopenia l ly lym lymp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 ., 2 7 0 0 0 0 1
exhibited exhaustion exhibited e ex exh exhi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 8 0 0 0 0 1
levels of levels l le lev leve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 7 0 0 0 0 1
death protein-1 death d de dea deat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 -(-) 4 8 0 0 0 0 1
domain-3, suggesting domain-3, d do dom doma BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 2 -, 2 8 0 0 0 0 1
activities. 26,27 activities. a ac act acti BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 .,-- 4 9 0 0 0 0 1
group 2 group g gr gro grou BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 - 1 8 0 0 0 0 1
increased in increased i in inc incr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 - 1 7 0 0 0 0 1
compared to compared c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 ., 2 5 0 0 0 0 1
Several mechanisms several S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 3 --- 3 8 0 0 0 0 1
depletion and depletion d de dep depl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 :()-- 5 8 0 0 0 0 1
directly infect directly d di dir dire BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 , 1 9 0 0 0 0 1
which results which w wh whi whic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 ;,()- 5 10 0 0 0 0 1
anti-inflammatory cytokines anti-inflammatory a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 3 - 1 8 0 0 0 0 1
exhaustion of exhaustion e ex exh exha BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 ., 2 9 0 0 0 0 1
the virus the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 no 0 8 0 0 0 0 1
lymph nodes, lymph l ly lym lymp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 ,, 2 9 0 0 0 0 1
observations of observations o ob obs obse BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 ,, 2 8 0 0 0 0 1
decreased lymphocyte decreased d de dec decr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 ;,-() 5 8 0 0 0 0 1
COVID-19 model covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 3 -- 2 8 0 0 0 0 1
response may response r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 no 0 7 0 0 0 0 1
regulatory T regulatory r re reg regu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 ()., 4 8 0 0 0 0 1
possibility that possibility p po pos poss BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 no 0 9 0 0 0 0 1
from anti-inflammatory from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 - 1 9 0 0 0 0 1
glucocorticoids. glucocorticoids. glucocorticoids. g gl glu gluc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 3 . 1 2 0 0 0 0 1
Collectively, lymphopenia collectively, C Co Col Coll BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 3 , 1 8 0 0 0 0 1
illness. A illness. i il ill illn BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 .,, 3 10 0 0 0 0 1
Han Chinese han H Ha Han Han BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 3 , 1 9 0 0 0 0 1
hospitalized COVID-19 hospitalized h ho hos hosp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 -() 3 9 0 0 0 0 1
showed that showed s sh sho show BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 / 1 9 0 0 0 0 1
critical cases, critical c cr cri crit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 , 1 8 0 0 0 0 1
decreased with decreased d de dec decr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 no 0 9 0 0 0 0 1
clinical status. clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 . 1 9 0 0 0 0 1
a marked a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 0 3 ., 2 8 0 0 0 0 1
the authors the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 no 0 9 0 0 0 0 1
of lymphocytes of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 no 0 9 0 0 0 0 1
clinical prognosis. clinical c cl cli clin BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 . 1 3 0 0 0 0 1
Antibody-dependent enhancement antibody-dependent A An Ant Anti BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 6 - 1 4 0 0 0 0 1
B cells b B B B B BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 6 -- 2 8 0 0 0 0 1
producing neutralizing producing p pr pro prod BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 no 0 8 0 0 0 0 1
prevent viral prevent p pr pre prev BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 .,- 3 8 0 0 0 0 1
antibodies are antibodies a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 6 , 1 8 0 0 0 0 1
virus element virus v vi vir viru BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 . 1 9 0 0 0 0 1
ADE is ade A AD ADE ADE BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 6 -- 2 8 0 0 0 0 1
bodies targeting bodies b bo bod bodi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 no 0 8 0 0 0 0 1
entry of entry e en ent entr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 no 0 9 0 0 0 0 1
into leukocytes into i in int into BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 no 0 8 0 0 0 0 1
of the of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 no 0 8 0 0 0 0 1
such cells. such s su suc such BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 .- 2 8 0 0 0 0 1
viral infections viral v vi vir vira BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 ,,-,-, 6 9 0 0 0 0 1
and Ebola. and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 .,,- 4 3 0 0 0 0 1
Recent studies recent R Re Rec Rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 6 no 0 9 0 0 0 0 1
or antibodies or o or or or BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 -- 2 8 0 0 0 0 1
ity, 32,53,54 ity, i it ity ity, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 6 ,,,-- 5 9 0 0 0 0 1
2 infection. 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 0 6 ., 2 9 0 0 0 0 1
antibody MW05 antibody a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 6 -- 2 7 0 0 0 0 1
activity by activity a ac act acti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 . 1 10 0 0 0 0 1
However, administration however, H Ho How Howe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 6 , 1 9 0 0 0 0 1
mutation in mutation m mu mut muta BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 -- 2 8 0 0 0 0 1
infection. 55 infection. i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 .- 2 9 0 0 0 0 1
tive neutralizing tive t ti tiv tive BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 6 --., 4 8 0 0 0 0 1
further investigations further f fu fur furt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 -- 2 8 0 0 0 0 1
required to required r re req requ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 -- 2 8 0 0 0 0 1
based therapy based b ba bas base BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 -. 2 3 0 0 0 0 1
Neutrophilia Neutrophilia neutrophilia N Ne Neu Neut BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 9 no 0 1 0 1 0 0 1
An increase an A An An An BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 0 9 - 1 9 0 1 0 0 1
recognized. It recognized. r re rec reco BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 9 ., 2 8 0 1 0 0 1
neutrophils play neutrophils n ne neu neut BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 9 no 0 10 0 1 0 0 1
neutrophil extracellular neutrophil n ne neu neut BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 9 ()- 3 9 0 1 0 0 1
gens; 56 gens; g ge gen gens BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 9 ;, 2 9 0 1 0 0 1
the surrounding the t th the the BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 9 . 1 8 0 1 0 0 1
Fig. 1 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 10 .-.-- 5 9 1 0 0 0 1
infects airway infects i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 10 no 0 9 1 0 0 0 1
receptors, causing receptors, r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 10 ,, 2 9 1 0 0 0 1
production of production p pr pro prod BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 10 no 0 8 1 0 0 0 1
immune cells. immune i im imm immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 10 ., 2 9 1 0 0 0 1
immune cells immune i im imm immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 10 , 1 9 1 0 0 0 1
mild forms mild m mi mil mild BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 10 (..,,,); 8 9 1 0 0 0 1
requiring hospitalization requiring r re req requ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 10 (); 3 9 1 0 0 0 1
to severe/critical to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 10 / 1 10 1 0 0 0 1
pneumonia, ARDS, pneumonia, p pn pne pneu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 10 ,,,,.- 6 8 1 0 0 0 1
associated molecular associated a as ass asso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 10 , 1 8 1 0 0 0 1
syndrome, DIC syndrome, s sy syn synd BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 10 , 1 7 1 0 0 0 1
The signal the T Th The The BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 11 - 1 10 1 1 0 0 0
Yang et yang Y Ya Yan Yang BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 11 . 1 1 1 1 0 0 0
2 2 2 2 2 2 2 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 0 11 no 0 10 1 1 0 0 0
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 11 (): 3 10 0 1 1 1 0
An earlier an A An An An BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 0 0 , 1 8 0 0 0 0 1
China, showed china, C Ch Chi Chin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 ,- 2 8 0 0 0 0 1
survivors compared survivors s su sur surv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 9 0 0 0 0 1
death in death d de dea deat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 -. 2 10 0 0 0 0 1
transcriptomic, proteomic, transcriptomic, t tr tra tran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 ,, 2 8 0 0 0 0 1
that neutrophil that t th tha that BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 , 1 9 0 0 0 0 1
not mild, not n no not not BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 ,-, 3 8 0 0 0 0 1
molecules associated molecules m mo mol mole BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 8 0 0 0 0 1
in severe in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 0 -. 2 4 0 0 0 0 1
The increased the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 7 0 0 0 0 1
numbers of numbers n nu num numb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 0 . 1 9 0 0 0 0 1
integrated single-cell integrated i in int inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 --- 3 9 0 0 0 0 1
of blood of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 (), 3 8 0 0 0 0 1
immature neutrophil immature i im imm imma BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 , 1 8 0 0 0 0 1
neutrophils expressing neutrophils n ne neu neut BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 - 1 8 0 0 0 0 1
severe COVID-19 severe s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 -.,- 4 9 0 0 0 0 1
analysis by analysis a an ana anal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 . 1 9 0 0 0 0 1
et al. et e et et et BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 . 1 10 0 0 0 0 1
various developmental various v va var vari BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 9 0 0 0 0 1
fluid (BALF) fluid f fl flu flui BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 ()-. 4 6 0 0 0 0 1
Although the although A Al Alt Alth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 7 0 0 0 0 1
neutrophil development neutrophil n ne neu neut BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 -, 2 9 0 0 0 0 1
McElvaney et mcelvaney M Mc McE McEl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 . 1 9 0 0 0 0 1
(PKM2), a (pkm2), ( (P (PK (PKM BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 0 (),- 4 9 0 0 0 0 1
inducible factor-1α, inducible i in ind indu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 -, 2 8 0 0 0 0 1
higher in higher h hi hig high BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 - 1 9 0 0 0 0 1
those of those t th tho thos BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 --.- 4 9 0 0 0 0 1
phils undergo phils p ph phi phil BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 no 0 7 0 0 0 0 1
COVID-19 cases, covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 0 -, 2 9 0 0 0 0 1
for excessive for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 9 0 0 0 0 1
critical COVID-19. critical c cr cri crit BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 -. 2 2 0 0 0 0 1
Dysregulation of dysregulation D Dy Dys Dysr BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 4 no 0 5 0 0 0 0 1
Monocytes and monocytes M Mo Mon Mono BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 4 no 0 8 0 0 0 0 1
infection and infection i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 8 0 0 0 0 1
numbers but numbers n nu num numb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 4 .-- 3 9 0 0 0 0 1
analysis showed analysis a an ana anal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 9 0 0 0 0 1
increased, whereas increased, i in inc incr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 , 1 9 0 0 0 0 1
CD14 + cd14 C CD CD1 CD14 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 4 no 0 8 0 0 0 0 1
COVID-19 patients covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 4 -. 2 8 0 0 0 0 1
differentiate into differentiate d di dif diff BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 9 0 0 0 0 1
response, whereas response, r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 ,- 2 8 0 0 0 0 1
inflammatory as inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 , 1 9 0 0 0 0 1
may explain may m ma may may BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 1 0 0 1 4 no 0 8 0 0 0 0 1
CD16 + cd16 C CD CD1 CD16 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 4 . 1 10 0 0 0 0 1
circulating monocyte-macrophages circulating c ci cir circ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 - 1 8 0 0 0 0 1
a transition a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 1 4 --.,- 5 9 0 0 0 0 1
ple pro-inflammatory ple p pl ple ple BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 - 1 8 0 0 0 0 1
expressed by expressed e ex exp expr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 -, 2 8 0 0 0 0 1
the cells the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 .- 2 9 0 0 0 0 1
peripheral blood peripheral p pe per peri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 8 0 0 0 0 1
remarkably depleted remarkably r re rem rema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 -, 2 8 0 0 0 0 1
phenotypic shift phenotypic p ph phe phen BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 ., 2 8 0 0 0 0 1
upregulation of upregulation u up upr upre BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 - 1 8 0 0 0 0 1
chemokines were chemokines c ch che chem BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 , 1 9 0 0 0 0 1
peripheral monocytes peripheral p pe per peri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 9 0 0 0 0 1
CS in cs C CS CS CS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 4 -., 3 9 0 0 0 0 1
in BALF in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 4 - 1 9 0 0 0 0 1
expression of expression e ex exp expr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 ,,, 3 8 0 0 0 0 1
HLA-DR was hla-dr H HL HLA HLA- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 4 - 1 7 0 0 0 0 1
macrophages. 33 macrophages. m ma mac macr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 ., 2 9 0 0 0 0 1
consistent and consistent c co con cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 -- 2 9 0 0 0 0 1
and the and a an and and BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 - 1 8 0 0 0 0 1
Fig. 2 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 8 .-.-, 5 8 1 0 0 0 1
dysregulation of dysregulation d dy dys dysr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 ,,,-,. 6 9 1 0 0 0 1
observed in observed o ob obs obse BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 -., 3 9 1 0 0 0 1
higher levels higher h hi hig high BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 -,-,., 6 9 1 0 0 0 1
macrophages are macrophages m ma mac macr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 --. 3 9 1 0 0 0 1
precursors in precursors p pr pre prec BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 ,-.-- 5 10 1 0 0 0 1
into cells into i in int into BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 ,-. 3 10 1 0 0 0 1
elevated levels elevated e el ele elev BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 - 1 9 1 0 0 0 1
infection. Reduced infection. i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 .-, 3 9 1 0 0 0 1
deterioration of deterioration d de det dete BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 -.,- 4 8 1 0 0 0 1
The signal the T Th The The BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 11 - 1 10 1 1 0 0 0
Yang et yang Y Ya Yan Yang BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 1 11 . 1 1 1 1 0 0 0
3 3 3 3 3 3 3 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 1 11 no 0 10 1 1 0 0 0
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 11 (): 3 10 0 1 1 0 0
via the via v vi via via BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 8 1 0 0 0 1
chemokines during chemokines c ch che chem BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 -. 2 5 1 0 0 0 1
Interestingly, a interestingly, I In Int Inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 ,-- 3 8 1 0 0 0 1
DR high dr D DR DR DR BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 no 0 9 1 0 0 0 1
patients with patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -,- 3 8 1 0 0 0 1
DR low dr D DR DR DR BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 (-) 3 10 1 0 0 0 1
monocytes were monocytes m mo mon mono BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 -. 2 9 1 0 0 0 1
further investigation further f fu fur furt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 8 1 0 0 0 1
and clinical and a an and and BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 . 1 3 1 0 0 0 1
Reduced or reduced R Re Red Redu BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 1 - 1 4 0 0 0 0 1
The IFN-I the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 1 - 1 9 0 0 0 0 1
critical to critical c cr cri crit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 no 0 9 0 0 0 0 1
regulating innate regulating r re reg regu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 . 1 9 0 0 0 0 1
detailed mechanism detailed d de det deta BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 , 1 9 0 0 0 0 1
the RNA the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 -- 2 8 0 0 0 0 1
immune cells immune i im imm immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 () 2 9 0 0 0 0 1
toll-like receptor toll-like t to tol toll BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 -();--(-)- 10 10 0 0 0 0 1
receptors (RLRs)/melanoma receptors r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 ()/- 4 8 0 0 0 0 1
(MDA5); and (mda5); ( (M (MD (MDA BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 1 ();-().,- 9 8 0 0 0 0 1
stream transcription stream s st str stre BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 -(-), 5 9 0 0 0 0 1
activator protein-1 activator a ac act acti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 1 -(-),/(/) 9 9 0 0 0 0 1
are activated are a ar are are BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 - 1 9 0 0 0 0 1
cytokines and cytokines c cy cyt cyto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 1 -.- 3 9 0 0 0 0 1
(JAK1)/tyrosine kinase (jak1)/tyrosine ( (J (JA (JAK BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 1 ()/- 4 8 0 0 0 0 1
transcription 1/2 transcription t tr tra tran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 /(/), 5 9 0 0 0 0 1
the STAT1/2/IRF9 the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 //- 3 8 0 0 0 0 1
stimulated genes stimulated s st sti stim BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 ()(.)., 7 5 0 0 0 0 1
However, accumulating however, H Ho How Howe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 1 , 1 7 0 0 0 0 1
protective IFN-I protective p pr pro prot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 - 1 8 0 0 0 0 1
COVID-19 patients. covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 1 -.,, 4 8 0 0 0 0 1
proposed to proposed p pr pro prop BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 -:() 4 9 0 0 0 0 1
studies have studies s st stu stud BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 -- 2 8 1 0 0 0 1
isms to isms i is ism isms BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 , 1 9 1 0 0 0 1
of its of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 ,,- 3 9 1 0 0 0 1
reading frame reading r re rea read BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 (),. 4 8 1 0 0 0 1
Considering that considering C Co Con Cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 4 -- 2 9 1 0 0 0 1
SARS-CoV, it sars-cov, S SA SAR SARS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 4 -,-- 4 9 1 0 0 0 1
effects on effects e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 .,. 3 9 1 0 0 0 1
NSP1 protein nsp1 N NS NSP NSP1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 4 -- 2 8 1 0 0 0 1
and ISG and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 .() 3 9 1 0 0 0 1
(pDCs) may (pdcs) ( (p (pD (pDC BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 ()-. 4 9 1 0 0 0 1
Sufficient evidence sufficient S Su Suf Suff BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 8 1 0 0 0 1
producer of producer p pr pro prod BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 -.-, 4 9 1 0 0 0 1
studies showed studies s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 9 1 0 0 0 1
of COVID-19 of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 -,., 4 8 1 0 0 0 1
Of note, of O Of Of Of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 4 ,-, 3 9 1 0 0 0 1
IFN-I and ifn-i I IF IFN IFN- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 4 - 1 9 1 0 0 0 1
patients, 78 patients, p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 ,- 2 9 1 0 0 0 1
response. 69 response. r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 .- 2 9 1 0 0 0 1
not only not n no not not BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 8 1 0 0 0 1
hyperinflammation, thereby hyperinflammation, h hy hyp hype BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 , 1 8 1 0 0 0 1
response. 79,80 response. r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 .,,-- 5 10 1 0 0 0 1
therapy for therapy t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 - 1 9 1 0 0 0 1
the infection the t th the the BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 . 1 4 1 0 0 0 1
Cytokine storm cytokine C Cy Cyt Cyto BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 8 no 0 2 0 0 0 0 1
In this in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 1 8 ,- 2 8 0 0 0 0 1
istics, possible istics, i is ist isti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 ,,, 3 8 0 0 0 0 1
of CS of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 -. 2 2 0 0 0 0 1
Sufficient evidence sufficient S Su Suf Suff BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 8 - 1 8 0 0 0 0 1
istics of istics i is ist isti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 -, 2 8 0 0 0 0 1
composed of composed c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 -(-),,, 7 9 0 0 0 0 1
7, 8, 7, 7 7, 7, 7, BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 8 ,,,,,;-(-);-; 13 10 0 0 0 0 1
Fig. 3 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 9 .---., 6 9 1 0 0 0 1
replicative dsRNA replicative r re rep repl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 9 ---,,,,-/ 9 10 1 0 0 0 1
MDA5; next, mda5; M MD MDA MDA5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 9 ;,-/- 5 9 1 0 0 0 1
cytokines and cytokines c cy cyt cyto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 9 -.-/-/,// 9 9 1 0 0 0 1
the transcription the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 -,- 3 9 1 0 0 0 1
and MAPK and a an and and BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 -- 2 8 1 0 0 0 1
The signal the T Th The The BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 11 - 1 10 1 1 0 0 0
Yang et yang Y Ya Yan Yang BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 1 11 . 1 1 1 1 0 0 0
4 4 4 4 4 4 4 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 1 11 no 0 10 1 1 0 0 0
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 11 (): 3 10 0 1 1 0 0
colony-stimulating factor colony-stimulating c co col colo BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -(-);-- 7 9 1 0 0 0 1
stimulating factor stimulating s st sti stim BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 (-); 4 8 1 0 0 0 1
protein-1 (MCP-1). protein-1 p pr pro prot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 0 -(-).,,,- 9 9 1 0 0 0 1
clinical benefits clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -- 2 9 1 0 0 0 1
19 patients 19 1 19 19 19 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 1 0 no 0 9 1 0 0 0 1
COVID-CS. 87,88 covid-cs. C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 -., 3 10 1 0 0 0 1
COVID-CS from covid-cs C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 - 1 9 1 0 0 0 1
specific viral specific s sp spe spec BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ,() 3 9 1 0 0 0 1
occurring after occurring o oc occ occu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 , 1 8 1 0 0 0 1
syndrome (CRS) syndrome s sy syn synd BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 (). 3 9 1 0 0 0 1
First, COVID-CS first, F Fi Fir Firs BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 ,- 2 9 1 0 0 0 1
conditions, thereby conditions, c co con cond BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 , 1 9 1 0 0 0 1
nature of nature n na nat natu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -.,, 4 9 1 0 0 0 1
frequent in frequent f fr fre freq BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ,- 2 9 1 0 0 0 1
CS, 88 cs, C CS CS, CS, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 ,- 2 9 1 0 0 0 1
-rather than -rather - -r -ra -rat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 -., 3 8 1 0 0 0 1
bacterial infection-induced bacterial b ba bac bact BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -(..,), 7 9 1 0 0 0 1
COVID-CS is covid-cs C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 -, 2 8 1 0 0 0 1
cytokine function cytokine c cy cyt cyto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 - 1 9 1 0 0 0 1
exacerbate the exacerbate e ex exa exac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 . 1 3 1 0 0 0 1
The initiation the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 8 1 0 0 0 1
predominant causative predominant p pr pre pred BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 8 1 0 0 0 1
remain largely remain r re rem rema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 .- 2 8 1 0 0 0 1
associated molecule associated a as ass asso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ()--, 5 8 1 0 0 0 1
with SARS-CoV with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 --, 3 8 1 0 0 0 1
cellular entry cellular c ce cel cell BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 --, 3 9 1 0 0 0 1
single-stranded RNA single-stranded s si sin sing BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -(- 3 9 1 0 0 0 1
RNA) as rna) R RN RNA RNA) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 ), 2 9 1 0 0 0 1
and RLRs and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ./ 2 9 1 0 0 0 1
7 and 7 7 7 7 7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 1 0 - 1 9 1 0 0 0 1
the production the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 --,- 4 9 1 0 0 0 1
tively. 91-93 tively. t ti tiv tive BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 .-,,- 5 9 1 0 0 0 1
response is response r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -- 2 9 1 0 0 0 1
different mechanisms. different d di dif diff BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 . 1 8 1 0 0 0 1
production of production p pr pro prod BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 4 - 1 8 1 0 0 0 1
COVID-19, which covid-19, C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 4 -, 2 8 1 0 0 0 1
promotes paradoxical promotes p pr pro prom BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 ., 2 8 1 0 0 0 1
from the from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 ,- 2 7 1 0 0 0 1
unfortunate event unfortunate u un unf unfo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 8 1 0 0 0 1
combating the combating c co com comb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 -- 2 8 1 0 0 0 1
an inflammatory an a an an an BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 4 . 1 3 1 0 0 0 1
In SARS-CoV-2 in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 1 4 --, 3 8 1 0 0 0 1
epithelial tissue epithelial e ep epi epit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 no 0 9 1 0 0 0 1
inflammatory cytokines inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 -,-,-,-,-, 10 9 1 0 0 0 1
other chemokines. other o ot oth othe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 . 1 8 1 0 0 0 1
then recruit then t th the then BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 (,, 3 8 1 0 0 0 1
neutrophils, DCs, neutrophils, n ne neu neut BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 ,,) 3 9 1 0 0 0 1
(CD4 + (cd4 ( (C (CD (CD4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 4 () 2 9 1 0 0 0 1
sustained inflammatory sustained s su sus sust BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 -,-,-, 6 9 1 0 0 0 1
induce myelopoiesis induce i in ind indu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 8 1 0 0 0 1
aggravate lung aggravate a ag agg aggr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 (.)., 5 8 1 0 0 0 1
overproduction of overproduction o ov ove over BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 ,-,-, 5 8 1 0 0 0 1
GM-CSF, and gm-csf, G GM GM- GM-C BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 4 -,-,(..,) 9 9 1 0 0 0 1
erythro-phagocytosis (i.e., erythro-phagocytosis e er ery eryt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 -(..,),,, 9 10 1 0 0 0 1
causes perturbation causes c ca cau caus BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 , 1 8 1 0 0 0 1
resulting in resulting r re res resu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 ,,. 3 9 1 0 0 0 1
events together events e ev eve even BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 4 ,, 2 8 1 0 0 0 1
(Fig. 4). (fig. ( (F (Fi (Fig BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 (.)., 5 9 1 0 0 0 1
capable of capable c ca cap capa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 - 1 9 1 0 0 0 1
to an to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 ., 2 9 1 0 0 0 1
produce regulatory produce p pr pro prod BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 -- 2 9 1 0 0 0 1
to antagonize to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 .,, 3 8 1 0 0 0 1
aggressive inflammatory aggressive a ag agg aggr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 8 1 0 0 0 1
by the by b by by by BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 '. 2 6 1 0 0 0 1
Although the although A Al Alt Alth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 8 1 0 0 0 1
COVID-CS has covid-cs C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 4 - 1 7 1 0 0 0 1
development of development d de dev deve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 4 , 1 8 1 0 0 0 1
guidelines are guidelines g gu gui guid BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 . 1 9 1 0 0 0 1
Fig. 4 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 9 .-.--, 6 9 1 0 0 0 1
release of release r re rel rele BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 (..,-,-,-,). 12 9 1 0 0 0 1
recruit innate recruit r re rec recr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 (,,,,)( 7 9 1 0 0 0 1
CD8 + cd8 C CD CD8 CD8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 9 ), 2 9 1 0 0 0 1
circulating cytokines circulating c ci cir circ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 ., 2 9 1 0 0 0 1
activation (i.e., activation a ac act acti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 (..,)-(..,),, 13 10 1 0 0 0 1
capillary leak capillary c ca cap capi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 ,,.,,. 6 8 1 0 0 0 1
lymphohistiocytosis, MAS lymphohistiocytosis, l ly lym lymp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 9 ,,, 3 8 1 0 0 0 1
coagulation coagulation coagulation c co coa coag BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 9 no 0 0 1 0 0 0 1
The signal the T Th The The BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 11 - 1 10 1 1 0 0 0
Yang et yang Y Ya Yan Yang BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 2 11 . 1 1 1 1 0 0 0
5 5 5 5 5 5 5 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 2 11 no 0 10 1 1 0 0 0
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 11 (): 3 10 0 1 1 0 0
HScore, MS hscore, H HS HSc HSco BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 ,,-,, 5 8 0 0 0 0 1
Common Terminology common C Co Com Comm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 7 0 0 0 0 1
beneficial to beneficial b be ben bene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 -. 2 8 0 0 0 0 1
et al. et e et et et BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 .-. 3 10 0 0 0 0 1
criteria comprise criteria c cr cri crit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 :()./, 6 8 0 0 0 0 1
lymphocytes <10.2%, lymphocytes l ly lym lymp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 .,./; 5 9 0 0 0 0 1
(2) alanine (2) ( (2 (2) (2) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 0 ()/, 4 9 0 0 0 0 1
>87 IU/L, >87 > >8 >87 >87 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 0 /,-/,/, 7 9 0 0 0 0 1
troponin I troponin t tr tro trop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 ./;()./, 8 9 0 0 0 0 1
>106 mmol/L, >106 > >1 >10 >106 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 0 /,./,: 6 8 0 0 0 0 1
creatinine ratio creatinine c cr cre crea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 .,/ 3 8 0 0 0 0 1
C-reactive protein c-reactive C C- C-r C-re BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 -()./ 5 9 0 0 0 0 1
of ongoing of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 ., 2 9 0 0 0 0 1
proposed that proposed p pr pro prop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 9 0 0 0 0 1
oxygen saturation oxygen o ox oxy oxyg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 (/), 4 10 0 0 0 0 1
CRP, ferritin, crp, C CR CRP CRP, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 ,,/,/ 5 9 0 0 0 0 1
ratio may ratio r ra rat rati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 -. 2 9 0 0 0 0 1
et al. et e et et et BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 .- 2 9 0 0 0 0 1
tion using tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 no 0 9 0 0 0 0 1
in all in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 2 0 --. 3 9 0 0 0 0 1
the requirement the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 , 1 8 0 0 0 0 1
provide constructive provide p pr pro prov BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 9 0 0 0 0 1
recognized guidelines recognized r re rec reco BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 -. 2 5 0 0 0 0 1
COVID-CS is covid-cs C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 - 1 8 0 0 0 0 1
caused by caused c ca cau caus BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 , 1 8 0 0 0 0 1
hyperactivation, to hyperactivation, h hy hyp hype BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 ,. 2 8 0 0 0 0 1
precise therapeutic precise p pr pre prec BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 9 0 0 0 0 1
to effectively to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 -., 3 8 0 0 0 0 1
strategy is strategy s st str stra BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 8 0 0 0 0 1
specifically or specifically s sp spe spec BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 9 0 0 0 0 1
or related or o or or or BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 7 0 0 0 0 1
immunoregulatory system. immunoregulatory i im imm immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 ., 2 8 0 0 0 0 1
key cytokines key k ke key key BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 2 0 no 0 8 0 0 0 0 1
COVID-CS (Fig. covid-cs C CO COV COVI BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 -(.). 5 2 0 0 0 0 1
IL-6/JAK/STAT signaling. il-6/jak/stat I IL IL- IL-6 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 4 -//., 5 8 0 0 0 0 1
including 150 including i in inc incl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 , 1 8 0 0 0 0 1
elevated levels elevated e el ele elev BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 --. 3 9 0 0 0 0 1
Germany showed germany G Ge Ger Germ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 4 -/ 2 8 0 0 0 0 1
>97 mg/L >97 > >9 >97 >97 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 4 / 1 9 0 0 0 0 1
predict respiratory predict p pr pre pred BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 ., 2 10 0 0 0 0 1
shown the shown s sh sho show BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 - 1 9 0 0 0 0 1
with severe with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 -.,, 4 4 0 0 0 0 1
IL-6, first il-6, I IL IL- IL-6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 4 -,,,, 5 8 0 0 0 0 1
serves as serves s se ser serv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 / 1 9 0 0 0 0 1
context of context c co con cont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 . 1 9 0 0 0 0 1
IL-6-JAK-STAT3 axis il-6-jak-stat3 I IL IL- IL-6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 4 ---- 4 9 0 0 0 0 1
19, 107,108 19, 1 19 19, 19, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 4 ,, 2 9 0 0 0 0 1
different subsets different d di dif diff BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 - 1 8 0 0 0 0 1
healthy controls. healthy h he hea heal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 .-- 3 9 0 0 0 0 1
cis-signaling and cis-signaling c ci cis cis- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 --- 3 9 0 0 0 0 1
downstream JAK/STAT3 downstream d do dow down BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 /- 2 8 0 0 0 0 1
(mIL-6R) and (mil-6r) ( (m (mI (mIL BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 4 (-)-(-),.- 10 10 0 0 0 0 1
signaling, IL-6 signaling, s si sig sign BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 ,-- 3 9 0 0 0 0 1
immune cells, immune i im imm immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 ,-/-/ 5 8 0 0 0 0 1
downstream JAK/STAT3, downstream d do dow down BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 /,/,. 5 8 0 0 0 0 1
exerts pleiotropic exerts e ex exe exer BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 , 1 9 0 0 0 0 1
as promoted as a as as as BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 -(),, 5 9 0 0 0 0 1
and B and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 ;; 2 8 0 0 0 0 1
development of development d de dev deve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 2 4 .,,, 4 9 0 0 0 0 1
secretion of secretion s se sec secr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 -.-, 4 9 0 0 0 0 1
circulating IL-6 circulating c ci cir circ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 --, 3 9 0 0 0 0 1
the gp130 the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 . 1 9 0 0 0 0 1
resultant activation resultant r re res resu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 - 1 9 0 0 0 0 1
absent expression absent a ab abs abse BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 -, 2 9 0 0 0 0 1
smooth muscle smooth s sm smo smoo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 (). 3 9 0 0 0 0 1
IL-6-IL-6R-JAK-STAT3 pathway il-6-il-6r-jak-stat3 I IL IL- IL-6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 4 ----- 5 9 0 0 0 0 1
mediators, such mediators, m me med medi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 ,-,-,-, 7 10 0 0 0 0 1
growth factor growth g gr gro grow BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 (),- 4 9 0 0 0 0 1
Fig. 5 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 9 .-.---(),, 10 10 1 0 0 0 1
8; RIG-I-like 8; 8 8; 8; 8; BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 9 ;--,-;-,, 9 9 1 0 0 0 1
apoptotic or apoptotic a ap apo apop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 9 ./- 3 9 1 0 0 0 1
paradoxical hyperinflammation; paradoxical p pa par para BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 ;--; 4 9 1 0 0 0 1
activated to activated a ac act acti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 --.--,-,-,- 11 9 1 0 0 0 1
the JAK-STAT the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 --- 3 9 1 0 0 0 1
genes, forming genes, g ge gen gene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 9 ,.,- 4 9 1 0 0 0 1
antagonize immune antagonize a an ant anta BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 no 0 2 1 0 0 0 1
The signal the T Th The The BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 11 - 1 10 1 1 0 0 0
Yang et yang Y Ya Yan Yang BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 2 11 . 1 1 1 1 0 0 0
6 6 6 6 6 6 6 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 2 11 no 0 10 1 1 0 0 0
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 11 (): 3 10 0 1 1 0 0
expressed on expressed e ex exp expr BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 . 1 9 0 0 0 0 1
MCP-1 can mcp-1 M MC MCP MCP- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 0 -, 2 9 0 0 0 0 1
of adhesion of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 ,, 2 9 0 0 0 0 1
VSMCs, 117 vsmcs, V VS VSM VSMC BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 , 1 9 0 0 0 0 1
symptoms observed symptoms s sy sym symp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 -., 3 8 0 0 0 0 1
decreased E-cadherin decreased d de dec decr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 - 1 8 0 0 0 0 1
leakage and leakage l le lea leak BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 7 0 0 0 0 1
pulmonary dysfunction pulmonary p pu pul pulm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 -.,- 4 7 0 0 0 0 1
promote the promote p pr pro prom BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 - 1 8 0 0 0 0 1
CRP, hepcidin, crp, C CR CRP CRP, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 ,,,,, 5 8 0 0 0 0 1
ferritin in ferritin f fe fer ferr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 .,,- 4 10 0 0 0 0 1
immune cell immune i im imm immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 . 1 8 0 0 0 0 1
Evidence has evidence E Ev Evi Evid BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 0 - 1 8 0 0 0 0 1
induced by induced i in ind indu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 . 1 8 0 0 0 0 1
mechanism is mechanism m me mec mech BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 8 0 0 0 0 1
(AT1) receptor (at1) ( (A (AT (AT1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 0 ()/- 4 9 0 0 0 0 1
6 production. 6 6 6 6 6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 2 0 .,, 3 9 0 0 0 0 1
SARS-CoV may sars-cov S SA SAR SARS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 - 1 7 0 0 0 0 1
downregulating ACE2, downregulating d do dow down BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 ,, 2 8 0 0 0 0 1
possibility that possibility p po pos poss BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 --- 3 8 0 0 0 0 1
angiotensin II/AT1 angiotensin a an ang angi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 ///,- 5 8 0 0 0 0 1
inflammatory feedback inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 -// 3 9 0 0 0 0 1
signatures of signatures s si sig sign BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 -,-. 4 6 0 0 0 0 1
IFN-γ/JAK/STAT signaling. ifn-γ/jak/stat I IF IFN IFN- BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 1 -//.-,- 7 8 0 0 0 0 1
phages, T phages, p ph pha phag BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 1 ,,, 3 8 0 0 0 0 1
processes such processes p pr pro proc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 . 1 8 0 0 0 0 1
macrophage, NK, macrophage, m ma mac macr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 1 ,,, 3 9 0 0 0 0 1
effect on effect e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 no 0 9 0 0 0 0 1
through the through t th thr thro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 / 1 8 0 0 0 0 1
STAT1-IFN-γ-activated site stat1-ifn-γ-activated S ST STA STAT BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 1 ---().- 7 7 0 0 0 0 1
Evidence has evidence E Ev Evi Evid BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 1 -- 2 9 0 0 0 0 1
related disorders, related r re rel rela BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 , 1 9 0 0 0 0 1
primary HLH, primary p pr pri prim BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 , 1 9 0 0 0 0 1
to impaired to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 ., 2 10 0 0 0 0 1
activation and activation a ac act acti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 -, 2 9 0 0 0 0 1
IFN-γ levels ifn-γ I IF IFN IFN- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 1 - 1 8 0 0 0 0 1
immunopathology because immunopathology i im imm immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 1 . 1 8 0 0 0 0 1
IFN-γ plays ifn-γ I IF IFN IFN- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 1 --;, 4 9 0 0 0 0 1
considering its considering c co con cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 , 1 9 0 0 0 0 1
speculate that speculate s sp spe spec BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 -. 2 8 0 0 0 0 1
Numerous studies numerous N Nu Num Nume BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 1 - 1 8 0 0 0 0 1
patients with patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 -.,,, 5 9 0 0 0 0 1
IFN-γ produced ifn-γ I IF IFN IFN- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 1 - 1 9 0 0 0 0 1
severe disease severe s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 , 1 8 0 0 0 0 1
could be could c co cou coul BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 no 0 8 0 0 0 0 1
exhaustion of exhaustion e ex exh exha BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 -,-. 4 9 0 0 0 0 1
Therefore, this therefore, T Th The Ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 1 ,- 2 9 0 0 0 0 1
COVID-19 are covid-19 C CO COV COVI BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 1 -,. 3 8 0 0 0 0 1
TNFα/NF-κB signaling. tnfα/nf-κb T TN TNF TNFα BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 4 /-.-- 5 8 0 0 0 0 1
cytokine and cytokine c cy cyt cyto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 ,- 2 8 0 0 0 0 1
immune diseases, immune i im imm immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 ,, 2 7 0 0 0 0 1
monocytes, macrophages, monocytes, m mo mon mono BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 ,,.,- 5 8 0 0 0 0 1
evolutionarily conserved evolutionarily e ev evo evol BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 ,,- 3 8 0 0 0 0 1
cially in cially c ci cia cial BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 no 0 9 0 0 0 0 1
in inflammation. in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 2 4 .,-, 4 10 0 0 0 0 1
activate the activate a ac act acti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 - 1 8 0 0 0 0 1
several pro-inflammatory several s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 - 1 8 0 0 0 0 1
receptor TNFR1 receptor r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 .-, 3 9 0 0 0 0 1
NF-κB can nf-κb N NF NF- NF-κ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 4 -, 2 8 0 0 0 0 1
such as such s su suc such BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 ().,/- 6 9 0 0 0 0 1
κB signaling κb κ κB κB κB BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 no 0 9 0 0 0 0 1
and immune and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 no 0 8 0 0 0 0 1
epithelial cells epithelial e ep epi epit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 - 1 9 0 0 0 0 1
augmenting systemic augmenting a au aug augm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 . 1 4 0 0 0 0 1
Previous studies previous P Pr Pre Prev BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 4 no 0 8 0 0 0 0 1
poor prognosis poor p po poo poor BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 -,- 3 9 0 0 0 0 1
of NF-κB of o of of of BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 --- 3 7 0 0 0 0 1
mice. 146 mice. m mi mic mice BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 .,-,, 5 9 0 0 0 0 1
entirely clear. entirely e en ent enti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 . 1 9 0 0 0 0 1
TNFα in tnfα T TN TNF TNFα BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 5 -.,,,, 6 9 0 0 0 0 1
from Wuhan, from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 ,, 2 8 0 0 0 0 1
showed that showed s sh sho show BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 no 0 8 0 0 0 0 1
with T with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 -., 3 10 0 0 0 0 1
from Chongqing, from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 ,, 2 8 0 0 0 0 1
showed that showed s sh sho show BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 no 0 9 0 0 0 0 1
COVID-19 patients covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 5 -(/)., 6 9 0 0 0 0 1
required to required r re req requ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 -. 2 8 0 0 0 0 1
Although a although A Al Alt Alth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 5 -- 2 8 0 0 0 0 1
κB pathway κb κ κB κB κB BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 -, 2 8 0 0 0 0 1
should be should s sh sho shou BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 :(), 4 8 0 0 0 0 1
the roles the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 -;()- 5 9 0 0 0 0 1
nonspecifically may nonspecifically n no non nons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 no 0 9 0 0 0 0 1
in cellular in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 2 5 , 1 9 0 0 0 0 1
innate immunity. innate i in inn inna BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 . 1 2 0 0 0 0 1
NLRP3/IL-1β signaling. nlrp3/il-1β N NL NLR NLRP BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 7 /-.-- 5 8 0 0 0 0 1
member of member m me mem memb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 - 1 8 0 0 0 0 1
autoinflammatory diseases autoinflammatory a au aut auto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 7 no 0 9 0 0 0 0 1
arthritis. 149-151 arthritis. a ar art arth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 .-- 3 9 0 0 0 0 1
apoptosis and apoptosis a ap apo apop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 7 no 0 8 0 0 0 0 1
migration of migration m mi mig migr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 ; 1 8 0 0 0 0 1
differentiation; expression differentiation; d di dif diff BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 ; 1 9 0 0 0 0 1
adhesion factors; adhesion a ad adh adhe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 ;- 2 9 0 0 0 0 1
feedback for feedback f fe fee feed BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 .,, 3 8 0 0 0 0 1
protein forms protein p pr pro prot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 -- 2 8 0 0 0 0 1
protein containing protein p pr pro prot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 () 2 8 0 0 0 0 1
cysteinyl aspartate-specific cysteinyl c cy cys cyst BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 7 --(-), 6 9 0 0 0 0 1
NLRP3 inflammasome, nlrp3 N NL NLR NLRP BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 7 ,- 2 9 0 0 0 0 1
mature form mature m ma mat matu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 -.,- 4 10 0 0 0 0 1
in activating in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 2 7 , 1 9 0 0 0 0 1
postulated that postulated p po pos post BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 -- 2 8 0 0 0 0 1
COVID-CS. COVID-CS. covid-cs. C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 7 -. 2 1 0 0 0 0 1
Multiple indicators multiple M Mu Mul Mult BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 7 no 0 9 0 0 0 0 1
IL-1β may il-1β I IL IL- IL-1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 7 -.- 3 9 0 0 0 0 1
et al. et e et et et BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 7 . 1 8 0 0 0 0 1
including IL-1β including i in inc incl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 --, 3 8 0 0 0 0 1
were also were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 ,,. 3 8 0 0 0 0 1
Consistently, Huang consistently, C Co Con Cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 7 ,. 2 9 0 0 0 0 1
of IL-1β of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 --., 4 9 0 0 0 0 1
that NLRP3 that t th tha that BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 - 1 9 0 0 0 0 1
such as such s su suc such BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 ,, 2 8 0 0 0 0 1
genome of genome g ge gen geno BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 7 --, 3 9 0 0 0 0 1
of direct of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 --. 3 8 0 0 0 0 1
potential roles potential p po pot pote BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 - 1 8 0 0 0 0 1
been discussed been b be bee been BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 ., 2 9 0 0 0 0 1
(ROS) was (ros) ( (R (RO (ROS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 7 ().-, 5 9 0 0 0 0 1
it was it i it it it BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 no 0 9 0 0 0 0 1
inflammation infiltration inflammation i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 - 1 9 0 0 0 0 1
activation and activation a ac act acti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 -, 2 8 0 0 0 0 1
inflammation in inflammation i in inf infl BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 -. 2 3 0 0 0 0 1
IL-2/IL-2R/JAK/STAT5 signaling. il-2/il-2r/jak/stat5 I IL IL- IL-2 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 10 -/-//.- 7 9 0 0 0 0 1
T cells t T T T T BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 2 10 no 0 9 0 0 0 0 1
of CD4 of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 10 ,,,- 4 7 0 0 0 0 1
2R-JAK-STAT5 signaling 2r-jak-stat5 2 2R 2R- 2R-J BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 10 --.,-- 6 8 0 0 0 0 1
immune responses immune i im imm immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 10 -, 2 8 0 0 0 0 1
deficiency accounts deficiency d de def defi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 10 - 1 7 0 0 0 0 1
eases. 172 eases. e ea eas ease BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 10 . 1 1 0 0 0 0 1
Elevated levels elevated E El Ele Elev BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 10 - 1 8 0 0 0 0 1
coronavirus infections. coronavirus c co cor coro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 10 ., 2 9 0 0 0 0 1
the concentrations the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 10 --- 3 8 0 0 0 0 1
patients, especially patients, p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 10 ,.,,,, 6 10 0 0 0 0 1
a clinical a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 2 10 -,, 3 9 0 0 0 0 1
reported a reported r re rep repo BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 10 . 1 9 0 0 0 0 1
The signal the T Th The The BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 11 - 1 10 0 1 0 0 0
Yang et yang Y Ya Yan Yang BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 3 11 . 1 1 0 1 0 0 0
7 7 7 7 7 7 7 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 11 no 0 10 0 1 0 0 0
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 11 (): 3 10 0 1 1 0 0
with severe with w wi wit with BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 (),() 5 10 0 0 0 0 1
had remarkably had h ha had had BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 -.,- 4 9 0 0 0 0 1
levels were levels l le lev leve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 9 0 0 0 0 1
severe and severe s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 () 2 9 0 0 0 0 1
or healthy or o or or or BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 ., 2 9 0 0 0 0 1
were significantly were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 8 0 0 0 0 1
controls. Considering controls. c co con cont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 .- 2 9 0 0 0 0 1
and differentiation and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 , 1 9 0 0 0 0 1
presence of presence p pr pre pres BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 - 1 8 0 0 0 0 1
attributed to attributed a at att attr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 -,-,,. 6 10 0 0 0 0 1
additionally, CD4 additionally, a ad add addi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 ,-, 3 9 0 0 0 0 1
reduced numbers reduced r re red redu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 8 0 0 0 0 1
COVID-19 infection covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 0 -- 2 9 0 0 0 0 1
level and level l le lev leve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 -. 2 9 0 0 0 0 1
are required are a ar are are BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 . 1 8 0 0 0 0 1
IL-7/IL-7R signaling. il-7/il-7r I IL IL- IL-7 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 1 -/-.-/- 7 10 0 0 0 0 1
homeostasis and homeostasis h ho hom home BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 1 ,, 2 9 0 0 0 0 1
T cells t T T T T BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 3 1 ,,,.- 5 9 0 0 0 0 1
179 It 179 1 17 179 179 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 1 no 0 9 0 0 0 0 1
of innate of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 (),, 4 9 0 0 0 0 1
and barrier and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 . 1 3 0 0 0 0 1
Recent reports recent R Re Rec Rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 1 -- 2 8 0 0 0 0 1
patients, and patients, p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 ,- 2 8 0 0 0 0 1
ity. 9,13,147 ity. i it ity ity. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 1 .,,,- 5 9 0 0 0 0 1
COVID-19 is covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 1 -. 2 9 0 0 0 0 1
IL-7, we il-7, I IL IL- IL-7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 1 -,- 3 9 0 0 0 0 1
mechanism in mechanism m me mec mech BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 no 0 8 0 0 0 0 1
severe/critical COVID-19. severe/critical s se sev seve BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 1 /-. 3 3 0 0 0 0 1
IL-10 signaling. il-10 I IL IL- IL-1 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 2 -.- 3 9 0 0 0 0 1
produced by produced p pr pro prod BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 ,, 2 9 0 0 0 0 1
CD8 + cd8 C CD CD8 CD8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 2 ,,,,, 5 9 0 0 0 0 1
through the through t th thr thro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 -//.-- 6 7 0 0 0 0 1
inflammatory functions inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 2 - 1 8 0 0 0 0 1
related functions related r re rel rela BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 no 0 8 0 0 0 0 1
paracrine manner paracrine p pa par para BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 2 . 1 9 0 0 0 0 1
addition, IL-10 addition, a ad add addi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 ,- 2 8 0 0 0 0 1
functions of functions f fu fun func BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 ,,. 3 6 0 0 0 0 1
A clinical a A A A A BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 3 2 - 1 9 0 0 0 0 1
from Wuhan, from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 ,,- 3 9 0 0 0 0 1
with a with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 () 2 9 0 0 0 0 1
of patients of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 ()(); 5 9 0 0 0 0 1
further, the further, f fu fur furt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 ,- 2 8 0 0 0 0 1
concentrations of concentrations c co con conc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 ,- 2 9 0 0 0 0 1
an indicator an a an an an BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 3 2 .. 2 10 0 0 0 0 1
significantly high significantly s si sig sign BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 -- 2 8 0 0 0 0 1
admitted to admitted a ad adm admi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 ., 2 9 0 0 0 0 1
a follow-up a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 3 2 --( 3 9 0 0 0 0 1
and 18 and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 ), 2 8 0 0 0 0 1
the production the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 - 1 8 0 0 0 0 1
correlated with correlated c co cor corr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 . 1 5 0 0 0 0 1
It can it I It It It BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 2 - 1 9 0 0 0 0 1
negative feedback negative n ne neg nega BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 no 0 8 0 0 0 0 1
the immune the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 ., 2 8 0 0 0 0 1
secretion of secretion s se sec secr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 - 1 8 0 0 0 0 1
inflammatory cells inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 2 -,-- 4 9 0 0 0 0 1
rather inadequate. rather r ra rat rath BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 .,- 3 8 0 0 0 0 1
recommended to recommended r re rec reco BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 -., 3 8 0 0 0 0 1
report showed report r re rep repo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 - 1 8 0 0 0 0 1
phase of phase p ph pha phas BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 --. 3 8 0 0 0 0 1
The authors the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 2 - 1 8 0 0 0 0 1
antibody in antibody a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 2 -- 2 9 0 0 0 0 1
promising therapeutic promising p pr pro prom BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 . 1 5 0 0 0 0 1
IL-12 signaling. il-12 I IL IL- IL-1 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 5 -.-,,, 6 10 0 1 0 0 1
and B and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 , 1 10 0 1 0 0 1
factor that factor f fa fac fact BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 ; 1 10 0 1 0 0 1
improve the improve i im imp impr BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 ;- 2 9 0 0 0 0 1
γ in γ γ γ γ γ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 3 6 ,,, 3 9 0 0 0 0 1
feedback mechanism. feedback f fe fee feed BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 .,,- 4 10 0 0 0 0 1
CS by cs C CS CS CS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 6 . 1 8 0 0 0 0 1
Existing studies existing E Ex Exi Exis BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 6 no 0 9 0 0 0 0 1
production of production p pr pro prod BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 3 6 -.- 3 9 0 0 0 0 1
instance, during instance, i in ins inst BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 ,,- 3 9 0 0 0 0 1
produced to produced p pr pro prod BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 -, 2 9 0 0 0 0 1
thereby inhibiting thereby t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 . 1 10 0 0 0 0 1
elevated plasma elevated e el ele elev BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 -- 2 8 0 0 0 0 1
CoV. 192 cov. C Co CoV CoV. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 6 .,. 3 9 0 0 0 0 1
levels of levels l le lev leve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 -- 2 8 0 0 0 0 1
patients and patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 .,- 3 10 0 0 0 0 1
sized samples sized s si siz size BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 no 0 9 0 0 0 0 1
and functions and a an and and BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 --,-. 5 8 0 0 0 0 1
IL-17 signaling. il-17 I IL IL- IL-1 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 7 -.-(-), 7 9 0 0 0 0 1
CD8 + cd8 C CD CD8 CD8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 7 ,()- 4 8 0 0 0 0 1
inflammatory processes inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 7 .-- 3 9 0 0 0 0 1
ing IL-17 ing i in ing ing BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 3 7 - 1 8 0 0 0 0 1
burden of burden b bu bur burd BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 3 7 no 0 8 0 0 0 0 1
psoriatic arthritis. psoriatic p ps pso psor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 7 ., 2 10 0 0 0 0 1
cytokine vary, cytokine c cy cyt cyto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 7 , 1 9 0 0 0 0 1
detrimental pro-inflammatory detrimental d de det detr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 -, 2 8 0 0 0 0 1
type and type t ty typ type BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 (,,) 4 9 0 0 0 0 1
and its and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 . 1 4 0 0 0 0 1
Increased levels increased I In Inc Incr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 7 --- 3 9 0 0 0 0 1
or MERS-CoV-infected or o or or or BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 --.,,- 6 8 0 0 0 0 1
augment lung augment a au aug augm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 no 0 8 0 0 0 0 1
recruitment of recruitment r re rec recr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 ;- 2 8 0 0 0 0 1
inflammatory factors; inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 7 ;- 2 8 0 0 0 0 1
prevent apoptosis prevent p pr pre prev BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 - 1 8 0 0 0 0 1
injury model. injury i in inj inju BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 .,,- 4 9 0 0 0 0 1
levels were levels l le lev leve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 -, 2 9 0 0 0 0 1
a severe a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 3 7 . 1 9 0 0 0 0 1
IL-17 plays il-17 I IL IL- IL-1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 7 -- 2 9 0 0 0 0 1
tion and tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 7 - 1 9 0 0 0 0 1
recruitment of recruitment r re rec recr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 no 0 8 0 0 0 0 1
fever, matrix fever, f fe fev feve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 ,,, 3 8 0 0 0 0 1
infiltration. infiltration. infiltration. i in inf infi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 . 1 2 0 0 0 0 1
Despite multiple despite D De Des Desp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 7 - 1 9 0 0 0 0 1
an intervention an a an an an BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 3 7 -, 2 9 0 0 0 0 1
levels of levels l le lev leve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 - 1 9 0 0 0 0 1
with mild with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 -,., 4 9 0 0 0 0 1
clinical trials clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 no 0 9 0 0 0 0 1
clarification. clarification. clarification. c cl cla clar BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 . 1 2 0 0 0 0 1
GM-CSF signaling. gm-csf G GM GM- GM-C BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 10 -.-,, 5 10 0 0 0 0 1
hematopoietic, and hematopoietic, h he hem hema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 10 ,. 2 9 0 0 0 0 1
conditions, low conditions, c co con cond BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 ,- 2 9 0 0 0 0 1
of alveolar of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 - 1 9 0 0 0 0 1
tions. 203,204 tions. t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 10 .,,- 4 10 0 0 0 0 1
CSF drives csf C CS CSF CSF BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 10 no 0 9 0 0 0 0 1
the inflammatory the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 . 1 10 0 0 0 0 1
Increased levels increased I In Inc Incr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 10 -, 2 9 0 0 0 0 1
ARDS, 207 ards, A AR ARD ARDS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 10 ,.- 3 9 0 0 0 0 1
CSF levels csf C CS CSF CSF BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 10 -. 2 7 0 0 0 0 1
Given the given G Gi Giv Give BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 10 - 1 9 0 0 0 0 1
of alveolar of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 ,- 2 9 0 0 0 0 1
with early-stage with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 -- 2 9 0 0 0 0 1
enhance viral enhance e en enh enha BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 .,- 3 10 0 0 0 0 1
signaling may signaling s si sig sign BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 10 -. 2 8 0 0 0 0 1
CYTOKINE-BASED INTERVENTIONS cytokine-based C CY CYT CYTO BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 11 - 1 4 0 1 0 0 1
The current the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 11 - 1 9 0 1 0 0 1
inflammatory drugs inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 11 , 1 10 0 1 0 0 1
chloroquine, and chloroquine, c ch chl chlo BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 11 ,.,, 4 9 0 1 0 0 1
The signal the T Th The The BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 11 - 1 10 0 1 0 0 0
Yang et yang Y Ya Yan Yang BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 3 11 . 1 1 0 1 0 0 0
8 8 8 8 8 8 8 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 11 no 0 10 0 1 0 0 0
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 11 (): 3 10 0 1 1 0 0
recombinant cytokines; recombinant r re rec reco BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 ;-,-, 5 9 1 0 0 0 1
TNF-α, and tnf-α, T TN TNF TNF- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 -,-; 4 8 1 0 0 0 1
available or available a av ava avai BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 . 1 9 1 0 0 0 1
section, we section, s se sec sect BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 , 1 10 1 0 0 0 1
potentially applied potentially p po pot pote BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 (.). 4 6 1 0 0 0 1
IFN-I IFN-I ifn-i I IF IFN IFN- BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 - 1 0 0 0 0 0 1
Administration of administration A Ad Adm Admi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 3 0 - 1 9 0 0 0 0 1
treatment of treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 --., 4 9 0 0 0 0 1
be relatively be b be be be BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 , 1 9 0 0 0 0 1
although human although a al alt alth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 . 1 6 0 0 0 0 1
The research the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 0 , 1 8 0 0 0 0 1
USA, showed usa, U US USA USA, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 ,-- 3 7 0 0 0 0 1
effectively reduced effectively e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 9 0 0 0 0 1
Vero cells vero V Ve Ver Vero BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 -, 2 9 0 0 0 0 1
SARS-CoV-2 is sars-cov-2 S SA SAR SARS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 0 ----. 5 10 0 0 0 0 1
uncontrolled, exploratory uncontrolled, u un unc unco BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 ,, 2 8 0 0 0 0 1
Wuhan, China, wuhan, W Wu Wuh Wuha BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 ,,- 3 9 0 0 0 0 1
combination with combination c co com comb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 9 0 0 0 0 1
as well as a as as as BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 -- 2 9 0 0 0 0 1
19 patients. 19 1 19 19 19 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 0 .,,, 4 9 0 0 0 0 1
clinical trial clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 9 0 0 0 0 1
that compared that t th tha that BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 (/),- 5 9 0 0 0 0 1
19 patients 19 1 19 19 19 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 0 (-/ 3 9 0 0 0 0 1
ribavirin) exhibited ribavirin) r ri rib riba BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 ); 2 9 0 0 0 0 1
virus shedding virus v vi vir viru BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 ; 1 8 0 0 0 0 1
conditions (NCT04276688). conditions c co con cond BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 (). 3 9 0 0 0 0 1
healthy medical healthy h he hea heal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 9 0 0 0 0 1
Shiyan City, shiyan S Sh Shi Shiy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 ,,, 3 8 0 0 0 0 1
COVID-19 was covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 0 --() 4 9 0 0 0 0 1
high-risk group high-risk h hi hig high BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 -()- 4 9 0 0 0 0 1
nose drops nose n no nos nose BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 (), 3 8 0 0 0 0 1
preventive roles preventive p pr pre prev BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 --. 3 8 0 0 0 0 1
comparing the comparing c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 - 1 8 0 0 0 0 1
lopinavir/ritonavir with lopinavir/ritonavir l lo lop lopi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 //;- 4 9 0 0 0 0 1
quine; and quine; q qu qui quin BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 ;-(). 5 9 0 0 0 0 1
Collectively, these collectively, C Co Col Coll BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 5 ,-- 3 9 1 0 0 0 1
CoV-2 infection cov-2 C Co CoV CoV- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 5 --. 3 5 1 0 0 0 1
Another type another A An Ano Anot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 5 --- 3 8 1 0 0 0 1
benefit in benefit b be ben bene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 -.. 3 9 1 0 0 0 1
anti-viral effect anti-viral a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 ----- 5 9 1 0 0 0 1
human airway human h hu hum huma BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 . 1 8 1 0 0 0 1
have determined have h ha hav have BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 - 1 9 1 0 0 0 1
I/III response i/iii I I/ I/I I/II BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 5 /-- 3 9 1 0 0 0 1
cells, 219-221 cells, c ce cel cell BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 ,- 2 8 1 0 0 0 1
response in response r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 -., 3 10 1 0 0 0 1
the clinical the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 -(, 3 9 1 0 0 0 1
NCT04331899). NCT04331899). nct04331899). N NC NCT NCT0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 3 5 ). 2 2 1 0 0 0 1
IL-7 IL-7 il-7 I IL IL- IL-7 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 7 - 1 0 0 0 0 0 1
The supportive the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 7 - 1 9 0 0 0 0 1
provides clinical provides p pr pro prov BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 no 0 8 0 0 0 0 1
lymphocytes in lymphocytes l ly lym lymp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 7 /-. 3 5 0 0 0 0 1
A case a A A A A BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 3 7 ,, 2 9 0 0 0 0 1
a period a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 3 7 -(-) 4 9 0 0 0 0 1
improved the improved i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 -- 2 8 0 0 0 0 1
severe COVID-19, severe s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 -, 2 8 0 0 0 0 1
and mHLA-DR and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 -.,- 4 9 0 0 0 0 1
late, on late, l la lat late BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 ,., 3 8 0 0 0 0 1
proposed that proposed p pr pro prop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 - 1 9 0 0 0 0 1
better clinical better b be bet bett BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 .. 2 10 0 0 0 0 1
Hospital, Brussels, hospital, H Ho Hos Hosp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 7 ,,, 3 9 0 0 0 0 1
the IL-7 the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 - 1 8 0 0 0 0 1
lymphocyte counts lymphocyte l ly lym lymp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 7 , 1 8 0 0 0 0 1
aggravated inflammation aggravated a ag agg aggr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 ., 2 9 0 0 0 0 1
the absence the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 no 0 8 0 0 0 0 1
lymphocytes weakens lymphocytes l ly lym lymp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 7 .- 2 8 0 0 0 0 1
center, double-blind center, c ce cen cent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 ,-- 3 9 0 0 0 0 1
evaluating whether evaluating e ev eva eval BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 ( 1 8 0 0 0 0 1
product of product p pr pro prod BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 -) 2 9 0 0 0 0 1
with severe with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 - 1 7 0 0 0 0 1
(NCT04379076). Clark (nct04379076). ( (N (NC (NCT BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 7 ().. 4 9 0 0 0 0 1
Fig. 6 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 10 .-. 3 9 1 0 0 0 1
consideration to consideration c co con cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 -,-. 4 10 1 0 0 0 1
addition, several addition, a ad add addi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 ,,,, 4 9 1 0 0 0 1
the potential the t th the the BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 -.- 3 8 1 0 0 0 1
The signal the T Th The The BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 11 - 1 10 1 1 0 0 0
Yang et yang Y Ya Yan Yang BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 4 11 . 1 1 1 1 0 0 0
9 9 9 9 9 9 9 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 11 no 0 10 1 1 0 0 0
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 11 (): 3 10 0 1 1 0 0
IL-7 in il-7 I IL IL- IL-7 BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 0 - 1 8 0 0 0 0 1
treatment for treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 -. 2 9 0 0 0 0 1
dexamethasone enhances dexamethasone d de dex dexa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 - 1 10 0 0 0 0 1
IL-7Rα, which il-7rα, I IL IL- IL-7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 0 -, 2 9 0 0 0 0 1
properties of properties p pr pro prop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 9 0 0 0 0 1
disease. 225,226 disease. d di dis dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ., 2 2 0 0 0 0 1
These studies these T Th The Thes BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 - 1 9 0 0 0 0 1
alone or alone a al alo alon BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 9 0 0 0 0 1
as early as a as as as BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 - 1 9 0 0 0 0 1
lymphopenia. lymphopenia. lymphopenia. l ly lym lymp BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 . 1 1 0 0 0 0 1
BLOCKADE OF blockade B BL BLO BLOC BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 3 0 0 0 0 1
Blockade of blockade B Bl Blo Bloc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 - 1 2 0 0 0 0 1
As mentioned as A As As As BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 ,- 2 8 0 0 0 0 1
COVID-CS. Currently, covid-cs. C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 0 -.,- 4 9 0 0 0 0 1
as IL-6 as a as as as BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 -(,,,- 6 9 0 0 0 0 1
mab) and mab) m ma mab mab) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 )-(,,) 6 9 0 0 0 0 1
available. 227-229 available. a av ava avai BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 .- 2 2 0 0 0 0 1
A retrospective a A A A A BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 4 0 ,, 2 8 0 0 0 0 1
COVID-19 patients covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 0 - 1 9 0 0 0 0 1
days of days d da day days BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 8 0 0 0 0 1
outcomes in outcomes o ou out outc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 , 1 8 0 0 0 0 1
requirements, serum requirements, r re req requ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ,,, 3 8 0 0 0 0 1
well as well w we wel well BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 . 1 9 0 0 0 0 1
multicenter cohort multicenter m mu mul mult BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 - 1 8 0 0 0 0 1
the ICU the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 9 0 0 0 0 1
risk of risk r ri ris risk BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 7 0 0 0 0 1
tocilizumab treatment tocilizumab t to toc toci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 no 0 8 0 0 0 0 1
those who those t th tho thos BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 . 1 9 0 0 0 0 1
addition, numerous addition, a ad add addi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 , 1 8 0 0 0 0 1
tocilizumab for tocilizumab t to toc toci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 -- 2 7 0 0 0 0 1
lished, 106,232-247 lished, l li lis lish BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 ,,- 3 9 0 0 0 0 1
registered in registered r re reg regi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 .. 2 4 0 0 0 0 1
An open-label an A An An An BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 4 0 - 1 9 0 0 0 0 1
COVID-19 showed covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 0 --, 3 8 0 0 0 0 1
treatment (n treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 () 2 8 0 0 0 0 1
with mild with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 (). 3 8 0 0 0 0 1
retrospective, single-center, retrospective, r re ret retr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ,-, 3 9 0 0 0 0 1
COVID-19 patients covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 0 - 1 8 0 0 0 0 1
clinical symptoms clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 8 0 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 ()., 4 10 0 0 0 0 1
registered in registered r re reg regi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 .-. 3 8 0 0 0 0 1
A randomized, a A A A A BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 4 0 ,,- 3 8 0 0 0 0 1
tion of tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 - 1 8 0 0 0 0 1
completed, but completed, c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 , 1 7 0 0 0 0 1
(NCT04397562). (NCT04397562). (nct04397562). ( (N (NC (NCT BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 0 (). 3 2 0 0 0 0 1
An observational, an A An An An BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 4 0 , 1 8 0 0 0 0 1
30 patients 30 3 30 30 30 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 0 - 1 8 0 0 0 0 1
mortality was mortality m mo mor mort BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 9 0 0 0 0 1
plus optimal plus p pl plu plus BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 8 0 0 0 0 1
who received who w wh who who BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ; 1 8 0 0 0 0 1
receiving siltuximab receiving r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 4 0 no 0 7 0 0 0 0 1
(NCT04322188). 250 (nct04322188). ( (N (NC (NCT BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 4 0 (). 3 9 0 0 0 0 1
and safety and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 - 1 7 0 0 0 0 1
(NCT04329650, NCT04330638, (nct04329650, ( (N (NC (NCT BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 4 0 (,,). 5 5 0 0 0 0 1
In general, in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 4 0 , 1 9 0 0 0 0 1
respect to respect r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 -- 2 7 0 0 0 0 1
treatment of treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 -.-- 4 9 0 0 0 0 1
antagonists including antagonists a an ant anta BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 (,, 3 8 0 0 0 0 1
NCT04343989, NCT04363502, nct04343989, N NC NCT NCT0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 0 ,,,); 5 7 0 0 0 0 1
sirukumab (NCT04380961); sirukumab s si sir siru BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 ();(, 5 7 0 0 0 0 1
NCT04452474) have nct04452474) N NC NCT NCT0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 4 0 ). 2 8 0 0 0 0 1
investigate their investigate i in inv inve BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 -. 2 7 0 0 0 0 1
Blockade of blockade B Bl Blo Bloc BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 5 - 1 2 0 1 0 0 1
Considering the considering C Co Con Cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 5 -, 2 10 0 1 0 0 1
drugs targeting drugs d dr dru drug BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 -,- 3 8 0 1 0 0 1
canakinumab and canakinumab c ca can cana BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 5 -, 2 8 0 0 0 0 1
clinical benefits clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 -,. 3 8 0 0 0 0 1
A retrospective, a A A A A BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 4 5 ,-, 3 9 0 0 0 0 1
patients with patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 /- 2 8 0 0 0 0 1
treatment, patients treatment, t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 ,() 3 8 0 0 0 0 1
improved clinical improved i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 no 0 8 0 0 0 0 1
ventilation requirements ventilation v ve ven vent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 ,- 2 8 0 0 0 0 1
pared with pared p pa par pare BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 ()(,). 6 8 0 0 0 0 1
prospective, cohort prospective, p pr pro pros BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 , 1 8 0 0 0 0 1
clinical parameters clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 ;; 2 8 0 0 0 0 1
and levels and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 ,,, 3 9 0 0 0 0 1
were decreased were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 . 1 9 0 0 0 0 1
studies have studies s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 no 0 8 0 0 0 0 1
COVID-19. 253-261 covid-19. C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 5 -.- 3 10 0 0 0 0 1
ClinicalTrials.gov. ClinicalTrials.gov. clinicaltrials.gov. C Cl Cli Clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 5 .. 2 2 0 0 0 0 1
A retrospective a A A A A BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 4 5 no 0 8 0 0 0 0 1
that subcutaneous that t th tha that BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 no 0 7 0 0 0 0 1
rapidly reduced rapidly r ra rap rapi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 - 1 7 0 0 0 0 1
tion in tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 5 -()- 4 7 0 0 0 0 1
flammation but flammation f fl fla flam BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 5 . 1 7 0 0 0 0 1
Another single-center, another A An Ano Anot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 5 -, 2 7 0 0 0 0 1
non-ICU patients non-icu n no non non- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 5 --, 3 7 0 0 0 0 1
receiving standard receiving r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 4 5 no 0 7 0 0 0 0 1
subcutaneous canakinumab. subcutaneous s su sub subc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 5 .- 2 7 0 0 0 0 1
numab treatment numab n nu num numa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 5 / 1 8 0 0 0 0 1
and reduced and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 . 1 7 0 0 0 0 1
suggest that suggest s su sug sugg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 no 0 7 0 0 0 0 1
potentials in potentials p po pot pote BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 --. 3 8 0 0 0 0 1
Several other several S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 5 no 0 8 0 0 0 0 1
canakinumab in canakinumab c ca can cana BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 5 -,- 3 8 0 0 0 0 1
currently registered currently c cu cur curr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 .(, 3 7 0 0 0 0 1
NCT04476706, NCT04362813, nct04476706, N NC NCT NCT0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 5 ,,,, 4 6 0 0 0 0 1
NCT04278404). NCT04278404). nct04278404). N NC NCT NCT0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 4 5 ). 2 1 0 0 0 0 1
Blockade of blockade B Bl Blo Bloc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 - 1 2 0 0 0 0 1
Emapalumab, a emapalumab, E Em Ema Emap BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 8 ,-, 3 8 0 0 0 0 1
approved to approved a ap app appr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 8 , 1 9 0 0 0 0 1
levels of levels l le lev leve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 8 -.- 3 9 0 0 0 0 1
mentioned above, mentioned m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 8 , 1 8 0 0 0 0 1
of COVID-CS. of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 8 -. 2 1 0 0 0 0 1
A randomized, a A A A A BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 4 8 ,, 2 9 0 0 0 0 1
to investigate to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 8 - 1 9 0 0 0 0 1
tion with tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 8 no 0 8 0 0 0 0 1
respiratory conditions respiratory r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 8 ()., 4 9 0 0 0 0 1
now terminated now n no now now BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 8 . 1 8 0 0 0 0 1
Therefore, other therefore, T Th The Ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 ,, 2 10 0 0 0 0 1
required to required r re req requ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 8 . 1 4 0 0 0 0 1
Blockade of blockade B Bl Blo Bloc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 9 no 0 2 0 0 0 0 1
Recent studies recent R Re Rec Rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 9 no 0 9 0 0 0 0 1
to support to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 9 no 0 8 0 0 0 0 1
cytokine release cytokine c cy cyt cyto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 9 -.- 3 8 0 0 0 0 1
Etanercept is etanercept E Et Eta Etan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 9 no 0 8 0 0 0 0 1
been used been b be bee been BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 9 (), 3 9 0 0 0 0 1
systemic hyperinflammation. systemic s sy sys syst BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 9 . 1 9 0 0 0 0 1
manifestations and manifestations m ma man mani BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 9 - 1 9 0 0 0 0 1
and TEN, and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 9 ,. 2 9 0 0 0 0 1
as a as a as as as BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 9 -. 2 8 0 0 0 0 1
described that described d de des desc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 9 -- 2 8 0 0 0 0 1
etanercept treatment etanercept e et eta etan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 9 -- 2 8 0 0 0 0 1
infection presented infection i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 9 no 0 9 0 0 0 0 1
deterioration and deterioration d de det dete BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 9 -. 2 8 0 0 0 0 1
Infliximab is infliximab I In Inf Infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 9 . 1 9 0 0 0 0 1
four clinical four f fo fou four BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 9 no 0 10 0 0 0 0 1
in COVID-19 in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 4 9 -(,, 4 8 0 0 0 0 1
NCT04593940, NCT04344249). nct04593940, N NC NCT NCT0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 9 ,). 3 7 0 0 0 0 1
antibody targeting antibody a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 9 no 0 8 0 0 0 0 1
in two in i in in in BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 4 9 (,). 4 7 0 0 0 0 1
The signal the T Th The The BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 11 - 1 10 0 1 0 0 0
Yang et yang Y Ya Yan Yang BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 4 11 . 1 1 0 1 0 0 0
10 10 10 1 10 10 10 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 11 no 0 10 0 1 0 0 0
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 11 (): 3 10 0 1 1 0 0
Despite these despite D De Des Desp BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 , 1 8 0 1 0 0 1
possibility of possibility p po pos poss BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ,,,,- 5 9 0 1 0 0 1
spective clinical spective s sp spe spec BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 no 0 10 0 1 0 0 1
required for required r re req requ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 . 1 5 0 1 0 0 1
Blockade of blockade B Bl Blo Bloc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 -/- 3 3 0 0 0 0 1
IL-12/23 inhibitors il-12/23 I IL IL- IL-1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 0 -/- 3 9 0 0 0 0 1
mab, guselkumab, mab, m ma mab mab, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 ,,(-),- 7 9 0 0 0 0 1
numab (targeting numab n nu num numa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 (-/-) 5 9 0 0 0 0 1
and autoimmune and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 8 0 0 0 0 1
bowel disease. bowel b bo bow bowe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 .--/-- 6 9 0 0 0 0 1
inhibitors as inhibitors i in inh inhi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 no 0 9 0 0 0 0 1
COVID-19 pandemic. covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 0 -. 2 3 0 0 0 0 1
Several case several S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 -/ 2 9 0 0 0 0 1
IL-23 inhibitors il-23 I IL IL- IL-2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 0 -,,, 4 9 0 0 0 0 1
and risankizumab and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 -.- 3 9 0 0 0 0 1
reliability of reliability r re rel reli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 , 1 8 0 0 0 0 1
randomized, controlled, randomized, r ra ran rand BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 ,,. 3 10 0 0 0 0 1
A multicenter, a A A A A BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 4 0 ,, 2 9 0 0 0 0 1
the efficacy the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 9 0 0 0 0 1
with remdesivir with w wi wit with BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 -(). 4 6 0 0 0 0 1
Blockade of blockade B Bl Blo Bloc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 1 - 1 2 0 0 0 0 1
Several review several S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 1 - 1 9 0 0 0 0 1
an intervening an a an an an BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 4 1 -.,- 4 8 0 0 0 0 1
Case reports case C Ca Cas Case BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 4 1 no 0 9 0 0 0 0 1
of psoriasis of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 1 - 1 8 0 0 0 0 1
including secukinumab including i in inc incl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 1 no 0 8 0 0 0 0 1
COVID-19 symptoms covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 1 -.-- 4 8 0 0 0 0 1
spective, observational, spective, s sp spe spec BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 1 ,,- 3 10 0 0 0 0 1
ing 5206 ing i in ing ing BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 4 1 no 0 8 0 0 0 0 1
medications including medications m me med medi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 1 - 1 8 0 0 0 0 1
patients were patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 1 -, 2 7 0 0 0 0 1
occurred, 293 occurred, o oc occ occu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 1 ,- 2 9 0 0 0 0 1
COVID-CS and covid-cs C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 1 -.,- 4 8 0 0 0 0 1
tion as tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 1 no 0 9 0 0 0 0 1
and reliability and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 1 . 1 9 0 0 0 0 1
experimental diagnosis experimental e ex exp expe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 1 -. 2 8 0 0 0 0 1
addition, other addition, a ad add addi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 1 ,,, 3 9 0 0 0 0 1
the administration the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 1 ()- 3 8 0 0 0 0 1
mab (NCT04403243) mab m ma mab mab BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 4 1 ()-., 5 8 0 0 0 0 1
many researchers many m ma man many BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 4 1 - 1 9 0 0 0 0 1
17A signaling 17a 1 17 17A 17A BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 1 - 1 9 0 0 0 0 1
benefit for benefit b be ben bene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 1 -, 2 8 0 0 0 0 1
experience CS. experience e ex exp expe BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 1 ., 2 3 0 0 0 0 1
Blockade of blockade B Bl Blo Bloc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 3 - 1 2 0 0 0 0 1
Several studies several S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 3 - 1 9 0 0 0 0 1
the early the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 ,- 2 10 0 0 0 0 1
human recombinant human h hu hum huma BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 -- 2 8 0 0 0 0 1
gramostim have gramostim g gr gra gram BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 3 -; 2 8 0 0 0 0 1
however, as however, h ho how howe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 ,,-- 4 8 0 0 0 0 1
gical function gical g gi gic gica BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 3 ,- 2 9 0 0 0 0 1
signaling may signaling s si sig sign BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 3 -. 2 7 0 0 0 0 1
Mavrilimumab is mavrilimumab M Ma Mav Mavr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 3 --. 3 8 0 0 0 0 1
A prospective a A A A A BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 4 3 no 0 9 0 0 0 0 1
severe COVID-19 severe s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 - 1 9 0 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 3 (), 3 8 0 0 0 0 1
mechanical ventilation, mechanical m me mec mech BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 , 1 9 0 0 0 0 1
the control the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 ()., 4 9 0 0 0 0 1
evaluating the evaluating e ev eva eval BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 - 1 8 0 0 0 0 1
19 have 19 1 19 19 19 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 3 (,, 3 7 0 0 0 0 1
NCT04492514, NCT04399980, nct04492514, N NC NCT NCT0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 4 3 ,,). 4 5 0 0 0 0 1
Lenzilumab is lenzilumab L Le Len Lenz BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 3 no 0 8 0 0 0 0 1
human GM-CSF. human h hu hum huma BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 -.- 3 8 0 0 0 0 1
severe COVID-19 severe s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 - 1 8 0 0 0 0 1
control group control c co con cont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 (), 3 8 0 0 0 0 1
treatment with treatment t tr tre trea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 () 2 9 0 0 0 0 1
clinical improvement; clinical c cl cli clin BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 ;; 2 8 0 0 0 0 1
decreased inflammatory decreased d de dec decr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 no 0 8 0 0 0 0 1
cells. 299 cells. c ce cel cell BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 ., 2 10 0 0 0 0 1
been registered been b be bee been BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 - 1 7 0 0 0 0 1
(NCT04351152, NCT04583969, (nct04351152, ( (N (NC (NCT BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 4 5 (,,). 5 6 0 0 0 0 1
These clinical these T Th The Thes BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 5 - 1 9 0 0 0 0 1
indeed improved indeed i in ind inde BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 -. 2 8 0 0 0 0 1
Moreover, several moreover, M Mo Mor More BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 5 ,-, 3 9 0 0 0 0 1
otilimab, and otilimab, o ot oti otil BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 5 , 1 8 0 0 0 0 1
potential COVID-19 potential p po pot pote BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 5 -(,, 4 7 0 0 0 0 1
NCT04341116, respectively). nct04341116, N NC NCT NCT0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 4 5 ,). 3 4 0 0 0 0 1
BLOCKADE OF blockade B BL BLO BLOC BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 4 6 no 0 4 0 0 0 0 1
Blockade of blockade B Bl Blo Bloc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 6 / 1 4 0 0 0 0 1
The JAK/STAT the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 6 / 1 7 0 0 0 0 1
involved in involved i in inv invo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 ., 2 8 0 0 0 0 1
JAK/STAT signaling jak/stat J JA JAK JAK/ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 6 / 1 8 0 0 0 0 1
therapeutic option therapeutic t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 -.,- 4 9 0 0 0 0 1
various JAK various v va var vari BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 () 2 9 0 0 0 0 1
and JAK3 and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 ,, 2 9 0 0 0 0 1
JAK1 and jak1 J JA JAK JAK1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 6 ,- 2 9 0 0 0 0 1
trials in trials t tr tri tria BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 -. 2 4 0 0 0 0 1
Hoang et hoang H Ho Hoa Hoan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 4 6 . 1 8 0 0 0 0 1
improved the improved i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 --- 3 7 0 0 0 0 1
rhesus macaque, rhesus r rh rhe rhes BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 , 1 7 0 0 0 0 1
infiltration and infiltration i in inf infi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 ;; 2 8 0 0 0 0 1
and suppressed and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 - 1 8 0 0 0 0 1
macrophages. Baricitinib macrophages. m ma mac macr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 . 1 8 0 0 0 0 1
clinical trials. clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 ., 2 9 0 0 0 0 1
COVID-19 patients covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 6 - 1 8 0 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 (),() 5 8 0 0 0 0 1
remarkably reduced remarkably r re rem rema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 -,-,-; 6 7 0 0 0 0 1
accelerated recovery accelerated a ac acc acce BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 ; 1 8 0 0 0 0 1
production of production p pr pro prod BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 4 6 --; 3 8 0 0 0 0 1
increased PaO increased i in inc incr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 /().- 5 8 0 0 0 0 1
tional cohort tional t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 no 0 8 0 0 0 0 1
lung function lung l lu lun lung BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 --- 3 7 0 0 0 0 1
receiving corticosteroid receiving r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 4 6 .,- 3 9 0 0 0 0 1
dies showed dies d di die dies BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 no 0 8 0 0 0 0 1
CS, baricitinib cs, C CS CS, CS, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 6 ,--- 4 7 0 0 0 0 1
endocytosis by endocytosis e en end endo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 - 1 8 0 0 0 0 1
cyclin G-associated cyclin c cy cyc cycl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 -,,- 4 9 0 0 0 0 1
ism of ism i is ism ism BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 -., 3 9 0 0 0 0 1
also been also a al als also BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 ,,- 3 8 0 0 0 0 1
baricitinib are baricitinib b ba bar bari BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 . 1 10 0 0 0 0 1
effects in effects e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 -. 2 3 0 0 0 0 1
Several studies several S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 6 no 0 7 0 0 0 0 1
effective in effective e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 /-.- 4 9 0 0 0 0 1
prospective, multicenter, prospective, p pr pro pros BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 ,,-, 4 8 0 0 0 0 1
including 41 including i in inc incl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 -,, 3 7 0 0 0 0 1
with patients with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 (), 3 7 0 0 0 0 1
ruxolitinib group ruxolitinib r ru rux ruxo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 () 2 8 0 0 0 0 1
seven cytokines, seven s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 , 1 8 0 0 0 0 1
and lymphocyte-count and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 -., 3 8 0 0 0 0 1
clinical trials clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 no 0 9 0 0 0 0 1
are evaluating are a ar are are BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 - 1 8 0 0 0 0 1
patients have patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 .(, 3 8 0 0 0 0 1
NCT04415151, NCT04750317, nct04415151, N NC NCT NCT0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 4 6 ,,,, 4 7 0 0 0 0 1
NCT04332042). NCT04332042). nct04332042). N NC NCT NCT0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 4 6 ). 2 1 0 0 0 0 1
Despite these despite D De Des Desp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 6 , 1 8 0 0 0 0 1
with caution with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 , 1 9 0 0 0 0 1
considerations: (1) considerations: c co con cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 :()/- 5 8 0 0 0 0 1
way increases way w wa way way BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 4 6 no 0 9 0 0 0 0 1
virus reactivation virus v vi vir viru BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 no 0 9 0 0 0 0 1
aspects of aspects a as asp aspe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 , 1 8 0 0 0 0 1
system. 327,328 system. s sy sys syst BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 .,,- 4 8 0 0 0 0 1
pressive nature, pressive p pr pre pres BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 , 1 8 0 0 0 0 1
The signal the T Th The The BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 11 - 1 10 0 1 0 0 0
Yang et yang Y Ya Yan Yang BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 5 11 . 1 1 0 1 0 0 0
11 11 11 1 11 11 11 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 11 no 0 10 0 1 0 0 0
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 11 (): 3 10 0 1 1 0 0
treatment with treatment t tr tre trea BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 8 0 0 0 0 1
the risk the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 -- 2 9 0 0 0 0 1
in COVID-19. in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 5 0 -., 3 10 0 0 0 0 1
conducted to conducted c co con cond BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ;-()- 5 9 0 0 0 0 1
is commonly is i is is is BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 , 1 8 0 0 0 0 1
the Food the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 9 0 0 0 0 1
of some of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ., 2 9 0 0 0 0 1
developing JAKinibs developing d de dev deve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 9 0 0 0 0 1
direction of direction d di dir dire BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 / 1 9 0 0 0 0 1
survival of survival s su sur surv BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 -. 2 4 0 0 0 0 1
Blockade of blockade B Bl Blo Bloc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 - 1 3 0 0 0 0 1
The overwhelming the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 - 1 8 0 0 0 0 1
proteins in proteins p pr pro prot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 -- 2 8 0 0 0 0 1
inflammatory signaling inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 ,,- 3 8 0 0 0 0 1
pathway. Immunomodulation pathway. p pa pat path BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 .- 2 7 0 0 0 0 1
proven effective proven p pr pro prov BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 --., 4 8 0 0 0 0 1
recent reviews recent r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 - 1 8 0 0 0 0 1
a potential a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 5 0 -.- 3 9 0 0 0 0 1
An in an A An An An BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 5 0 (-),- 5 8 0 0 0 0 1
anti-inflammatory and anti-inflammatory a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 -, 2 9 0 0 0 0 1
the replication the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 --- 3 9 0 0 0 0 1
factors in factors f fa fac fact BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 -- 2 8 0 0 0 0 1
pathway. 339 pathway. p pa pat path BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 . 1 7 0 0 0 0 1
derivative remarkably derivative d de der deri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 -,, 3 9 0 0 0 0 1
IL-1β in il-1β I IL IL- IL-1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 0 --.- 4 8 0 0 0 0 1
signaling pathway signaling s si sig sign BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 . 1 8 0 0 0 0 1
blocking phosphorylation blocking b bl blo bloc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 - 1 9 0 0 0 0 1
beta, a beta, b be bet beta BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ,-, 3 8 0 0 0 0 1
pharmacological inhibitors pharmacological p ph pha phar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 8 0 0 0 0 1
COVID-CS treatment. covid-cs C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 -.,, 4 9 0 0 0 0 1
Chinese medicine, chinese C Ch Chi Chin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 ,-- 3 9 0 0 0 0 1
inflammatory effects inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 ---- 4 8 0 0 0 0 1
cells, respectively, cells, c ce cel cell BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ,,-. 4 9 0 0 0 0 1
The effect the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 -- 2 8 0 0 0 0 1
COVID-19 such covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 0 -,, 3 8 0 0 0 0 1
macrolide antibiotics, macrolide m ma mac macr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 ,,-, 4 9 0 0 0 0 1
related to related r re rel rela BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 -. 2 5 0 0 0 0 1
Despite the despite D De Des Desp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 - 1 8 0 0 0 0 1
inhibition, developing inhibition, i in inh inhi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ,- 2 9 0 0 0 0 1
clinical trials clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 10 0 0 0 0 1
benefits. benefits. benefits. b be ben bene BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 . 1 1 0 0 0 0 1
Blockade of blockade B Bl Blo Bloc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 3 no 0 4 0 0 0 0 1
Several studies several S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 3 no 0 8 0 0 0 0 1
potential therapeutic potential p po pot pote BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 -.,, 4 7 0 0 0 0 1
NLRP3 signaling nlrp3 N NL NLR NLRP BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 3 no 0 8 0 0 0 0 1
action for action a ac act acti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 --, 3 9 0 0 0 0 1
such as such s su suc such BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 . 1 8 0 0 0 0 1
nonselectively inhibit nonselectively n no non nons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 - 1 9 0 0 0 0 1
tion of tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 no 0 9 0 0 0 0 1
ASC. 350,351 asc. A AS ASC ASC. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 3 .,, 3 9 0 0 0 0 1
capable of capable c ca cap capa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 . 1 10 0 0 0 0 1
capable of capable c ca cap capa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 ,, 2 9 0 0 0 0 1
dapansutrile (OLT1177, dapansutrile d da dap dapa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 (,),- 5 10 0 0 0 0 1
sulfonylurea derivative sulfonylurea s su sul sulf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 ,- 2 10 0 0 0 0 1
treatment as treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 ., 2 9 0 0 0 0 1
nonselective or nonselective n no non nons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 no 0 8 0 0 0 0 1
including melatonin including i in inc incl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 (),(), 6 9 0 0 0 0 1
palm berry palm p pa pal palm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 ()(), 5 9 0 0 0 0 1
(selective inhibitor) (selective ( (s (se (sel BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 ()(). 5 8 0 0 0 0 1
INTERVENTIONS TARGETING interventions I IN INT INTE BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 5 5 no 0 7 0 1 0 0 1
PATHWAYS PATHWAYS pathways P PA PAT PATH BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 5 5 no 0 1 0 1 0 0 1
Intravenous immunoglobulin intravenous I In Int Intr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 5 () 2 7 0 1 0 0 1
IVIg is ivig I IV IVI IVIg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 5 no 0 10 0 1 0 0 1
antibody network antibody a an ant anti BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 5 no 0 9 0 1 0 0 1
patient's imbalanced patient's p pa pat pati BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 5 '. 2 9 0 0 0 0 1
been known been b be bee been BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 - 1 10 0 0 0 0 1
autoantibodies such autoantibodies a au aut auto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 5 -,-,- 5 9 0 0 0 0 1
detected in detected d de det dete BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 .- 2 9 0 0 0 0 1
the autoantibodies the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 , 1 9 0 0 0 0 1
been demonstrated been b be bee been BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 - 1 9 0 0 0 0 1
are neutralizing are a ar are are BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 - 1 9 0 0 0 0 1
inflammatory effect inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 5 no 0 8 0 0 0 0 1
disorders. disorders. disorders. d di dis diso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 . 1 1 0 0 0 0 1
The potential the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 5 no 0 8 0 0 0 0 1
and the and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 .,, 3 9 0 0 0 0 1
controlled trial controlled c co con cont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 -, 2 9 0 0 0 0 1
did not did d di did did BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 ; 1 9 0 0 0 0 1
however, a however, h ho how howe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 , 1 9 0 0 0 0 1
of days of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 no 0 8 0 0 0 0 1
hospitalization was hospitalization h ho hos hosp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 , 1 9 0 0 0 0 1
clinical benefit clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 no 0 9 0 0 0 0 1
COVID-19. In covid-19. C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 5 -.,. 4 9 0 0 0 0 1
efficacy of efficacy e ef eff effi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 , 1 10 0 0 0 0 1
methylprednisolone, favipiravir, methylprednisolone, m me met meth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 5 ,,, 3 9 0 0 0 0 1
therapy in therapy t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 no 0 8 0 0 0 0 1
COVID-19. COVID-19. covid-19. C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 5 -. 2 1 0 0 0 0 1
In general, in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 5 5 , 1 9 0 0 0 0 1
timing of timing t ti tim timi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 ,..,.; 6 9 0 0 0 0 1
therefore, a therefore, t th the ther BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 ,. 2 9 0 0 0 0 1
Corticosteroid treatment corticosteroid C Co Cor Cort BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 7 no 0 3 0 0 0 0 1
Corticosteroids are corticosteroids C Co Cor Cort BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 7 - 1 7 0 0 0 0 1
inflammatory drugs inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 7 no 0 7 0 0 0 0 1
disorders. They disorders. d di dis diso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 . 1 9 0 0 0 0 1
expression of expression e ex exp expr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 - 1 9 0 0 0 0 1
various immune various v va var vari BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 ., 2 8 0 0 0 0 1
treatment in treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 -- 2 8 0 0 0 0 1
mended, 365 mended, m me men mend BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 , 1 9 0 0 0 0 1
a benefit a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 5 7 ., 2 9 0 0 0 0 1
the mortality the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 -- 2 9 0 0 0 0 1
CoV. 366 cov. C Co CoV CoV. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 7 .,, 3 8 0 0 0 0 1
randomized, controlled randomized, r ra ran rand BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 7 ,- 2 8 0 0 0 0 1
~15% of ~15% ~ ~1 ~15 ~15% BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 7 -,. 3 9 0 0 0 0 1
The dexamethasone the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 7 -- 2 8 0 0 0 0 1
moderate dexamethasone moderate m mo mod mode BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 no 0 8 0 0 0 0 1
control arm control c co con cont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 . 1 8 0 0 0 0 1
Compared to compared C Co Com Comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 7 , 1 8 0 0 0 0 1
the 28-day the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 -- 2 9 0 0 0 0 1
and by and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 -, 2 10 0 0 0 0 1
with no with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 .,- 3 9 0 0 0 0 1
ment (https://www.gov.uk/government/news/world-first-coronaviru ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 7 (://..///-- 11 8 0 0 0 0 1
s-treatment-approved-for-nhs-use-by-government/) and s-treatment-approved-for-nhs-use-by-government/) s s- s-t s-tr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 7 -------/) 9 9 0 0 0 0 1
Institutes of institutes I In Ins Inst BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 7 (://. 5 9 0 0 0 0 1
mentguidelines.nih.gov/dexamethasone/) have mentguidelines.nih.gov/dexamethasone/) m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 7 ..//)- 6 8 0 0 0 0 1
dard use dard d da dar dard BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 7 - 1 8 0 0 0 0 1
require oxygen. require r re req requ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 .,- 3 9 0 0 0 0 1
showed that showed s sh sho show BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 no 0 9 0 0 0 0 1
28-day all-cause 28-day 2 28 28- 28-d BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 7 ---. 4 9 0 0 0 0 1
Collectively, the collectively, C Co Col Coll BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 7 ,- 2 9 0 0 0 0 1
treatment is treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 , 1 9 0 0 0 0 1
patient, and patient, p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 ,. 2 8 0 0 0 0 1
temporal dynamics temporal t te tem temp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 --.- 4 9 0 0 0 0 1
the replicative the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 , 1 8 0 0 0 0 1
dominant role dominant d do dom domi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 , 1 9 0 0 0 0 1
a secondary a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 5 7 ., 2 8 0 0 0 0 1
indicator to indicator i in ind indi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 no 0 8 0 0 0 0 1
treatment. Moreover, treatment. t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 .,, 3 8 0 0 0 0 1
is readily is i is is is BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 , 1 9 0 0 0 0 1
developing countries developing d de dev deve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 ., 2 9 0 0 0 0 1
although corticosteroid although a al alt alth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 no 0 9 0 0 0 0 1
COVID-19 patients, covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 7 -, 2 9 0 0 0 0 1
further investigation. further f fu fur furt BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 . 1 3 0 0 0 0 1
The signal the T Th The The BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 11 - 1 10 0 1 0 0 0
Yang et yang Y Ya Yan Yang BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 5 11 . 1 1 0 1 0 0 0
12 12 12 1 12 12 12 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 11 no 0 10 0 1 0 0 0
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 11 (): 3 10 0 1 1 0 0
Traditional Chinese traditional T Tr Tra Trad BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 () 2 6 0 0 0 0 1
Previous studies previous P Pr Pre Prev BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 9 0 0 0 0 1
TCMs such tcms T TC TCM TCMs BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 ,, 2 8 0 0 0 0 1
Huanglian Jiedu huanglian H Hu Hua Huan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 ., 2 9 0 0 0 0 1
TCM treatment tcm T TC TCM TCM BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 - 1 8 0 0 0 0 1
contributed substantially contributed c co con cont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 . 1 8 0 0 0 0 1
example, a example, e ex exa exam BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ,,, 3 8 0 0 0 0 1
Zhong' research zhong' Z Zh Zho Zhon BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 ', 2 8 0 0 0 0 1
repurposed Chinese repurposed r re rep repu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 , 1 8 0 0 0 0 1
shorten the shorten s sh sho shor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 - 1 8 0 0 0 0 1
adverse effects. adverse a ad adv adve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 . 1 2 0 0 0 0 1
Several TCMs several S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 8 0 0 0 0 1
multiple cytokines multiple m mu mul mult BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 .. 2 9 0 0 0 0 1
showed that showed s sh sho show BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ,- 2 8 0 0 0 0 1
anti-COVID-19 formulae, anti-covid-19 a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 0 --,- 4 9 0 0 0 0 1
multiple CS-related multiple m mu mul mult BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 -- 2 9 0 0 0 0 1
pathways and pathways p pa pat path BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 -,-,-., 7 9 0 0 0 0 1
Dai et dai D Da Dai Dai BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 5 0 .- 2 10 0 0 0 0 1
the effects the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 -- 2 8 0 0 0 0 1
formulae on formulae f fo for form BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 -,- 3 8 0 0 0 0 1
sequencing-based screening sequencing-based s se seq sequ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 - 1 7 0 0 0 0 1
computer-aided drug computer-aided c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 -. 2 8 0 0 0 0 1
might inhibit might m mi mig migh BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 -,,-, 5 9 0 0 0 0 1
drugs such drugs d dr dru drug BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 9 0 0 0 0 1
pathways. Together, pathways. p pa pat path BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ., 2 9 0 0 0 0 1
administration of administration a ad adm admi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 5 0 -. 2 4 0 0 0 0 1
Blockade of blockade B Bl Blo Bloc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 2 -() 3 6 0 0 0 0 1
It is it I It It It BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 2 no 0 10 0 0 0 0 1
clinical benefit clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 2 no 0 10 0 0 0 0 1
during CS. during d du dur duri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 2 .,- 3 9 0 0 0 0 1
wide-spectrum inhibitory wide-spectrum w wi wid wide BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 2 -. 2 7 0 0 0 0 1
CDK7 can cdk7 C CD CDK CDK7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 2 . 1 9 0 0 0 0 1
studies have studies s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 2 no 0 7 0 0 0 0 1
inflammation resolution inflammation i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 2 no 0 8 0 0 0 0 1
and regulating and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 2 . 1 8 0 0 0 0 1
et al. et e et et et BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 2 .-,, 4 9 0 0 0 0 1
blockade of blockade b bl blo bloc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 2 no 0 8 0 0 0 0 1
and CRS and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 2 ., 2 9 0 0 0 0 1
is blocked is i is is is BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 2 ,-, 3 8 0 0 0 0 1
STAT1 and stat1 S ST STA STAT BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 2 /- 2 8 0 0 0 0 1
enhancers, are enhancers, e en enh enha BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 2 , 1 9 0 0 0 0 1
level. This level. l le lev leve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 2 . 1 8 0 0 0 0 1
strategy to strategy s st str stra BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 2 . 1 8 0 0 0 0 1
between COVID-CS between b be bet betw BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 2 -, 2 8 0 0 0 0 1
may also may m ma may may BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 1 0 0 5 2 -. 2 3 0 0 0 0 1
CONCLUSIONS CONCLUSIONS conclusions C CO CON CONC BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 1 0 0 0 0 1
Clinical and clinical C Cl Cli Clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 4 - 1 9 0 0 0 0 1
ized COVID-CS, ized i iz ize ized BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 4 -, 2 8 0 0 0 0 1
CS and cs C CS CS CS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 4 -. 2 8 0 0 0 0 1
COVID-CS is covid-cs C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 4 -, 2 8 0 0 0 0 1
scale and scale s sc sca scal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 9 0 0 0 0 1
conditions, and conditions, c co con cond BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 ,. 2 9 0 0 0 0 1
still unclear still s st sti stil BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 10 0 0 0 0 1
an inflammatory an a an an an BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 5 4 , 1 7 0 0 0 0 1
predominantly by predominantly p pr pre pred BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 8 0 0 0 0 1
frequently reported frequently f fr fre freq BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 . 1 9 0 0 0 0 1
of individual of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 - 1 8 0 0 0 0 1
pathogenic parameters pathogenic p pa pat path BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 4 no 0 8 0 0 0 0 1
understood; it understood; u un und unde BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 ;- 2 8 0 0 0 0 1
associated with associated a as ass asso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 -. 2 8 0 0 0 0 1
treat COVID-CS, treat t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 5 4 -,- 3 9 0 0 0 0 1
ing inflammatory ing i in ing ing BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 5 4 no 0 8 0 0 0 0 1
been clinically been b be bee been BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 9 0 0 0 0 1
are in are a ar are are BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 . 1 2 0 0 0 0 1
In principle, in I In In In BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 5 5 , 1 8 0 0 0 0 1
ongoing inflammatory ongoing o on ong ongo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 no 0 9 0 0 0 0 1
the host's the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 '., 3 9 0 0 0 0 1
drugs to drugs d dr dru drug BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 ,, 2 9 0 0 0 0 1
been proved been b be bee been BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 :() 3 9 0 0 0 0 1
are not are a ar are are BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 , 1 9 0 0 0 0 1
treatment guidelines treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 ;()- 4 9 0 0 0 0 1
tical challenge tical t ti tic tica BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 5 . 1 9 0 0 0 0 1
therefore important therefore t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 no 0 8 0 0 0 0 1
upstream and upstream u up ups upst BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 , 1 9 0 0 0 0 1
the predominant the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 - 1 8 0 0 0 0 1
macrophages. Alternatively, macrophages. m ma mac macr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 5 .,- 3 8 0 0 0 0 1
latory system latory l la lat lato BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 5 - 1 8 0 0 0 0 1
inflammatory factor/cytokines inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 5 /- 2 8 0 0 0 0 1
effect may effect e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 ;- 2 9 0 0 0 0 1
37 has 37 3 37 37 37 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 5 ;-() 4 10 0 0 0 0 1
balance CS balance b ba bal bala BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 , 1 9 0 0 0 0 1
appropriate level appropriate a ap app appr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 no 0 9 0 0 0 0 1
infections and infections i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 no 0 9 0 0 0 0 1
may lead may m ma may may BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 1 0 0 5 5 - 1 8 0 0 0 0 1
tions; (4) tions; t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 5 ;(), 4 8 0 0 0 0 1
immune status, immune i im imm immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 , 1 8 0 0 0 0 1
differences in differences d di dif diff BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 . 1 9 0 0 0 0 1
Therefore, precise therefore, T Th The Ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 5 ,., 3 9 0 0 0 0 1
predominant cytokines predominant p pr pre pred BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 no 0 8 0 0 0 0 1
condition should condition c co con cond BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 . 1 8 0 0 0 0 1
COVID-19 has covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 5 - 1 8 0 0 0 0 1
with natural with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 . 1 8 0 0 0 0 1
options developed options o op opt opti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 -, 2 9 0 0 0 0 1
this disease this t th thi this BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 . 1 6 0 0 0 0 1
ACKNOWLEDGEMENTS ACKNOWLEDGEMENTS acknowledgements A AC ACK ACKN BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 6 8 no 0 10 0 0 0 0 1
We thank we W We We We BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 8 ,,- 3 9 0 0 0 0 1
pandemic. This pandemic. p pa pan pand BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 8 . 1 9 0 0 0 0 1
China (2016YFC1305102 china C Ch Chi Chin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 6 8 (..); 5 9 0 0 0 0 1
(81671561, 81974248 (81671561, ( (8 (81 (816 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 8 (,..); 6 10 0 0 0 0 1
Children's Medical children's C Ch Chi Chil BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 8 '(..); 6 9 0 0 0 0 1
Academic Leader academic A Ac Aca Acad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 8 (..); 5 9 0 0 0 0 1
Science and science S Sc Sci Scie BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 8 (..). 5 9 0 0 0 0 1
Technology (21140902400 technology T Te Tec Tech BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 8 (..,,..); 9 9 0 0 0 0 1
UK (21327 uk U UK UK UK BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 8 (..); 5 9 0 0 0 0 1
(KQTD20170331145453160). Figure (kqtd20170331145453160). ( (K (KQ (KQT BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 8 (). 3 9 0 0 0 0 1
of Servier of o of of of BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 8 (://..). 8 6 0 0 0 0 1
AUTHOR CONTRIBUTIONS author A AU AUT AUTH BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 6 9 no 0 10 0 0 0 0 1
L.Y., X.X., l.y., L L. L.Y L.Y. BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 9 ..,..,..,.. 11 9 0 0 0 0 1
preparation. D.X. preparation. p pr pre prep BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 9 ...... 6 10 0 0 0 0 1
ADDITIONAL INFORMATION additional A AD ADD ADDI BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 6 10 no 0 10 0 0 0 0 1
Competing interests: competing C Co Com Comp BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 10 :. 2 10 0 0 0 0 1
REFERENCES REFERENCES references R RE REF REFE BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 6 10 no 0 10 0 0 0 0 1
1. Wan, 1. 1 1. 1. 1. BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 10 .,..: 5 9 0 0 0 0 1
analysis based analysis a an ana anal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 10 -.., 4 9 0 0 0 0 1
e00127-20 (2020). e00127-20 e e0 e00 e001 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 10 -(). 4 2 0 0 0 0 1
2. Hamming, 2. 2 2. 2. 2. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 10 .,.., 5 10 0 0 0 0 1
SARS coronavirus. sars S SA SAR SARS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 10 .... 4 8 0 0 0 0 1
203, 631-637 203, 2 20 203 203, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 10 ,-(). 5 2 0 0 0 0 1
3. Crackower, 3. 3 3. 3. 3. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 10 .,...-- 7 9 0 0 0 0 1
ulator of ulator u ul ula ulat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 10 .,-(). 6 6 0 0 0 0 1
4. Donoghue, 4. 4 4. 4. 4. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 10 .,..--- 7 8 0 0 0 0 1
ypeptidase (ACE2) ypeptidase y yp ype ypep BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 10 ()-...,- 8 9 0 0 0 0 1
(2000). (2000). (2000). ( (2 (20 (200 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 10 (). 3 0 0 0 0 0 1
5. Tipnis, 5. 5 5. 5. 5. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 10 .,...-. 7 9 0 0 0 0 1
and functional and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 10 -... 4 9 0 0 0 0 1
Chem. 275, chem. C Ch Che Chem BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 10 .,-(). 6 3 0 0 0 0 1
The signal the T Th The The BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 11 - 1 10 0 1 0 0 0
Yang et yang Y Ya Yan Yang BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 6 11 . 1 1 0 1 0 0 0
13 13 13 1 13 13 13 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 11 no 0 10 0 1 0 0 0
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 11 (): 3 10 0 1 1 0 0
6. Siddiqi, 6. 6 6. 6. 6. BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,..,..- 8 9 0 0 0 0 1
states: a states: s st sta stat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 :-..., 6 8 0 0 0 0 1
405-407 (2020). 405-407 4 40 405 405- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 -(). 4 1 0 0 0 0 1
7. Fu, 7. 7 7. 7. 7. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,..(-) 7 9 0 0 0 0 1
China: a china: C Ch Chi Chin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 :-...,-(). 10 8 0 0 0 0 1
8. Zhu, 8. 8 8. 8. 8. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,..,. 6 9 0 0 0 0 1
N. Engl. n. N N. N. N. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 0 ....,-(). 9 4 0 0 0 0 1
9. Huang, 9. 9 9. 9. 9. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,.. 4 9 0 0 0 0 1
in Wuhan, in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 6 0 ,.,-(). 7 5 0 0 0 0 1
10. Chen, 10. 1 10 10. 10. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,.. 4 9 0 0 0 0 1
novel coronavirus novel n no nov nove BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 ,:., 4 8 0 0 0 0 1
507-513 (2020). 507-513 5 50 507 507- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 -(). 4 1 0 0 0 0 1
11. Wang, 11. 1 11 11. 11. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,.. 4 9 0 0 0 0 1
novel coronavirus-infected novel n no nov nove BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 -,.,- 5 8 0 0 0 0 1
(2020). (2020). (2020). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 0 (). 3 0 0 0 0 0 1
12. Henderson, 12. 1 12 12. 12. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,...: 6 8 0 0 0 0 1
COVID-19. Arthritis covid-19. C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 -..,-(). 8 5 0 0 0 0 1
13. Mehta, 13. 1 13 13. 13. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,..-:- 7 8 0 0 0 0 1
suppression. Lancet suppression. s su sup supp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 .,-(). 6 4 0 0 0 0 1
14. Tufan, 14. 1 14 14. 14. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,.,,.-,.-, 11 8 0 0 0 0 1
response, hyperinflammation response, r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 ,... 4 8 0 0 0 0 1
Med. Sci. med. M Me Med Med. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 0 ..,-(). 7 3 0 0 0 0 1
15. Mangalmurti, 15. 1 15 15. 15. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,.,..:-. 9 8 0 0 0 0 1
Immunity 53, immunity I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 ,-(). 5 3 0 0 0 0 1
16. Ferrara, 16. 1 16 16. 16. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,..,,.,..-- 12 9 0 0 0 0 1
disease: a disease: d di dis dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 :-...,- 7 9 0 0 0 0 1
(1993). (1993). (1993). ( (1 (19 (199 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 0 (). 3 0 0 0 0 0 1
17. Chousterman, 17. 1 17 17. 17. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,..,,..,.. 11 8 0 0 0 0 1
disease pathogenesis. disease d di dis dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 ...,-(). 8 7 0 0 0 0 1
18. Kumar, 18. 1 18 18. 18. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,.-- 5 8 0 0 0 0 1
endogenous negative endogenous e en end endo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 .. 2 8 0 0 0 0 1
Immunopharmacol. 89, immunopharmacol. I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 0 .,(). 5 4 0 0 0 0 1
19. London, 19. 1 19 19. 19. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,...- 6 9 0 0 0 0 1
cytokine storm cytokine c cy cyt cyto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ....,(). 8 8 0 0 0 0 1
20. Imus, 20. 2 20 20. 20. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,...- 6 9 0 0 0 0 1
ipheral blood ipheral i ip iph iphe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ..., 4 8 0 0 0 0 1
2431-2437 (2019). 2431-2437 2 24 243 2431 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 0 -(). 4 2 0 0 0 0 1
21. Wadia, 21. 2 21 21. 21. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,..,.. 7 9 0 0 0 0 1
graft rejection graft g gr gra graf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 ....,-,-(). 11 8 0 0 0 0 1
22. Davila, 22. 2 22 22. 22. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,...- 6 9 0 0 0 0 1
in B in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 6 0 ....,(). 8 8 0 0 0 0 1
23. Grupp, 23. 2 23 23. 23. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,...- 6 9 0 0 0 0 1
leukemia. N. leukemia. l le leu leuk BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 .....,-(). 10 5 0 0 0 0 1
24. Qin, 24. 2 24 24. 24. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,.. 4 9 0 0 0 0 1
2019 (COVID-19) 2019 2 20 201 2019 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 6 0 (-),....,-(). 13 8 0 0 0 0 1
25. Wang, 25. 2 25 25. 25. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,.. 4 9 0 0 0 0 1
COVID-19 pneumonia. covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 -....,-(). 10 6 0 0 0 0 1
26. Hadjadj, 26. 2 26 26. 26. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,.. 4 9 0 0 0 0 1
in severe in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 6 0 -.,-(). 7 6 0 0 0 0 1
27. Diao, 27. 2 27 27. 27. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,.. 4 9 0 0 0 0 1
coronavirus disease coronavirus c co cor coro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 (-)...,(). 10 7 0 0 0 0 1
28. Zhang, 28. 2 28 28. 28. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,...-- 7 10 0 0 0 0 1
in Wuhan, in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 6 0 ,.,-(). 7 5 0 0 0 0 1
29. Fang, 29. 2 29 29. 29. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,.,,.,. 8 9 0 0 0 0 1
mellitus at mellitus m me mel mell BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 -?.., 5 8 0 0 0 0 1
(2020). (2020). (2020). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 0 (). 3 0 0 0 0 0 1
30. Wang, 30. 3 30 30. 30. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,..--- 7 9 0 0 0 0 1
host cells. host h ho hos host BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 ...,(). 7 6 0 0 0 0 1
31. Yang, 31. 3 31 31. 31. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,..-:. 7 8 0 0 0 0 1
Transduct. Target transduct. T Tr Tra Tran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 0 ..,(). 6 4 0 0 0 0 1
32. Wilk, 32. 3 32 32. 32. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,...- 6 9 0 0 0 0 1
with severe with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 -...,-(). 9 6 0 0 0 0 1
33. Ronit, 33. 3 33 33. 33. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,..-: 6 8 0 0 0 0 1
series. J. series. s se ser seri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 ....,-(). 9 5 0 0 0 0 1
34. Zheng, 34. 3 34 34. 34. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,..-- 6 9 0 0 0 0 1
macaques: a macaques: m ma mac maca BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 :-.. 4 8 0 0 0 0 1
16, e1008949 16, 1 16 16, 16, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 ,(). 4 2 0 0 0 0 1
35. Li, 35. 3 35 35. 35. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,..() 6 9 0 0 0 0 1
progression and progression p pr pro prog BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 -..., 5 8 0 0 0 0 1
(2020). (2020). (2020). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 0 (). 3 0 0 0 0 0 1
36. Zheng, 36. 3 36 36. 36. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,..- 5 8 0 0 0 0 1
patients. Cell. patients. p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 ....,-(). 9 5 0 0 0 0 1
37. Wang, 37. 3 37 37. 37. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,..:-- 7 9 0 0 0 0 1
spike protein-mediated spike s sp spi spik BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 6 0 -....,(). 9 8 0 0 0 0 1
38. Yue, 38. 3 38 38. 38. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,..-- 6 8 0 0 0 0 1
necrotic cell necrotic n ne nec necr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 ..,(). 6 5 0 0 0 0 1
39. Tan, 39. 3 39 39. 39. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,... 5 9 0 0 0 0 1
coronavirus 7a coronavirus c co cor coro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 -.. 3 9 0 0 0 0 1
Virol. 81, virol. V Vi Vir Viro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 5 .,-(). 6 3 0 0 0 0 1
40. Tan, 40. 4 40 40. 40. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,..-: 6 9 0 0 0 0 1
and predictive and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 ...,(). 7 7 0 0 0 0 1
41. Cao, 41. 4 41 41. 41. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,.-:... 8 9 0 0 0 0 1
Immunol. 20, immunol. I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 5 .,-(). 6 3 0 0 0 0 1
42. Li, 42. 4 42 42. 42. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,.. 4 9 0 0 0 0 1
with COVID-19 with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 -:--.. 6 8 0 0 0 0 1
Target Ther. target T Ta Tar Targ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 5 .,(). 5 3 0 0 0 0 1
43. Xu, 43. 4 43 43. 43. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,..-- 6 8 0 0 0 0 1
controls in controls c co con cont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 .://././ 8 9 0 0 0 0 1
2020.03.08.20031658 (2020). 2020.03.08.20031658 2 20 202 2020 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 5 ...(). 6 3 0 0 0 0 1
44. Nielsen, 44. 4 44 44. 44. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,.... 6 9 0 0 0 0 1
responses to responses r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 --.,-().. 9 7 0 0 0 0 1
45. Halstead, 45. 4 45 45. 45. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,..',..- 9 9 0 0 0 0 1
primate leukocytes. primate p pr pri prim BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 .,-(). 6 5 0 0 0 0 1
46. Halstead, 46. 4 46 46. 46. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,..',.... 10 9 0 0 0 0 1
Infection enhancement infection I In Inf Infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 5 -....,- 7 8 0 0 0 0 1
(1977). (1977). (1977). ( (1 (19 (197 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 5 (). 3 0 0 0 0 0 1
47. Halstead, 47. 4 47 47. 47. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,..,',..,.. 12 9 0 0 0 0 1
phagocytes. II. phagocytes. p ph pha phag BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 .. 2 8 0 0 0 0 1
infection. J. infection. i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 ....,-(). 9 5 0 0 0 0 1
48. Peiris, 48. 4 48 48. 48. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,..,..- 8 9 0 0 0 0 1
replication in replication r re rep repl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 -.,-(). 7 8 0 0 0 0 1
49. Peiris, 49. 4 49 49. 49. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,..,,.,,..,..- 15 9 0 0 0 0 1
receptor IgG receptor r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 . 1 8 0 0 0 0 1
Nature 289, nature N Na Nat Natu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 5 ,-(). 5 3 0 0 0 0 1
50. Yang, 50. 5 50 50. 50. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,... 5 9 0 0 0 0 1
respiratory syndrome respiratory r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 ....,- 6 8 0 0 0 0 1
(2005). (2005). (2005). ( (2 (20 (200 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 5 (). 3 0 0 0 0 0 1
51. Wan, 51. 5 51 51. 51. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,..- 5 8 0 0 0 0 1
coronavirus entry. coronavirus c co cor coro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 ..,-(). 7 5 0 0 0 0 1
52. Kuzmina, 52. 5 52 52. 52. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,...- 6 9 0 0 0 0 1
by human by b by by by BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 ..,-. 5 8 0 0 0 0 1
(2018). (2018). (2018). ( (2 (20 (201 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 5 (). 3 0 0 0 0 0 1
53. Zhao, 53. 5 53 53. 53. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,..--- 7 9 0 0 0 0 1
onavirus disease onavirus o on ona onav BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 ....,-(). 9 7 0 0 0 0 1
54. Zhang, 54. 5 54 54. 54. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,..-- 6 8 0 0 0 0 1
ratio and ratio r ra rat rati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 no 0 8 0 0 0 0 1
COVID-19. Front. covid-19. C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 -....,(). 9 5 0 0 0 0 1
55. Wang, 55. 5 55 55. 55. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,.. 4 9 0 0 0 0 1
therapeutic efficacy therapeutic t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 --..., 6 8 0 0 0 0 1
5752 (2020). 5752 5 57 575 5752 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 5 (). 3 1 0 0 0 0 1
56. Brinkmann, 56. 5 56 56. 56. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,..., 6 9 0 0 0 0 1
1532-1535 (2004). 1532-1535 1 15 153 1532 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 5 -(). 4 2 0 0 0 0 1
57. Weiss, 57. 5 57 57. 57. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,.......,- 11 9 0 0 0 0 1
(1989). (1989). (1989). ( (1 (19 (198 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 5 (). 3 0 0 0 0 0 1
58. Chen, 58. 5 58 58. 58. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,...-- 7 8 0 0 0 0 1
nopathology and nopathology n no nop nopa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 -..,(). 7 7 0 0 0 0 1
59. Schulte-Schrepping, 59. 5 59 59. 59. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .-,..- 6 8 0 0 0 0 1
myeloid cell myeloid m my mye myel BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 .,-.(). 7 6 0 0 0 0 1
60. McElvaney, 60. 6 60 60. 60. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,... 5 9 0 0 0 0 1
COVID-19 illness. covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 -......,-(). 12 7 0 0 0 0 1
61. Palsson-McDermott, 61. 6 61 61. 61. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .-,...- 7 9 0 0 0 0 1
and IL-1beta and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 - 1 8 0 0 0 0 1
LPS-activated macrophages. lps-activated L LP LPS LPS- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 5 -..,(). 7 6 0 0 0 0 1
62. Luo, 62. 6 62 62. 62. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,..-- 6 9 0 0 0 0 1
inducible factor inducible i in ind indu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 .,-(). 6 5 0 0 0 0 1
63. Narasimhan, 63. 6 63 63. 63. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,..,,.,,...,.. 15 10 0 0 0 0 1
monocytes in monocytes m mo mon mono BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 ....,-(). 9 8 0 0 0 0 1
64. Xu, 64. 6 64 64. 64. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,..- 5 9 0 0 0 0 1
lung revealed lung l lu lun lung BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 -..,(). 7 8 0 0 0 0 1
65. Honda, 65. 6 65 65. 65. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,.,,.,.[] 10 8 0 0 0 0 1
induction by induction i in ind indu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 . 1 8 0 0 0 0 1
Immunity 25, immunity I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 5 ,-(). 5 3 0 0 0 0 1
66. Jensen, 66. 6 66 66. 66. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,.,..: 7 9 0 0 0 0 1
receptors involved receptors r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 ...,- 5 8 0 0 0 0 1
(2012). (2012). (2012). ( (2 (20 (201 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 5 (). 3 0 0 0 0 0 1
67. Park, 67. 6 67 67. 67. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,.,.-,, 8 9 0 0 0 0 1
evasion, and evasion, e ev eva evas BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 ,-.,- 5 8 0 0 0 0 1
(2020). (2020). (2020). ( (2 (20 (202 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 5 (). 3 0 0 0 0 0 1
The signal the T Th The The BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 11 - 1 10 0 1 0 0 0
Yang et yang Y Ya Yan Yang BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 7 11 . 1 1 0 1 0 0 0
14 14 14 1 14 14 14 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 11 no 0 10 0 1 0 0 0
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 11 (): 3 10 0 1 1 0 0
68. Blanco-Melo, 68. 6 68 68. 68. BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .-,..--- 8 8 0 0 0 0 1
opment of opment o op opm opme BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 -.,-.(). 8 6 0 0 0 0 1
69. Galani, 69. 6 69 69. 69. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,...- 6 9 0 0 0 0 1
type I/III type t ty typ type BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 /...,-(). 9 9 0 0 0 0 1
70. Siu, 70. 7 70 70. 70. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,... 5 9 0 0 0 0 1
type I type t ty typ type BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ../ 3 8 0 0 0 0 1
IKKepsilon complex. ikkepsilon I IK IKK IKKe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 ....,-(). 9 6 0 0 0 0 1
71. Hu, 71. 7 71 71. 71. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,.. 4 9 0 0 0 0 1
inhibits Type inhibits i in inh inhi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 -- 2 9 0 0 0 0 1
ubiquitination. J. ubiquitination. u ub ubi ubiq BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 ...,-(). 8 5 0 0 0 0 1
72. Minakshi, 72. 7 72 72. 72. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,..- 5 9 0 0 0 0 1
culum stress culum c cu cul culu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 - 1 8 0 0 0 0 1
interferon receptor. interferon i in int inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 .,(). 5 5 0 0 0 0 1
73. Kopecky-Bromberg, 73. 7 73 73. 73. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .-,... 6 9 0 0 0 0 1
open reading open o op ope open BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 (),, 4 8 0 0 0 0 1
interferon antagonists. interferon i in int inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 ...,-(). 8 6 0 0 0 0 1
74. Yang, 74. 7 74 74. 74. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,..- 5 8 0 0 0 0 1
CoV-2-infected human cov-2-infected C Co CoV CoV- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 -- 2 8 0 0 0 0 1
STAT1 phosphorylation. stat1 S ST STA STAT BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 ....,-(). 9 6 0 0 0 0 1
75. Webster, 75. 7 75 75. 75. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,.,,.,.-- 10 9 0 0 0 0 1
cytoid dendritic cytoid c cy cyt cyto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 ...,-(). 8 6 0 0 0 0 1
76. Cervantes-Barragan, 76. 7 76 76. 76. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .-,..- 6 9 0 0 0 0 1
to chronic to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ....,-(). 9 8 0 0 0 0 1
77. Honda, 77. 7 77 77. 77. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,..-- 6 9 0 0 0 0 1
type-I interferon type-i t ty typ type BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 -.,-(). 7 6 0 0 0 0 1
78. Zhou, 78. 7 78 78. 78. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,.. 4 9 0 0 0 0 1
COVID-19 patients. covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 -.,-.(). 8 7 0 0 0 0 1
79. Channappanavar, 79. 7 79 79. 79. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,.. 4 8 0 0 0 0 1
monocyte-macrophage responses monocyte-macrophage m mo mon mono BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 --- 3 7 0 0 0 0 1
infected mice. infected i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 .,-(). 6 6 0 0 0 0 1
80. Channappanavar, 80. 8 80 80. 80. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,..- 5 9 0 0 0 0 1
determines MERS determines d de det dete BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ....,- 6 9 0 0 0 0 1
(2019). (2019). (2019). ( (2 (20 (201 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 7 0 (). 3 0 0 0 0 0 1
81. Lucas, 81. 8 81 81. 81. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,.. 4 9 0 0 0 0 1
COVID-19. Nature covid-19. C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 -.,-(). 7 4 0 0 0 0 1
82. Azkur, 82. 8 82 82. 82. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,...--- 8 8 0 0 0 0 1
nopathological changes nopathological n no nop nopa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 -.,-(). 7 7 0 0 0 0 1
83. Debuc, 83. 8 83 83. 83. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,.,..-? 8 8 0 0 0 0 1
Rev. Rep. rev. R Re Rev Rev. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 ..,-(). 7 2 0 0 0 0 1
84. Li, 84. 8 84 84. 84. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,..-.. 7 8 0 0 0 0 1
Pharm. Anal. pharm. P Ph Pha Phar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 ..,-(). 7 3 0 0 0 0 1
85. Nile, 85. 8 85 85. 85. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,...-:, 8 8 0 0 0 0 1
potential of potential p po pot pote BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ..,-(). 7 8 0 0 0 0 1
86. Wilson, 86. 8 86 86. 86. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,..,..(-) 10 9 0 0 0 0 1
neurosurgery: a neurosurgery: n ne neu neur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 :.... 5 9 0 0 0 0 1
193, 105866 193, 1 19 193 193, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 ,(). 4 2 0 0 0 0 1
87. Moore, 87. 8 87 87. 87. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,..,..-. 9 9 0 0 0 0 1
368, 473-474 368, 3 36 368 368, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 ,-(). 5 2 0 0 0 0 1
88. Fajgenbaum, 88. 8 88 88. 88. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,..,.......,- 14 9 0 0 0 0 1
(2020). (2020). (2020). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 7 0 (). 3 0 0 0 0 0 1
89. Esteban, 89. 8 89 89. 89. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,..,,...,.. 12 9 0 0 0 0 1
lymphohistiocytosis. Pediatr. lymphohistiocytosis. l ly lym lymp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 ...,-(). 8 6 0 0 0 0 1
90. Carter, 90. 9 90 90. 90. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,..,,..,.. 11 10 0 0 0 0 1
adults: recent adults: a ad adu adul BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 :,.- 4 8 0 0 0 0 1
matology 58, matology m ma mat mato BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 ,-(). 5 2 0 0 0 0 1
91. Khanmohammadi, 91. 9 91 91. 91. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,.,.- 6 9 0 0 0 0 1
of COVID-19. of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 -....,-(). 10 5 0 0 0 0 1
92. Trasino, 92. 9 92 92. 92. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,..-?.. 8 9 0 0 0 0 1
Pharmacol. Physiol. pharmacol. P Ph Pha Phar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 ..,-(). 7 4 0 0 0 0 1
93. Onomoto, 93. 9 93 93. 93. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,.,,.,.--- 11 8 0 0 0 0 1
mediated signaling: mediated m me med medi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 :... 4 8 0 0 0 0 1
Immunol. 18, immunol. I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 .,-(). 6 3 0 0 0 0 1
94. Al-Samkari, 94. 9 94 94. 94. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .-,.,.... 9 9 0 0 0 0 1
Pathol. 13, pathol. P Pa Pat Path BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 .,-(). 6 2 0 0 0 0 1
95. Suntharalingam, 95. 9 95 95. 95. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,..- 5 9 0 0 0 0 1
monoclonal antibody monoclonal m mo mon mono BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 .....,-(). 10 7 0 0 0 0 1
96. Engelmann, 96. 9 96 96. 96. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,.,. 5 9 0 0 0 0 1
immunity. Nat. immunity. i im imm immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ....,-(). 9 5 0 0 0 0 1
97. Sakaguchi, 97. 9 97 97. 97. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,.- 4 9 0 0 0 0 1
tolerance and tolerance t to tol tole BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ...., 5 8 0 0 0 0 1
531-562 (2004). 531-562 5 53 531 531- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 -(). 4 1 0 0 0 0 1
98. Sakaguchi, 98. 9 98 98. 98. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,.. 4 9 0 0 0 0 1
self-tolerance and self-tolerance s se sel self BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 -...,-(). 9 8 0 0 0 0 1
99. de 99. 9 99 99. 99. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .,..(-)- 8 9 0 0 0 0 1
antigen-specific human antigen-specific a an ant anti BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 -- 2 8 0 0 0 0 1
presenting capacity presenting p pr pre pres BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 - 1 8 0 0 0 0 1
compatibility complex compatibility c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 ....,-(). 9 7 0 0 0 0 1
100. Bogdan, 100. 1 10 100 100. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,.,,.,. 8 8 0 0 0 0 1
10. J. 10. 1 10 10. 10. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 ....,-(). 9 4 0 0 0 0 1
101. Caricchio, 101. 1 10 101 101. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,..-. 6 9 0 0 0 0 1
Ann. Rheum. ann. A An Ann Ann. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 5 ...,-(). 8 3 0 0 0 0 1
102. Chen, 102. 1 10 102 102. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,....:-- 9 9 0 0 0 0 1
cytokine storm cytokine c cy cyt cyto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 5 ....,(). 8 6 0 0 0 0 1
103. Ruan, 103. 1 10 103 103. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,..- 5 8 0 0 0 0 1
analysis of analysis a an ana anal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 ,..., 5 8 0 0 0 0 1
846-848 (2020). 846-848 8 84 846 846- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 -(). 4 1 0 0 0 0 1
104. Herold, 104. 1 10 104 104. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,..- 5 9 0 0 0 0 1
ventilation in ventilation v ve ven vent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 -....,-().. 11 8 0 0 0 0 1
105. Laing, 105. 1 10 105 105. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,...- 6 9 0 0 0 0 1
with poor with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 ...,-(). 8 5 0 0 0 0 1
106. Price, 106. 1 10 106 106. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,...- 6 9 0 0 0 0 1
pitalized patients pitalized p pi pit pita BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 5 :. 2 8 0 0 0 0 1
Chest 158, chest C Ch Che Ches BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 5 ,-(). 5 3 0 0 0 0 1
107. Giamarellos-Bourboulis, 107. 1 10 107 107. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .-,...- 7 9 0 0 0 0 1
patients with patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 .,-. 4 8 0 0 0 0 1
(2020). (2020). (2020). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 7 5 (). 3 0 0 0 0 0 1
108. Hirano, 108. 1 10 108 108. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,.,.-:, 8 8 0 0 0 0 1
cytokine release cytokine c cy cyt cyto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 5 .,-(). 6 6 0 0 0 0 1
109. Bronte, 109. 1 10 109 109. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,.. 4 9 0 0 0 0 1
severe COVID-19. severe s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 -....,-(). 10 6 0 0 0 0 1
110. Kang, 110. 1 11 110 110. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,.,,.,,.,.- 12 9 0 0 0 0 1
in clinic. in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 5 .,-(). 6 4 0 0 0 0 1
111. Tanaka, 111. 1 11 111 111. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,.,,.,.-,, 11 8 0 0 0 0 1
disease. Cold disease. d di dis dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 ....,(). 8 6 0 0 0 0 1
112. Ulich, 112. 1 11 112 112. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,..,,.,.. 10 10 0 0 0 0 1
interleukin-6 on interleukin-6 i in int inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 -. 2 7 0 0 0 0 1
Blood 73, blood B Bl Blo Bloo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 5 ,-(). 5 2 0 0 0 0 1
113. Tanaka, 113. 1 11 113 113. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,.,,.,.- 9 9 0 0 0 0 1
blockade for blockade b bl blo bloc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 .,-(). 6 6 0 0 0 0 1
114. Biswas, 114. 1 11 114 114. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,..--- 7 9 0 0 0 0 1
ipheral blood ipheral i ip iph iphe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 5 .,- 3 8 0 0 0 0 1
(1998). (1998). (1998). ( (1 (19 (199 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 7 5 (). 3 0 0 0 0 0 1
115. McLoughlin, 115. 1 11 115 115. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,...-- 7 9 0 0 0 0 1
kines by kines k ki kin kine BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 5 -...,- 6 8 0 0 0 0 1
(2004). (2004). (2004). ( (2 (20 (200 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 7 5 (). 3 0 0 0 0 0 1
116. van 116. 1 11 116 116. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,... 5 9 0 0 0 0 1
indicators of indicators i in ind indi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 :.. 3 8 0 0 0 0 1
Thromb. Vasc. thromb. T Th Thr Thro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 5 ...,-(). 8 4 0 0 0 0 1
117. Xiang, 117. 1 11 117 117. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,.. 4 8 0 0 0 0 1
inflammatory cytokine inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 5 -/- 3 8 0 0 0 0 1
gamma-induced vascular gamma-induced g ga gam gamm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 -..... 6 8 0 0 0 0 1
Med. Sci. med. M Me Med Med. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 5 ..,-(). 7 3 0 0 0 0 1
118. Schultz, 118. 1 11 118 118. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,..,..:- 9 9 0 0 0 0 1
protein, serum protein, p pr pro prot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 ,,-,. 5 8 0 0 0 0 1
Semin. Arthritis semin. S Se Sem Semi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 5 ..,-(). 7 4 0 0 0 0 1
119. Alonzi, 119. 1 11 119 119. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,..- 5 9 0 0 0 0 1
as revealed as a as as as BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 []. 3 9 0 0 0 0 1
Mol. Cell. mol. M Mo Mol Mol. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 5 ...,-(). 8 4 0 0 0 0 1
120. Schieffer, 120. 1 12 120 120. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,..()-/ 8 9 0 0 0 0 1
signaling and signaling s si sig sign BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 5 ...,-(). 8 7 0 0 0 0 1
121. Marrero, 121. 1 12 121 121. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,.../ 6 9 0 0 0 0 1
AT1 receptor. at1 A AT AT1 AT1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,-(). 6 4 0 0 0 0 1
122. Kuba, 122. 1 12 122 122. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,..() 6 9 0 0 0 0 1
coronavirus-induced lung coronavirus-induced c co cor coro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 5 -...,-(). 9 6 0 0 0 0 1
123. Glowacka, 123. 1 12 123 123. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,.. 4 9 0 0 0 0 1
severe acute severe s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 .. 2 8 0 0 0 0 1
Virol. 84, virol. V Vi Vir Viro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 5 .,-(). 6 3 0 0 0 0 1
124. Catanzaro, 124. 1 12 124 124. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,..-:- 7 8 0 0 0 0 1
gical challenge gical g gi gic gica BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 5 --.- 4 8 0 0 0 0 1
duct. Target duct. d du duc duct BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 ..,(). 6 3 0 0 0 0 1
125. Decker, 125. 1 12 125 125. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,.,,.,. 8 9 0 0 0 0 1
activity in activity a ac act acti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 ....,-(). 9 7 0 0 0 0 1
126. Luo, 126. 1 12 126 126. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,..- 5 9 0 0 0 0 1
in COVID-19. in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 5 -...,-(). 9 5 0 0 0 0 1
127. Farrar, 127. 1 12 127 127. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,..,..- 8 9 0 0 0 0 1
and its and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 ....,-(). 9 6 0 0 0 0 1
128. Tisoncik, 128. 1 12 128 128. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,........ 10 9 0 0 0 0 1
76, 16-32 76, 7 76 76, 76, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 ,-(). 5 1 0 0 0 0 1
129. Bhattacharyya, 129. 1 12 129 129. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .,.,..- 7 8 0 0 0 0 1
concept. J. concept. c co con conc BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 ...,-(). 8 6 0 0 0 0 1
The signal the T Th The The BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 11 - 1 10 0 1 0 0 0
Yang et yang Y Ya Yan Yang BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 8 11 . 1 1 0 1 0 0 0
15 15 15 1 15 15 15 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 11 no 0 10 0 1 0 0 0
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 11 (): 3 10 0 1 1 0 0
130. Wang, 130. 1 13 130 130. BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.. 4 9 0 0 0 0 1
ill COVID-19 ill i il ill ill BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 -:.. 4 8 0 0 0 0 1
Infect. Dis. infect. I In Inf Infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 0 ..,-(). 7 4 0 0 0 0 1
131. Chen, 131. 1 13 131 131. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.,,..,,..,.. 14 8 0 0 0 0 1
mechanism and mechanism m me mec mech BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 7 0 0 0 0 1
coronavirus disease coronavirus c co cor coro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 .,-(). 6 8 0 0 0 0 1
132. Chen, 132. 1 13 132 132. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.. 4 8 0 0 0 0 1
coronavirus disease coronavirus c co cor coro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ....,-(). 9 7 0 0 0 0 1
133. Pasquereau, 133. 1 13 133 133. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.,,.,.- 9 9 0 0 0 0 1
way in way w wa way way BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 0 -:., 4 9 0 0 0 0 1
(2017). (2017). (2017). ( (2 (20 (201 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 8 0 (). 3 0 0 0 0 0 1
134. Filik, 134. 1 13 134 134. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.,.. 6 8 0 0 0 0 1
cytokine tumor cytokine c cy cyt cyto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 :.,(). 6 8 0 0 0 0 1
135. Gilmore, 135. 1 13 135 135. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..,..-:? 10 9 0 0 0 0 1
Immunol. Rev. immunol. I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ..,-(). 7 3 0 0 0 0 1
136. Hayden, 136. 1 13 136 136. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..,.-..,- 11 9 0 0 0 0 1
(2011). (2011). (2011). ( (2 (20 (201 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 8 0 (). 3 0 0 0 0 0 1
137. Acar, 137. 1 13 137 137. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.,,.,,..,.- 13 10 0 0 0 0 1
nuclear factor-kappa nuclear n nu nuc nucl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 -...,-(). 9 8 0 0 0 0 1
138. Aggarwal, 138. 1 13 138 138. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..:- 6 8 0 0 0 0 1
sword. Nat. sword. s sw swo swor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ....,-(). 9 5 0 0 0 0 1
139. Vanden 139. 1 13 139 139. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..:- 6 8 0 0 0 0 1
apoptotic cell apoptotic a ap apo apop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 .....,-(). 10 8 0 0 0 0 1
140. Dutta, 140. 1 14 140 140. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.. 4 9 0 0 0 0 1
NF-kappaB. Oncogene nf-kappab. N NF NF- NF-k BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 -.,-(). 7 4 0 0 0 0 1
141. Shakhov, 141. 1 14 141 141. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,...-- 7 9 0 0 0 0 1
mediated transcriptional mediated m me med medi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 8 0 0 0 0 1
primary macrophages. primary p pr pri prim BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ....,-(). 9 5 0 0 0 0 1
142. Cheung, 142. 1 14 142 142. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,... 5 9 0 0 0 0 1
coronavirus-infected macrophages coronavirus-infected c co cor coro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 -:. 3 8 0 0 0 0 1
J. Virol. j. J J. J. J. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ..,-(). 7 3 0 0 0 0 1
143. Law, 143. 1 14 143 143. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,...---, 9 8 0 0 0 0 1
monocyte-derived human monocyte-derived m mo mon mono BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 -.,-(). 7 7 0 0 0 0 1
144. Chu, 144. 1 14 144 144. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.. 4 9 0 0 0 0 1
human primary human h hu hum huma BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 - 1 8 0 0 0 0 1
tosis pathways. tosis t to tos tosi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ....,-(). 9 5 0 0 0 0 1
145. Mahallawi, 145. 1 14 145 145. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,...-- 7 9 0 0 0 0 1
inflammatory Th1 inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 .,-(). 6 7 0 0 0 0 1
146. DeDiego, 146. 1 14 146 146. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,...-- 7 9 0 0 0 0 1
acute respiratory acute a ac acu acut BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 -... 4 9 0 0 0 0 1
88, 913-924 88, 8 88 88, 88, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 ,-(). 5 2 0 0 0 0 1
147. Wan, 147. 1 14 147 147. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.. 4 9 0 0 0 0 1
blood of blood b bl blo bloo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 8 0 0 0 0 1
(NCP). Preprint (ncp). ( (N (NC (NCP BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ().://././...(). 16 8 0 0 0 0 1
148. Hiscott, 148. 1 14 148 148. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..- 5 9 0 0 0 0 1
innate immune innate i in inn inna BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 .,-(). 6 7 0 0 0 0 1
149. Martinon, 149. 1 14 149 149. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..- 5 8 0 0 0 0 1
inflammasome. Nature inflammasome. i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 .,-(). 6 4 0 0 0 0 1
150. Martin, 150. 1 15 150 150. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..,,.,. 9 8 0 0 0 0 1
driving inflammation driving d dr dri driv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 - 1 7 0 0 0 0 1
murine peritoneal murine m mu mur muri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ..,-(). 7 8 0 0 0 0 1
151. Bucala, 151. 1 15 151 151. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.,,.,,.,. 11 9 0 0 0 0 1
inflammatory and inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 .. 2 8 0 0 0 0 1
Exp. Med. exp. E Ex Exp Exp. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ..,-(). 7 3 0 0 0 0 1
152. Mridha, 152. 1 15 152 152. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,... 5 9 0 0 0 0 1
and fibrosis and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ...,-(). 8 8 0 0 0 0 1
153. Ather, 153. 1 15 153 153. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,... 5 8 0 0 0 0 1
promotes Th17 promotes p pr pro prom BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ...,-(). 8 7 0 0 0 0 1
154. Petrilli, 154. 1 15 154 154. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.,,.,,..,.: 13 9 0 0 0 0 1
sensing complex sensing s se sen sens BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ....,- 6 8 0 0 0 0 1
(2007). (2007). (2007). ( (2 (20 (200 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 8 0 (). 3 0 0 0 0 0 1
155. Ting, 155. 1 15 155 155. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..,,..,.. 11 10 0 0 0 0 1
death and death d de dea deat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ....,-(). 9 6 0 0 0 0 1
156. Asrani, 156. 1 15 156 156. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.,..-- 8 9 0 0 0 0 1
host: targeting host: h ho hos host BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 :...- 5 9 0 0 0 0 1
chem. 476, chem. c ch che chem BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 .,-(). 6 3 0 0 0 0 1
157. He, 157. 1 15 157 157. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..-- 6 9 0 0 0 0 1
CoV-infected ACE2+ cov-infected C Co CoV CoV- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 -: 2 9 0 0 0 0 1
pathogenesis of pathogenesis p pa pat path BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ...,-(). 8 6 0 0 0 0 1
158. Alosaimi, 158. 1 15 158 158. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..- 5 9 0 0 0 0 1
genes encoding genes g ge gen gene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 / 1 8 0 0 0 0 1
innate immune innate i in inn inna BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ., 2 8 0 0 0 0 1
(2020). (2020). (2020). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 8 0 (). 3 0 0 0 0 0 1
159. Lau, 159. 1 15 159 159. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,....- 7 9 0 0 0 0 1
pression of pression p pr pre pres BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 no 0 8 0 0 0 0 1
syndrome coronavirus: syndrome s sy syn synd BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 :... 4 8 0 0 0 0 1
Virol. 94, virol. V Vi Vir Viro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 .,-(). 6 3 0 0 0 0 1
160. Zhang, 160. 1 16 160 160. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,..- 5 9 0 0 0 0 1
with severe with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 (-): 4 8 0 0 0 0 1
immunologists from immunologists i im imm immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 ...,(). 7 6 0 0 0 0 1
161. Chen, 161. 1 16 161 161. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,..,,.,,..,. 13 9 0 0 0 0 1
syndrome coronavirus syndrome s sy syn synd BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 .. 2 8 0 0 0 0 1
Microbiol. 10, microbiol. M Mi Mic Micr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 .,(). 5 2 0 0 0 0 1
162. Shi, 162. 1 16 162 162. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,..,,..,,..,..- 16 9 0 0 0 0 1
frame-8b triggers frame-8b f fr fra fram BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 -- 2 8 0 0 0 0 1
somes. Cell somes. s so som some BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 ..,(). 6 4 0 0 0 0 1
163. Mousavizadeh, 163. 1 16 163 163. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,.,.-: 7 8 0 0 0 0 1
roles in roles r ro rol role BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 .....,-(). 10 8 0 0 0 0 1
164. Freeman, 164. 1 16 164 164. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,..,.. 7 8 0 0 0 0 1
COVID-19. Front. covid-19. C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 -...,(). 8 4 0 0 0 0 1
165. van 165. 1 16 165 165. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,..,..-: 9 8 0 0 0 0 1
dysregulated. Front. dysregulated. d dy dys dysr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 ...,(). 7 5 0 0 0 0 1
166. Dostert, 166. 1 16 166 166. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,..- 5 8 0 0 0 0 1
sing of sing s si sin sing BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 .,-(). 6 6 0 0 0 0 1
167. Cassel, 167. 1 16 167 167. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,... 5 9 0 0 0 0 1
silicosis. Proc. silicosis. s si sil sili BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 ....,-(). 9 6 0 0 0 0 1
168. Cruz, 168. 1 16 168 168. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,...- 6 9 0 0 0 0 1
stress response stress s st str stre BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 .. 2 8 0 0 0 0 1
Biol. Chem. biol. B Bi Bio Biol BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ..,-(). 7 3 0 0 0 0 1
169. Rosenberg, 169. 1 16 169 169. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,..-:.. 8 9 0 0 0 0 1
Immunol. 192, immunol. I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 .,-(). 6 3 0 0 0 0 1
170. Fu, 170. 1 17 170 170. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,.. 4 8 0 0 0 0 1
MHC II-independent mhc M MH MHC MHC BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 -/--/ 5 8 0 0 0 0 1
STAT5 signaling stat5 S ST STA STAT BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 ....,-(). 9 7 0 0 0 0 1
171. Yuan, 171. 1 17 171 171. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,.,,.,..-- 11 9 0 0 0 0 1
geneity in geneity g ge gen gene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 -...,-(). 9 8 0 0 0 0 1
172. Abbas, 172. 1 17 172 172. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,...-:.. 9 8 0 0 0 0 1
Immunol. 3, immunol. I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 .,(). 5 3 0 0 0 0 1
173. Li, 173. 1 17 173 173. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,...... 8 9 0 0 0 0 1
181, 5490-5500 181, 1 18 181 181, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 ,-(). 5 2 0 0 0 0 1
174. Channappanavar, 174. 1 17 174 174. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,..- 5 9 0 0 0 0 1
protection from protection p pr pro prot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 . 1 8 0 0 0 0 1
J. Virol. j. J J. J. J. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ..,-(). 7 3 0 0 0 0 1
175. Shi, 175. 1 17 175 175. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,..-/-()- 10 9 0 0 0 0 1
phocyte decrease phocyte p ph pho phoc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 -- 2 7 0 0 0 0 1
pneumonia. Cell pneumonia. p pn pne pneu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ..,(). 6 4 0 0 0 0 1
176. Schluns, 176. 1 17 176 176. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,..,,..,,..,.- 15 9 0 0 0 0 1
the homeostasis the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ..., 4 8 0 0 0 0 1
426-432 (2000). 426-432 4 42 426 426- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 -(). 4 1 0 0 0 0 1
177. Tan, 177. 1 17 177 177. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,...- 6 10 0 0 0 0 1
T cells. t T T T T BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 8 5 ....,-(). 9 6 0 0 0 0 1
178. Seddon, 178. 1 17 178 178. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,.,,.,. 8 9 0 0 0 0 1
regulate homeostasis regulate r re reg regu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ...,-(). 8 8 0 0 0 0 1
179. Fry, 179. 1 17 179 179. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,..,..-: 9 9 0 0 0 0 1
T cell t T T T T BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 8 5 ...,-(). 8 5 0 0 0 0 1
180. Barata, 180. 1 18 180 180. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,..,,..,.:-- 13 9 0 0 0 0 1
disease. Nat. disease. d di dis dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ...,-(). 8 4 0 0 0 0 1
181. Saraiva, 181. 1 18 181 181. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,.',.-. 8 9 0 0 0 0 1
Nat. Rev. nat. N Na Nat Nat. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ...,-(). 8 4 0 0 0 0 1
182. Han, 182. 1 18 182 182. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,..--- 7 9 0 0 0 0 1
10 are 10 1 10 10 10 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 5 ...,-(). 8 8 0 0 0 0 1
183. Zhao, 183. 1 18 183 183. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,..--- 7 9 0 0 0 0 1
disease severity disease d di dis dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 .,(). 5 8 0 0 0 0 1
184. Hu, 184. 1 18 184 184. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,.--. 6 9 0 0 0 0 1
https://doi.org/10.31219/osf.io/arfhb (2020). https://doi.org/10.31219/osf.io/arfhb h ht htt http BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 1 8 5 ://./././(). 12 5 0 0 0 0 1
185. Lu, 185. 1 18 185 185. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,.,,.,,..,.. 13 9 0 0 0 0 1
COVID-19 pathogenesis. covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 -..,-(). 8 5 0 0 0 0 1
186. Ma, 186. 1 18 186 186. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,.,.-- 7 8 0 0 0 0 1
presenting cells. presenting p pr pre pres BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ...,-(). 8 5 0 0 0 0 1
187. Vignali, 187. 1 18 187 187. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,..,..-:. 10 9 0 0 0 0 1
Nat. Immunol. nat. N Na Nat Nat. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ..,-(). 7 3 0 0 0 0 1
188. O'Shea, 188. 1 18 188 188. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .',..,..()- 11 9 0 0 0 0 1
controllers. Nat. controllers. c co con cont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ...,-(). 8 5 0 0 0 0 1
189. Ozmen, 189. 1 18 189 189. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,.,,.,,.,. 11 9 0 0 0 0 1
interleukin-12 is interleukin-12 i in int inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 -...,-(). 9 8 0 0 0 0 1
190. Monteiro, 190. 1 19 190 190. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,..,,.,.- 10 9 0 0 0 0 1
influenza virus influenza i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ...,-(). 8 6 0 0 0 0 1
191. Orange, 191. 1 19 191 191. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 5 .,..,,..,..- 12 9 0 0 0 0 1
susceptibility to susceptibility s su sus susc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ...,- 5 8 0 0 0 0 1
(1994). (1994). (1994). ( (1 (19 (199 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 8 5 (). 3 0 0 0 0 0 1
The signal the T Th The The BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 11 - 1 10 0 1 0 0 0
Yang et yang Y Ya Yan Yang BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 8 11 . 1 1 0 1 0 0 0
16 16 16 1 16 16 16 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 11 no 0 10 0 1 0 0 0
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 11 (): 3 10 0 1 1 0 0
192. Wong, 192. 1 19 192 192. BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,... 5 8 0 0 0 0 1
acute respiratory acute a ac acu acut BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ....,-(). 9 7 0 0 0 0 1
193. Cua, 193. 1 19 193 193. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..,..--: 10 9 0 0 0 0 1
system. Nat. system. s sy sys syst BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ....,-(). 9 5 0 0 0 0 1
194. Langrish, 194. 1 19 194 194. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,...- 6 9 0 0 0 0 1
autoimmune inflammation. autoimmune a au aut auto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ....,-(). 9 6 0 0 0 0 1
195. McInnes, 195. 1 19 195 195. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,... 5 9 0 0 0 0 1
of psoriatic of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 :.- 3 8 0 0 0 0 1
matology 56, matology m ma mat mato BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ,-(). 5 3 0 0 0 0 1
196. Pacha, 196. 1 19 196 196. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.,,..,..-:-?. 15 9 0 0 0 0 1
Rev. Immunol. rev. R Re Rev Rev. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 0 ..,-(). 7 3 0 0 0 0 1
197. Josset, 197. 1 19 197 197. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.. 4 9 0 0 0 0 1
EMC predicts emc E EM EMC EMC BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 - 1 8 0 0 0 0 1
onavirus. mBio onavirus. o on ona onav BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 .,-(). 6 4 0 0 0 0 1
198. Faure, 198. 1 19 198 198. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..--: 7 9 0 0 0 0 1
can we can c ca can can BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ?,(). 5 6 0 0 0 0 1
199. Muir, 199. 1 19 199 199. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..- 5 9 0 0 0 0 1
the early the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ..... 5 9 0 0 0 0 1
Care Med. care C Ca Car Care BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 0 .,-(). 6 3 0 0 0 0 1
200. Li, 200. 2 20 200 200. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..- 5 9 0 0 0 0 1
injury. Scand. injury. i in inj inju BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ....,-(). 9 5 0 0 0 0 1
201. Liu, 201. 2 20 201 201. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..-(-)- 9 9 0 0 0 0 1
gerated cytokine gerated g ge ger gera BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 .://./ 6 8 0 0 0 0 1
10.12074/202002.00018 (2020). 10.12074/202002.00018 1 10 10. 10.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 8 0 ./.(). 6 3 0 0 0 0 1
202. Becher, 202. 2 20 202 202. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.,,.,.-: 10 8 0 0 0 0 1
mediator of mediator m me med medi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 .,-(). 6 6 0 0 0 0 1
203. Guilliams, 203. 2 20 203 203. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.. 4 8 0 0 0 0 1
differentiate into differentiate d di dif diff BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 --.... 6 9 0 0 0 0 1
210, 1977-1992 210, 2 21 210 210, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 ,-(). 5 2 0 0 0 0 1
204. Trapnell, 204. 2 20 204 204. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,........, 11 9 0 0 0 0 1
(2019). (2019). (2019). ( (2 (20 (201 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 8 0 (). 3 0 0 0 0 0 1
205. Hamilton, 205. 2 20 205 205. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..-....,(). 13 8 0 0 0 0 1
206. Reghunathan, 206. 2 20 206 206. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.. 4 9 0 0 0 0 1
with Severe with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ..,(). 6 7 0 0 0 0 1
207. Matute-Bello, 207. 2 20 207 207. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .-,.. 5 9 0 0 0 0 1
syndrome. Am. syndrome. s sy syn synd BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ......,-(). 11 7 0 0 0 0 1
208. Ahmed, 208. 2 20 208 208. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.--:., 8 8 0 0 0 0 1
2114-2116 (2019). 2114-2116 2 21 211 2114 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 8 0 -(). 4 1 0 0 0 0 1
209. Lang, 209. 2 20 209 209. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,...---: 9 9 0 0 0 0 1
therapeutic approaches. therapeutic t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ....,-(). 9 6 0 0 0 0 1
210. Liu, 210. 2 21 210 210. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.,,..,.. 10 9 0 0 0 0 1
development of development d de dev deve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 0 ....,- 6 7 0 0 0 0 1
(2016). (2016). (2016). ( (2 (20 (201 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 8 0 (). 3 0 0 0 0 0 1
211. Lee, 211. 2 21 211 211. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,... 5 9 0 0 0 0 1
release syndrome. release r re rel rele BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 .,-(). 6 4 0 0 0 0 1
212. Chan, 212. 2 21 212 212. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.../- 7 8 0 0 0 0 1
improves outcome improves i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 - 1 7 0 0 0 0 1
common marmoset. common c co com comm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ....,-(). 9 6 0 0 0 0 1
213. Stockman, 213. 2 21 213 213. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..,,.,.: 10 9 0 0 0 0 1
effects. PLoS effects. e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ..,(). 6 3 0 0 0 0 1
214. Mantlo, 214. 2 21 214 214. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..--. 7 10 0 0 0 0 1
Antivir. Res. antivir. A An Ant Anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ..,(). 6 3 0 0 0 0 1
215. Zhou, 215. 2 21 215 215. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..--..., 10 9 0 0 0 0 1
1061 (2020). 1061 1 10 106 1061 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 8 0 (). 3 1 0 0 0 0 1
216. Hung, 216. 2 21 216 216. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,...-,-, 9 10 0 0 0 0 1
ribavirin in ribavirin r ri rib riba BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 -: 2 8 0 0 0 0 1
open-label, randomised, open-label, o op ope open BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 -,,.,-(). 9 7 0 0 0 0 1
217. Meng, 217. 2 21 217 217. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.. 4 9 0 0 0 0 1
prevent COVID-19 prevent p pr pre prev BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 -. 2 8 0 0 0 0 1
Med Chem med M Me Med Med BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ,-(). 5 3 0 0 0 0 1
218. Dinnon, 218. 2 21 218 218. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,...:-- 8 9 0 0 0 0 1
CoV-2 to cov-2 C Co CoV CoV- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 --.,(). 7 7 0 0 0 0 1
219. Yang, 219. 2 21 219 219. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,.,,.,,..,.-- 14 9 0 0 0 0 1
receptors in receptors r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 --.://././ 10 8 0 0 0 0 1
2021.02.10.430677 (2021). 2021.02.10.430677 2 20 202 2021 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 8 0 ...(). 6 2 0 0 0 0 1
220. Yin, 220. 2 22 220 220. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..-- 6 9 0 0 0 0 1
epithelial cells. epithelial e ep epi epit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ..,(). 6 5 0 0 0 0 1
221. Rebendenne, 221. 2 22 221 221. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..---- 8 8 0 0 0 0 1
response which response r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ... 3 9 0 0 0 0 1
95, e02415-20 95, 9 95 95, 95, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 ,-(). 5 2 0 0 0 0 1
222. Monneret, 222. 2 22 222 222. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,..- 5 9 0 0 0 0 1
critically ill critically c cr cri crit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 -....,-(). 10 8 0 0 0 0 1
223. Laterre, 223. 2 22 223 223. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 0 .,... 5 9 0 0 0 0 1
counts among counts c co cou coun BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 0 (-). 4 8 0 0 0 0 1
Netw. Open. netw. N Ne Net Netw BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ..,(). 6 3 0 0 0 0 1
224. Clark, 224. 2 22 224 224. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,..-,, 7 9 0 0 0 0 1
through altering through t th thr thro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 ....(). 7 8 0 0 0 0 1
225. WHOREAfC-TW 225. 2 22 225 225. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .-.- 4 8 0 0 0 0 1
costeroids and costeroids c co cos cost BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 6 -:- 3 8 0 0 0 0 1
analysis. JAMA analysis. a an ana anal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 .,-(). 6 4 0 0 0 0 1
226. Johnson, 226. 2 22 226 226. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,..,..-. 9 9 0 0 0 0 1
BMJ 370, bmj B BM BMJ BMJ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 ,(). 4 2 0 0 0 0 1
227. Lin, 227. 2 22 227 227. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,.-..., 8 9 0 0 0 0 1
1697-1702 (2015). 1697-1702 1 16 169 1697 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 6 -(). 4 1 0 0 0 0 1
228. Karkhur, 228. 2 22 228 228. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,..-- 6 9 0 0 0 0 1
uveitis and uveitis u uv uve uvei BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 6 ....,(). 8 7 0 0 0 0 1
229. Kaplon, 229. 2 22 229 229. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,.,..., 8 8 0 0 0 0 1
(2021). (2021). (2021). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 6 (). 3 0 0 0 0 0 1
230. Xu, 230. 2 23 230 230. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,..-. 6 9 0 0 0 0 1
Proc. Natl proc. P Pr Pro Proc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 ...,-(). 8 5 0 0 0 0 1
231. Gupta, 231. 2 23 231 231. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,.. 4 8 0 0 0 0 1
mortality among mortality m mo mor mort BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 -..., 5 8 0 0 0 0 1
41-51 (2021). 41-51 4 41 41- 41-5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 -(). 4 1 0 0 0 0 1
232. Veiga, 232. 2 23 232 232. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,... 5 10 0 0 0 0 1
with severe with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 :. 2 9 0 0 0 0 1
372, n84 372, 3 37 372 372, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 ,(). 4 1 0 0 0 0 1
233. Salama, 233. 2 23 233 233. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,..-. 6 9 0 0 0 0 1
N. Engl. n. N N. N. N. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 ....,-(). 9 3 0 0 0 0 1
234. Galvan-Roman, 234. 2 23 234 234. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .-,...- 7 9 0 0 0 0 1
tocilizumab in tocilizumab t to toc toci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 6 -:...., 7 8 0 0 0 0 1
72-80 (2021). 72-80 7 72 72- 72-8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 -().. 5 2 0 0 0 0 1
235. Hermine, 235. 2 23 235 235. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,.. 4 9 0 0 0 0 1
COVID-19 and covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 -:. 3 8 0 0 0 0 1
Intern. Med. intern. I In Int Inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 6 ..,-(). 7 3 0 0 0 0 1
236. Salvarani, 236. 2 23 236 236. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,.. 4 9 0 0 0 0 1
patients hospitalized patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 -:. 3 8 0 0 0 0 1
JAMA Intern. jama J JA JAM JAMA BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 9 6 ..,-(). 7 4 0 0 0 0 1
237. Stone, 237. 2 23 237 237. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,...-. 7 9 0 0 0 0 1
N. Engl. n. N N. N. N. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 ....,-(). 9 4 0 0 0 0 1
238. Ramiro, 238. 2 23 238 238. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,.. 4 9 0 0 0 0 1
without tocilizumab without w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 -- 2 8 0 0 0 0 1
associated cytokine associated a as ass asso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 :.... 5 8 0 0 0 0 1
79, 1143-1151 79, 7 79 79, 79, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 ,-(). 5 2 0 0 0 0 1
239. Roumier, 239. 2 23 239 239. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,..-: 6 8 0 0 0 0 1
propensity score propensity p pr pro prop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 ....,-(). 9 7 0 0 0 0 1
240. Martinez-Sanz, 240. 2 24 240 240. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .-,.. 5 9 0 0 0 0 1
patients with patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 -:...., 7 8 0 0 0 0 1
238-243 (2021). 238-243 2 23 238 238- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 -(). 4 1 0 0 0 0 1
241. Rodriguez-Bano, 241. 2 24 241 241. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .-,.. 5 8 0 0 0 0 1
COVID-19 patients covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 -: 2 8 0 0 0 0 1
(SAM-COVID-19). Clin. (sam-covid-19). ( (S (SA (SAM BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 (--)....,-(). 13 6 0 0 0 0 1
242. Sanz 242. 2 24 242 242. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,..- 5 8 0 0 0 0 1
tality in tality t ta tal tali BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 6 --:...., 8 8 0 0 0 0 1
259-263 (2021). 259-263 2 25 259 259- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 -(). 4 1 0 0 0 0 1
243. Strohbehn, 243. 2 24 243 243. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,...:- 7 9 0 0 0 0 1
in the in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 6 -...., 6 8 0 0 0 0 1
688-696 (2021). 688-696 6 68 688 688- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 -(). 4 1 0 0 0 0 1
244. Pomponio, 244. 2 24 244 244. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,..-... 8 9 0 0 0 0 1
Med. 289, med. M Me Med Med. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 .,-(). 6 2 0 0 0 0 1
245. Perez-Saez, 245. 2 24 245 245. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .-,... 6 9 0 0 0 0 1
COVID-19. Am. covid-19. C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 -....,-(). 10 5 0 0 0 0 1
246. Morillas, 246. 2 24 246 246. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,...- 6 9 0 0 0 0 1
plant recipients plant p pl pla plan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 --...., 7 8 0 0 0 0 1
3191-3197 (2020). 3191-3197 3 31 319 3191 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 -(). 4 1 0 0 0 0 1
247. Menzella, 247. 2 24 247 247. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,..- 5 8 0 0 0 0 1
undergoing noninvasive undergoing u un und unde BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 ..,(). 6 6 0 0 0 0 1
248. Della-Torre, 248. 2 24 248 248. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .-,..-- 7 9 0 0 0 0 1
pneumonia with pneumonia p pn pne pneu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 :-.. 4 8 0 0 0 0 1
Rheum. Dis. rheum. R Rh Rhe Rheu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 ..,-(). 7 3 0 0 0 0 1
249. Montesarchio, 249. 2 24 249 249. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,.. 4 8 0 0 0 0 1
COVID-19 treated covid-19 C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 -(-) 4 8 0 0 0 0 1
single institution single s si sin sing BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 ...,(). 7 7 0 0 0 0 1
250. Gritti, 250. 2 25 250 250. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,..- 5 9 0 0 0 0 1
with COVID-19 with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 -:. 3 8 0 0 0 0 1
medRxiv https://doi.org/10.1101/2020.04.01.20048561 medrxiv m me med medR BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 6 ://././...(). 13 6 0 0 0 0 1
251. Cauchois, 251. 2 25 251 251. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,..-- 6 9 0 0 0 0 1
tory failure tory t to tor tory BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 9 6 -....,- 7 8 0 0 0 0 1
(2020). (2020). (2020). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 6 (). 3 0 0 0 0 0 1
252. Kooistra, 252. 2 25 252 252. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,...-: 7 9 0 0 0 0 1
prospective cohort prospective p pr pro pros BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 ..,(). 6 5 0 0 0 0 1
The signal the T Th The The BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 11 - 1 10 0 1 0 0 0
Yang et yang Y Ya Yan Yang BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 9 11 . 1 1 0 1 0 0 0
17 17 17 1 17 17 17 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 11 no 0 10 0 1 0 0 0
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 11 (): 3 10 0 1 1 0 0
253. Dimopoulos, 253. 2 25 253 253. BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,..- 5 9 0 0 0 0 1
with secondary with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ., 2 7 0 0 0 0 1
117-123.e111 (2020). 117-123.e111 1 11 117 117- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 -.(). 5 2 0 0 0 0 1
254. Huet, 254. 2 25 254 254. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,..-:. 7 9 0 0 0 0 1
Rheumatol. 2, rheumatol. R Rh Rhe Rheu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 .,-(). 6 3 0 0 0 0 1
255. Cavalli, 255. 2 25 255 255. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,..-- 6 9 0 0 0 0 1
COVID-19, acute covid-19, C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 -,,:- 5 8 0 0 0 0 1
rospective cohort rospective r ro ros rosp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 ..,-(). 7 6 0 0 0 0 1
256. Balkhair, 256. 2 25 256 256. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,..- 5 8 0 0 0 0 1
pneumonia requiring pneumonia p pn pne pneu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 :,-, 4 8 0 0 0 0 1
interventional study. interventional i in int inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 .....,-(). 10 6 0 0 0 0 1
257. Bozzi, 257. 2 25 257 257. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,.. 4 8 0 0 0 0 1
severe COVID-19 severe s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 -: 2 7 0 0 0 0 1
study. J. study. s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ....,-.(). 10 6 0 0 0 0 1
258. The 258. 2 25 258 258. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .-. 3 8 0 0 0 0 1
adults in adults a ad adu adul BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ---(- 5 7 0 0 0 0 1
IMUNO-ANA-1): a imuno-ana-1): I IM IMU IMUN BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 --):...,- 9 8 0 0 0 0 1
(2021). (2021). (2021). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 0 (). 3 0 0 0 0 0 1
259. Iglesias-Julian, 259. 2 25 259 259. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .-,.. 5 8 0 0 0 0 1
respiratory distress respiratory r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 7 0 0 0 0 1
severely ill severely s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 -...,(). 8 7 0 0 0 0 1
260. Navarro-Millan, 260. 2 26 260 260. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .-,.. 5 9 0 0 0 0 1
severe COVID-19: severe s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 -:..,-(). 9 8 0 0 0 0 1
261. Kyriazopoulou, 261. 2 26 261 261. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,.. 4 9 0 0 0 0 1
failure in failure f fa fai fail BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 -.,(). 6 5 0 0 0 0 1
262. Ucciferri, 262. 2 26 262 262. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,..-. 6 9 0 0 0 0 1
Rheumatol. 2, rheumatol. R Rh Rhe Rheu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 .,-(). 6 3 0 0 0 0 1
263. Katia, 263. 2 26 263 263. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,..-. 6 9 0 0 0 0 1
Immun. Inflamm. immun. I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ..,-(). 7 4 0 0 0 0 1
264. Sheng, 264. 2 26 264 264. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,... 5 8 0 0 0 0 1
respiratory function respiratory r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 --- 3 8 0 0 0 0 1
tened inflammation tened t te ten tene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 (-:). 5 8 0 0 0 0 1
Clin. Cardiol. clin. C Cl Cli Clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ..,-(). 7 4 0 0 0 0 1
265. Generali, 265. 2 26 265 265. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,..--: 7 9 0 0 0 0 1
prospective case-control prospective p pr pro pros BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 -.....,-(). 11 8 0 0 0 0 1
266. Landi, 266. 2 26 266 266. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,..- 5 9 0 0 0 0 1
Covid-19. Sci. covid-19. C Co Cov Covi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 -...,(). 8 4 0 0 0 0 1
267. National 267. 2 26 267 267. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 ... 3 8 0 0 0 0 1
LiverTox: Clinical livertox: L Li Liv Live BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 :-( 3 9 0 0 0 0 1
Institute of institute I In Ins Inst BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ,). 3 6 0 0 0 0 1
268. Chen, 268. 2 26 268 268. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,..,,..,.. 11 9 0 0 0 0 1
COVID-19: learning covid-19: C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 -:....., 8 8 0 0 0 0 1
1753466620926800 (2020). 1753466620926800 1 17 175 1753 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 9 0 (). 3 2 0 0 0 0 1
269. Duret, 269. 2 26 269 269. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,...- 6 9 0 0 0 0 1
treated with treated t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 -....,- 7 8 0 0 0 0 1
(2020). (2020). (2020). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 0 (). 3 0 0 0 0 0 1
270. Kunisaki, 270. 2 27 270 270. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,.,,.,.-- 10 8 0 0 0 0 1
pneumonia by pneumonia p pn pne pneu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 -: 2 7 0 0 0 0 1
case report. case c ca cas case BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 0 ..,-(). 7 5 0 0 0 0 1
271. Feldmann, 271. 2 27 271 271. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,..-- 6 9 0 0 0 0 1
are urgently are a ar are are BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 .,-(). 6 5 0 0 0 0 1
272. Bai, 272. 2 27 272 272. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,..--,-/,- 11 10 0 0 0 0 1
brodalumab, secukinumab, brodalumab, b br bro brod BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,,,,- 6 7 0 0 0 0 1
drakizumab, and drakizumab, d dr dra drak BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 , 1 8 0 0 0 0 1
psoriasis: a psoriasis: p ps pso psor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 :-- 3 8 0 0 0 0 1
trolled trials. trolled t tr tro trol BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 ....,(). 8 5 0 0 0 0 1
273. Armstrong, 273. 2 27 273 273. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,..,.,,- 9 9 0 0 0 0 1
ment of ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 :.,-(). 7 6 0 0 0 0 1
274. Almradi, 274. 2 27 274 274. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,..-/- 7 9 0 0 0 0 1
disease. BioDrugs disease. d di dis dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 .,-(). 6 4 0 0 0 0 1
275. Feagan, 275. 2 27 275 275. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,... 5 8 0 0 0 0 1
Crohn's disease. crohn's C Cr Cro Croh BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 '.....,-(). 11 6 0 0 0 0 1
276. Moschen, 276. 2 27 276 276. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,..,,.,.-,--: 14 9 0 0 0 0 1
and therapeutic and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 .....,-(). 10 8 0 0 0 0 1
277. Sadeghinia, 277. 2 27 277 277. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,.,. 5 8 0 0 0 0 1
with psoriasis with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 -...., 6 8 0 0 0 0 1
e14498 (2021). e14498 e e1 e14 e144 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 0 (). 3 1 0 0 0 0 1
278. Ward, 278. 2 27 278 278. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,.,.- 6 8 0 0 0 0 1
receiving risankizumab, receiving r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 0 ,..,- 5 8 0 0 0 0 1
(2021). (2021). (2021). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 0 (). 3 0 0 0 0 0 1
279. Kiss, 279. 2 27 279 279. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,.. 4 9 0 0 0 0 1
chronic obstructive chronic c ch chr chro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 7 0 0 0 0 1
Dermatol. Ther. dermatol. D De Der Derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ..,(). 6 3 0 0 0 0 1
280. Messina, 280. 2 28 280 280. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,.,,.,.:- 10 9 0 0 0 0 1
in a in i in in in BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 0 -. 2 8 0 0 0 0 1
A report a A A A A BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 10 5 -- 2 8 0 0 0 0 1
numab. Ann. numab. n nu num numa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 ....,-(). 9 4 0 0 0 0 1
281. Messina, 281. 2 28 281 281. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,.,.-- 7 9 0 0 0 0 1
with IL-23 with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 -......,-(). 12 8 0 0 0 0 1
282. Wang, 282. 2 28 282 282. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,..,..--.. 11 9 0 0 0 0 1
Ther. 33, ther. T Th The Ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 5 .,(). 5 2 0 0 0 0 1
283. Shibabaw, 283. 2 28 283 283. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,.:-- 6 8 0 0 0 0 1
sent with sent s se sen sent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 -....,- 7 8 0 0 0 0 1
(2020). (2020). (2020). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 5 (). 3 0 0 0 0 0 1
284. Mendoza, 284. 2 28 284 284. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,...-:-.. 10 9 0 0 0 0 1
Infect. 81, infect. I In Inf Infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 5 .,-(). 6 3 0 0 0 0 1
285. Ayhan, 285. 2 28 285 285. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,..---. 8 9 0 0 0 0 1
Dermatol. Ther. dermatol. D De Der Derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 5 ..,(). 6 3 0 0 0 0 1
286. Casillo, 286. 2 28 286 286. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,...- 6 8 0 0 0 0 1
treatment and/or treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 /--? 4 7 0 0 0 0 1
Pharm. Res. pharm. P Ph Pha Phar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 5 ..,(). 6 3 0 0 0 0 1
287. Piaserico, 287. 2 28 287 287. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,.,,.,.:-: 11 9 0 0 0 0 1
therapeutic target therapeutic t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 -...,-(). 9 6 0 0 0 0 1
288. Cafarotti, 288. 2 28 288 288. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,.-- 5 8 0 0 0 0 1
patients with patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 :-.. 4 9 0 0 0 0 1
Thorac. Oncol. thorac. T Th Tho Thor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 5 ..,-(). 7 4 0 0 0 0 1
289. Wiche 289. 2 28 289 289. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,..,,.,,..,.- 14 9 0 0 0 0 1
17 pathway 17 1 17 17 17 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 no 0 8 0 0 0 0 1
SARS-CoV-2 infection. sars-cov-2 S SA SAR SARS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 --.,-(). 8 5 0 0 0 0 1
290. Conti, 290. 2 29 290 290. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,.,,.,,.,.- 12 9 0 0 0 0 1
four psoriatic four f fo fou four BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 ..... 5 8 0 0 0 0 1
Venereol. 34, venereol. V Ve Ven Vene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 5 .,-(). 6 3 0 0 0 0 1
291. Balestri, 291. 2 29 291 291. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,.,,.,..-- 11 10 0 0 0 0 1
treated with treated t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 -......,- 9 8 0 0 0 0 1
(2020). (2020). (2020). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 5 (). 3 0 0 0 0 0 1
292. Carugno, 292. 2 29 292 292. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,..(-) 7 9 0 0 0 0 1
treated with treated t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 :?.., 5 8 0 0 0 0 1
e14011 (2020). e14011 e e1 e14 e140 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 5 (). 3 1 0 0 0 0 1
293. Gisondi, 293. 2 29 293 293. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,..- 5 9 0 0 0 0 1
plaque psoriasis plaque p pl pla plaq BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 : 1 8 0 0 0 0 1
experience. Br. experience. e ex exp expe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 ....,-(). 9 5 0 0 0 0 1
294. Presneill, 294. 2 29 294 294. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,...- 6 9 0 0 0 0 1
colony-stimulating factor colony-stimulating c co col colo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 -. 2 8 0 0 0 0 1
Am. J. am. A Am Am. Am. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 5 .....,-(). 10 5 0 0 0 0 1
295. Orozco, 295. 2 29 295 295. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,..(-) 7 9 0 0 0 0 1
nontraumatic abdominal nontraumatic n no non nont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 :,-,- 5 7 0 0 0 0 1
controlled clinical controlled c co con cont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 ...,-();. 9 8 0 0 0 0 1
296. Paine, 296. 2 29 296 296. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,..- 5 8 0 0 0 0 1
macrophage colony macrophage m ma mac macr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 .. 2 8 0 0 0 0 1
Care Med. care C Ca Car Care BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 5 .,-(). 6 3 0 0 0 0 1
297. Crotti, 297. 2 29 297 297. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,..: 5 9 0 0 0 0 1
in the in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 10 5 ...,- 5 9 0 0 0 0 1
(2019). (2019). (2019). ( (2 (20 (201 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 5 (). 3 0 0 0 0 0 1
298. De 298. 2 29 298 298. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,..-- 6 8 0 0 0 0 1
pneumonia and pneumonia p pn pne pneu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 :-, 3 7 0 0 0 0 1
cohort study. cohort c co coh coho BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 ..,-(). 7 5 0 0 0 0 1
299. Temesgen, 299. 2 29 299 299. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,..-- 6 8 0 0 0 0 1
pneumonia: a pneumonia: p pn pne pneu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 :-...,-(). 10 7 0 0 0 0 1
300. Zhang, 300. 3 30 300 300. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,..,-- 7 9 0 0 0 0 1
from entering from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 -.. 3 8 0 0 0 0 1
Immunopharmacol. 86, immunopharmacol. I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 5 .,(). 5 3 0 0 0 0 1
301. Yeleswaram, 301. 3 30 301 301. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,..- 5 9 0 0 0 0 1
cations for cations c ca cat cati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 -...,(). 8 7 0 0 0 0 1
302. Seif, 302. 3 30 302 302. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,..- 5 9 0 0 0 0 1
19. Int. 19. 1 19 19. 19. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 ....,-(). 9 5 0 0 0 0 1
303. Pearce, 303. 3 30 303 303. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,.,,..,..-: 12 9 0 0 0 0 1
spotlight on spotlight s sp spo spot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 ...,- 5 8 0 0 0 0 1
(2020). (2020). (2020). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 5 (). 3 0 0 0 0 0 1
304. Satarker, 304. 3 30 304 304. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,..-- 6 9 0 0 0 0 1
19 therapy. 19 1 19 19 19 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 ...,-(). 8 5 0 0 0 0 1
305. Calabrese, 305. 3 30 305 305. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,..,,.,. 9 9 0 0 0 0 1
the prospects the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 -,:- 4 8 0 0 0 0 1
bition: posted bition: b bi bit biti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 :,.....(). 10 6 0 0 0 0 1
306. Flanagan, 306. 3 30 306 306. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,...-,: 8 8 0 0 0 0 1
kinase (JAK) kinase k ki kin kina BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 () 2 8 0 0 0 0 1
transplant rejection. transplant t tr tra tran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 ....,-(). 9 6 0 0 0 0 1
307. Danese, 307. 3 30 307 307. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,.,,.,,.,..- 13 9 0 0 0 0 1
tinib for tinib t ti tin tini BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 :- 2 8 0 0 0 0 1
matory cytokines. matory m ma mat mato BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 ......,- 8 8 0 0 0 0 1
(2016). (2016). (2016). ( (2 (20 (201 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 5 (). 3 0 0 0 0 0 1
The signal the T Th The The BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 11 - 1 10 0 1 0 0 0
Yang et yang Y Ya Yan Yang BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 10 11 . 1 1 0 1 0 0 0
18 18 18 1 18 18 18 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 11 no 0 10 0 1 0 0 0
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 11 (): 3 10 0 1 1 0 0
308. Quintas-Cardama, 308. 3 30 308 308. BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .-,../ 6 9 0 0 0 0 1
inhibitor INCB018424: inhibitor i in inh inhi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 0 :- 2 8 0 0 0 0 1
liferative neoplasms. liferative l li lif life BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 0 .,-(). 6 5 0 0 0 0 1
309. Verstovsek, 309. 3 30 309 309. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,..,- 6 9 0 0 0 0 1
bitor, in bitor, b bi bit bito BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 0 ,.....,-(). 11 7 0 0 0 0 1
310. van 310. 3 31 310 310. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,..- 5 8 0 0 0 0 1
matoid arthritis. matoid m ma mat mato BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 0 ....,-(). 9 6 0 0 0 0 1
311. Hoang, 311. 3 31 311 311. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,...- 6 8 0 0 0 0 1
inflammation and inflammation i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 --- 3 7 0 0 0 0 1
macaques. Cell macaques. m ma mac maca BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 0 .,-.(). 7 4 0 0 0 0 1
312. Rodriguez-Garcia, 312. 3 31 312 312. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .-,... 6 9 0 0 0 0 1
treated with treated t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 --: 3 8 0 0 0 0 1
study. Rheumatology study. s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 .,-(). 6 4 0 0 0 0 1
313. Moreno-Gonzalez, 313. 3 31 313 313. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .-,../ 6 9 0 0 0 0 1
baricitinib to baricitinib b ba bar bari BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 0 - 1 7 0 0 0 0 1
hematological patients hematological h he hem hema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 0 : 1 7 0 0 0 0 1
study protocol study s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 .,(). 5 7 0 0 0 0 1
314. Stebbing, 314. 3 31 314 314. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,..- 5 9 0 0 0 0 1
predicted testing predicted p pr pre pred BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 -...,(). 8 8 0 0 0 0 1
315. Cantini, 315. 3 31 315 315. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,..-: 6 9 0 0 0 0 1
clinical impact. clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 ...,-(). 8 5 0 0 0 0 1
316. Kalil, 316. 3 31 316 316. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,...-. 7 10 0 0 0 0 1
N. Engl. n. N N. N. N. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 10 0 ....,-(). 9 4 0 0 0 0 1
317. Cantini, 317. 3 31 317 317. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,..-- 6 9 0 0 0 0 1
monia; multicentre monia; m mo mon moni BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 0 ;...,-(). 9 6 0 0 0 0 1
318. Titanji, 318. 3 31 318 318. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,...- 6 9 0 0 0 0 1
19. Clin. 19. 1 19 19. 19. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 ....,-(). 9 4 0 0 0 0 1
319. Cingolani, 319. 3 31 319 319. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,..- 5 9 0 0 0 0 1
no complete no n no no no BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 .,-(). 6 7 0 0 0 0 1
320. Hasan, 320. 3 32 320 320. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,..,,.,,..,... 15 9 0 0 0 0 1
loading dose loading l lo loa load BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 -..,- 5 7 0 0 0 0 1
(2021). (2021). (2021). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 0 (). 3 0 0 0 0 0 1
321. Sodani, 321. 3 32 321 321. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,..- 5 9 0 0 0 0 1
baricitinib, tocilizumab, baricitinib, b ba bar bari BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 0 ,,.: 4 8 0 0 0 0 1
clinical role clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 ...., 5 8 0 0 0 0 1
(2020). (2020). (2020). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 0 (). 3 0 0 0 0 0 1
322. Rosas, 322. 3 32 322 322. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,..- 5 8 0 0 0 0 1
therapy or therapy t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 , 1 8 0 0 0 0 1
coronavirus COVID19: coronavirus c co cor coro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 0 :-...-,- 8 8 0 0 0 0 1
(2020). (2020). (2020). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 0 (). 3 0 0 0 0 0 1
323. Goker 323. 3 32 323 323. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,.,./ 6 9 0 0 0 0 1
ruxolitinib in ruxolitinib r ru rux ruxo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 0 -..,- 5 8 0 0 0 0 1
(2020). (2020). (2020). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 0 (). 3 0 0 0 0 0 1
324. Innes, 324. 3 32 324 324. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,...--. 8 9 0 0 0 0 1
Br. J. br. B Br Br. Br. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 0 ...,-(). 8 4 0 0 0 0 1
325. Cao, 325. 3 32 325 325. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,..(- 6 9 0 0 0 0 1
19): a 19): 1 19 19) 19): BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 ):,-,... 8 8 0 0 0 0 1
Immunol. 146, immunol. I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 0 .,-.(). 7 3 0 0 0 0 1
326. Caocci, 326. 3 32 326 326. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,.,.- 6 9 0 0 0 0 1
infection at infection i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 ()?.. 5 8 0 0 0 0 1
99, 1675-1676 99, 9 99 99, 99, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 ,-(). 5 2 0 0 0 0 1
327. Winthrop, 327. 3 32 327 327. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,... 5 9 0 0 0 0 1
receiving Tofacitinib. receiving r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 10 0 ...,-(). 8 7 0 0 0 0 1
328. Colombel, 328. 3 32 328 328. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,.. 4 9 0 0 0 0 1
colitis: mechanism, colitis: c co col coli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 0 :,,,.. 6 7 0 0 0 0 1
Bowel Dis. bowel B Bo Bow Bowe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 0 .,-(). 6 3 0 0 0 0 1
329. Askin, 329. 3 32 329 329. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,.,,.,,..,.,.. 15 9 0 0 0 0 1
Serdaroglu, S. serdaroglu, S Se Ser Serd BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 0 ,. 2 9 0 0 0 0 1
during the during d du dur duri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 -...,(). 8 7 0 0 0 0 1
330. Beyzarov, 330. 3 33 330 330. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,..-- 6 8 0 0 0 0 1
utilization-safety surveillance: utilization-safety u ut uti util BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 -:'..,- 7 8 0 0 0 0 1
(2021). (2021). (2021). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 0 (). 3 0 0 0 0 0 1
331. Agrawal, 331. 3 33 331 331. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,..- 5 9 0 0 0 0 1
on Tofacitinib on o on on on BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 -..., 5 8 0 0 0 0 1
585-589 (2020). 585-589 5 58 585 585- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 -(). 4 1 0 0 0 0 1
332. Favalli, 332. 3 33 332 332. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,..,,.,,.,.-: 14 10 0 0 0 0 1
suitable treatment? suitable s su sui suit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 ?..,-(). 8 6 0 0 0 0 1
333. Praveen, 333. 3 33 333 333. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,.,,..,.. 10 9 0 0 0 0 1
ideal option ideal i id ide idea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 -...., 6 8 0 0 0 0 1
(2020). (2020). (2020). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 0 (). 3 0 0 0 0 0 1
334. Picchianti 334. 3 33 334 334. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,..-, 6 9 0 0 0 0 1
new scenario new n ne new new BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 : 1 8 0 0 0 0 1
autoimmunity. Int. autoimmunity. a au aut auto BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 0 .....,(). 9 5 0 0 0 0 1
335. US 335. 3 33 335 335. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 ... 3 9 0 0 0 0 1
Increased Risk increased I In Inc Incr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 5 no 0 8 0 0 0 0 1
Ulcerative Colitis ulcerative U Ul Ulc Ulce BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 5 (,). 4 6 0 0 0 0 1
336. Kircheis, 336. 3 33 336 336. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,..- 5 9 0 0 0 0 1
critical stage critical c cr cri crit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 -...,(). 8 7 0 0 0 0 1
337. Kandasamy, 337. 3 33 337 337. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,.--: 6 8 0 0 0 0 1
potential roles potential p po pot pote BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 ... 3 8 0 0 0 0 1
394, 561-567 394, 3 39 394 394, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 ,-(). 5 2 0 0 0 0 1
338. Hariharan, 338. 3 33 338 338. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,..-- 6 9 0 0 0 0 1
severe COVID-19 severe s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 -.,-(). 7 7 0 0 0 0 1
339. Ma, 339. 3 33 339 339. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,..(-)-- 9 9 0 0 0 0 1
against novel against a ag aga agai BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 (--)(- 6 7 0 0 0 0 1
229E) by 229e) 2 22 229 229E BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 )(-). 5 8 0 0 0 0 1
Phytomedicine 78, phytomedicine P Ph Phy Phyt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 5 ,(). 4 3 0 0 0 0 1
340. Masih, 340. 3 34 340 340. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,..- 5 8 0 0 0 0 1
inflammatory agent inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 5 .- 2 8 0 0 0 0 1
benefit against benefit b be ben bene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 --.....,(). 11 8 0 0 0 0 1
341. Ma, 341. 3 34 341 341. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,..- 5 9 0 0 0 0 1
against novel against a ag aga agai BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 --- 3 8 0 0 0 0 1
pathway. Pharm. pathway. p pa pat path BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 ...,(). 7 4 0 0 0 0 1
342. D'Acquisto, 342. 3 34 342 342. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .',.,,..,.(- 12 9 0 0 0 0 1
B): an b): B B) B): B): BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 11 5 ):-...,- 8 8 0 0 0 0 1
(2002). (2002). (2002). ( (2 (20 (200 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 5 (). 3 0 0 0 0 0 1
343. Liang, 343. 3 34 343 343. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,..- 5 8 0 0 0 0 1
sinin combination sinin s si sin sini BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 5 - 1 8 0 0 0 0 1
lupus nephritis lupus l lu lup lupu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 5 ....,-(). 9 6 0 0 0 0 1
344. Cheung, 344. 3 34 344 344. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,..,,..,.- 11 10 0 0 0 0 1
measured by measured m me mea meas BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 -,...., 7 8 0 0 0 0 1
32-37 (2010). 32-37 3 32 32- 32-3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 -(). 4 1 0 0 0 0 1
345. Bleyzac, 345. 3 34 345 345. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,.,,.,,.,.-: 13 9 0 0 0 0 1
more than more m mo mor more BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 ?..,-(). 8 8 0 0 0 0 1
346. Assimakopoulos, 346. 3 34 346 346. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,..,.---- 10 8 0 0 0 0 1
associated cytokine associated a as ass asso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 .. 2 7 0 0 0 0 1
Hypotheses 140, hypotheses H Hy Hyp Hypo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 5 ,(). 4 3 0 0 0 0 1
347. Oka, 347. 3 34 347 347. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,..--- 7 8 0 0 0 0 1
through inhibition through t th thr thro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 ..,-(). 7 7 0 0 0 0 1
348. McCarty, 348. 3 34 348 348. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,...- 6 9 0 0 0 0 1
some activation: some s so som some BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 :-. 3 7 0 0 0 0 1
Nutrients 13, nutrients N Nu Nut Nutr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 5 ,(). 4 2 0 0 0 0 1
349. Shah, 349. 3 34 349 349. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,.-:- 6 8 0 0 0 0 1
tial drug tial t ti tia tial BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 5 -...,(). 8 8 0 0 0 0 1
350. Toldo, 350. 3 35 350 350. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,.,.. 6 9 0 0 0 0 1
Nat. Rev. nat. N Na Nat Nat. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 5 ...,-(). 8 4 0 0 0 0 1
351. Marques-da-Silva, 351. 3 35 351 351. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .--,.. 6 9 0 0 0 0 1
ATP in atp A AT ATP ATP BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 11 5 -: 2 8 0 0 0 0 1
action. Br. action. a ac act acti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 ....,-(). 9 5 0 0 0 0 1
352. Chen, 352. 3 35 352 352. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,..- 5 8 0 0 0 0 1
inflammasome activation inflammasome i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 5 no 0 7 0 0 0 0 1
shock. Mediat. shock. s sh sho shoc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 ...,(). 7 5 0 0 0 0 1
353. Saeedi-Boroujeni, 353. 3 35 353 353. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .-,.,-,..,,.,. 14 8 0 0 0 0 1
COVID-19: a covid-19: C CO COV COVI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 -:,- 4 8 0 0 0 0 1
mation with mation m ma mat mati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 5 ?...,-(). 9 8 0 0 0 0 1
354. Quagliariello, 354. 3 35 354 354. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,..--: 7 9 0 0 0 0 1
target to target t ta tar targ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 ?..... 6 8 0 0 0 0 1
24, 9169-9171 24, 2 24 24, 24, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 ,-(). 5 2 0 0 0 0 1
355. Agarwal, 355. 3 35 355 355. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,..- 5 9 0 0 0 0 1
some inhibitor. some s so som some BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 .....,(). 9 6 0 0 0 0 1
356. Kohler, 356. 3 35 356 356. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,.,.-: 7 9 0 0 0 0 1
immune network immune i im imm immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 .....,- 7 8 0 0 0 0 1
(2021). (2021). (2021). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 5 (). 3 0 0 0 0 0 1
357. Ross, 357. 3 35 357 357. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,..-- 6 9 0 0 0 0 1
pared human pared p pa par pare BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 ....,-(). 9 6 0 0 0 0 1
358. Mohan, 358. 3 35 358 358. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,... 5 9 0 0 0 0 1
mediated cerebral mediated m me med medi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 ?. 2 8 0 0 0 0 1
Dis. Child dis. D Di Dis Dis. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 5 ..,-(). 7 5 0 0 0 0 1
359. Dalakas, 359. 3 35 359 359. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,..- 5 8 0 0 0 0 1
apeutic considerations apeutic a ap ape apeu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 5 . 1 8 0 0 0 0 1
Neurology 51, neurology N Ne Neu Neur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 5 ,-(). 5 3 0 0 0 0 1
360. Watanabe, 360. 3 36 360 360. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,..: 5 9 0 0 0 0 1
pathogenesis and pathogenesis p pa pat path BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 5 ..,-(). 7 8 0 0 0 0 1
361. Hung, 361. 3 36 361 361. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,....: 7 9 0 0 0 0 1
double-blind randomized double-blind d do dou doub BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 - 1 8 0 0 0 0 1
A(H1N1) infection. a(h1n1) A A( A(H A(H1 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 ().,-(). 8 5 0 0 0 0 1
The signal the T Th The The BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 11 - 1 10 0 1 0 0 0
Yang et yang Y Ya Yan Yang BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 11 11 . 1 1 0 1 0 0 0
19 19 19 1 19 19 19 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 11 11 no 0 10 0 1 0 0 0
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEEND NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 11 (): 3 10 0 1 1 0 0
362. Chong, 362. 3 36 362 362. BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,...- 6 9 0 0 0 0 1
drome (SARS) drome d dr dro drom BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 0 ():- 4 8 0 0 0 0 1
nosis. Arch. nosis. n no nos nosi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 0 .....,-(). 10 5 0 0 0 0 1
363. Tabarsi, 363. 3 36 363 363. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,..() 6 9 0 0 0 0 1
the management the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 -:.. 4 8 0 0 0 0 1
Immunopharmacol. 90, immunopharmacol. I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 0 .,(). 5 4 0 0 0 0 1
364. Suzuki, 364. 3 36 364 364. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,.. 4 9 0 0 0 0 1
failure by failure f fa fai fail BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 -. 2 8 0 0 0 0 1
Intern. Med. intern. I In Int Inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 0 ..,-(). 7 3 0 0 0 0 1
365. Dagens, 365. 3 36 365 365. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,..,, 6 9 0 0 0 0 1
early in early e ea ear earl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 11 0 -:.,(). 7 7 0 0 0 0 1
366. Russell, 366. 3 36 366 366. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,..,,..,.. 11 9 0 0 0 0 1
corticosteroid treatment corticosteroid c co cor cort BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 0 -.,-(). 7 9 0 0 0 0 1
367. Group, 367. 3 36 367 367. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,...-... 9 10 0 0 0 0 1
J. Med. j. J J. J. J. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 11 0 ..,-(). 7 3 0 0 0 0 1
368. He, 368. 3 36 368 368. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,..- 5 9 0 0 0 0 1
19. Nat. 19. 1 19 19. 19. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 ...,-(). 8 3 0 0 0 0 1
369. Wolfel, 369. 3 36 369 369. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,..-. 6 10 0 0 0 0 1
Nature 581, nature N Na Nat Natu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 0 ,-(). 5 3 0 0 0 0 1
370. To, 370. 3 37 370 370. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,... 5 10 0 0 0 0 1
samples and samples s sa sam samp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 11 0 --: 3 8 0 0 0 0 1
observational cohort observational o ob obs obse BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 ...,-(). 8 7 0 0 0 0 1
371. Shen, 371. 3 37 371 371. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,.. 4 9 0 0 0 0 1
mice by mice m mi mic mice BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 ..- 3 8 0 0 0 0 1
pharmacol. 259, pharmacol. p ph pha phar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 0 .,(). 5 3 0 0 0 0 1
372. Chen, 372. 3 37 372 372. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,.. 4 10 0 0 0 0 1
in treating in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 11 0 . 1 8 0 0 0 0 1
Yao Za yao Y Ya Yao Yao BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 11 0 ,-(). 5 3 0 0 0 0 1
373. Zhou, 373. 3 37 373 373. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,..- 5 9 0 0 0 0 1
Decoction on decoction D De Dec Deco BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 0 /- 2 8 0 0 0 0 1
induced zebrafish. induced i in ind indu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 ...,(). 7 5 0 0 0 0 1
374. Hu, 374. 3 37 374 374. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,.., 5 9 0 0 0 0 1
Chinese herb, chinese C Ch Chi Chin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 0 ,:,- 4 8 0 0 0 0 1
spective, randomized spective, s sp spe spec BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 0 ,.,(). 6 8 0 0 0 0 1
375. Yang, 375. 3 37 375 375. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,.. 4 8 0 0 0 0 1
Qingfei Paidu qingfei Q Qi Qin Qing BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 0 no 0 8 0 0 0 0 1
disease 2019 disease d di dis dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 (-):..., 8 8 0 0 0 0 1
104820 (2020). 104820 1 10 104 1048 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 11 0 (). 3 1 0 0 0 0 1
376. Dai, 376. 3 37 376 376. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,..-- 6 9 0 0 0 0 1
related cytokine related r re rel rela BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 ...,- 5 9 0 0 0 0 1
(2021). (2021). (2021). ( (2 (20 (202 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 6 (). 3 0 0 0 0 0 1
377. Bonifant, 377. 3 37 377 377. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,..,,..,,..,..- 16 10 0 0 0 0 1
agement in agement a ag age agem BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 6 -...,(). 8 7 0 0 0 0 1
378. Zhang, 378. 3 37 378 378. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,..- 5 9 0 0 0 0 1
tumor immunity tumor t tu tum tumo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 .,-().. 7 8 0 0 0 0 1
379. Cartwright, 379. 3 37 379 379. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,..,,..,.. 11 9 0 0 0 0 1
induction of induction i in ind indu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 -. 2 8 0 0 0 0 1
Front. Pharmacol. front. F Fr Fro Fron BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 6 ..,(). 6 3 0 0 0 0 1
380. Wei, 380. 3 38 380 380. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,..- 5 9 0 0 0 0 1
genes and genes g ge gen gene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 6 -.. 3 8 0 0 0 0 1
20, 5 20, 2 20 20, 20, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 ,(). 4 1 0 0 0 0 1
381. Cavalli, 381. 3 38 381 381. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,.,.. 6 9 0 0 0 0 1
by IL-37. by b by by by BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 -...,-(). 9 5 0 0 0 0 1
382. Dinarello, 382. 3 38 382 382. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,..-. 6 10 0 0 0 0 1
Nat. Rev. nat. N Na Nat Nat. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 6 ...,-(). 8 4 0 0 0 0 1
383. Nold, 383. 3 38 383 383. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,...-.. 8 9 0 0 0 0 1
Immunol. 11, immunol. I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 6 .,-(). 6 3 0 0 0 0 1
384. Banchereau, 384. 3 38 384 384. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,.,,.',.--: 12 9 0 0 0 0 1
spectrum of spectrum s sp spe spec BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 -...,-(). 9 8 0 0 0 0 1
Open Access open O Op Ope Open BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 9 no 0 6 0 0 0 0 1
Attribution 4.0 attribution A At Att Attr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 9 .,,, 4 7 0 0 0 0 1
adaptation, distribution adaptation, a ad ada adap BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 9 ,, 2 9 0 0 0 0 1
appropriate credit appropriate a ap app appr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 9 (), 3 10 0 0 0 0 1
Commons license, commons C Co Com Comm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 11 9 ,. 2 9 0 0 0 0 1
material in material m ma mat mate BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 9 ', 2 9 0 0 0 0 1
indicated otherwise indicated i in ind indi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 9 . 1 9 0 0 0 0 1
article's Creative article's a ar art arti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 9 ' 1 9 0 0 0 0 1
regulation or regulation r re reg regu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 9 , 1 9 0 0 0 0 1
from the from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 9 .,://. 6 9 0 0 0 0 1
org/licenses/by/4.0/. org/licenses/by/4.0/. org/licenses/by/4.0/. o or org org/ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 9 ///./. 6 2 0 0 0 0 1
© The © © © © © BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 11 11 (), 3 10 0 0 0 0 1
The signal the T Th The The BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 11 - 1 10 0 1 0 0 0
Yang et yang Y Ya Yan Yang BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 11 11 . 1 1 0 1 0 0 0
20 20 20 2 20 20 20 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 11 11 no 0 10 0 1 0 0 0
Signal Transduction signal S Si Sig Sign BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 11 (): 3 10 0 1 1 0 0

